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Abstract 
Introduction 
Cystic fibrosis (CF) lung disease is characterised by early airways infection and 
inflammation, chronic suppuration, frequent infective exacerbations and an 
increased influx of acute, and chronic inflammatory cells.  The inflammatory 
process involves activation of many cell types including neutrophils, 
macrophages and epithelial cells, and leads ultimately to the development of 
progressive respiratory failure and death.  Accurate assessment of the 
inflammatory process is a crucial part of disease monitoring and should allow 
appropriate evaluation of therapeutic interventions so as to maximize control of 
the respiratory sequelae of the disorder. 
Lung function markers such as FEV1 are insensitive and indirect.  Direct but 
invasive methods such as fibreoptic bronchoscopy and biopsy are limited in 
application, repeatability and safety.  Non-invasive methods of assessment are, 
therefore, attractive.  Exhaled Breath Gases, Exhaled Breath Condensate and 
Induced Sputum provide potential for such measures.  These techniques are 
safe, simple, repeatable and could assess all airways and can be used in 
children as young as 6 years. We hypothesised that biomarkers of inflammation 
in Cystic Fibrosis Lung Disease are measurable in samples collected non-
invasively, and can be developed into clinically useful assays. These assays 
would have the ability to reflect the level of inflammation in the CF lungs as well 
as holding the potential to act as surrogate markers of CFTR function. 
Methods 
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Exhaled breath gases, exhaled breath condensate, bronchoalveolar lavage fluid 
and induced sputum were investigated using a number of analysis techniques 
to identify the markers which best discriminated CF from non CF subjects.  
Analysis techniques used were electrochemical cells, chemiluminescene, 
ELISA, EIA, ion selective probes and mass spectrometry.  
Results 
Markers found to discriminate CF from non CF subjects were EBC pH and 
ammonium, and 38 proteomic markers were found in induced sputum.  21 
proteomic markers were found in bronchoalveolar lavage fluid.  One biomarker 
has been identified with confidence, Calgranulin A.  
Discussion 
A large component of the work of this thesis was focussed on exhaled breath 
condensate.  Two markers, pH and Ammonium were different between the CF 
and control groups.  The measurement of EBC pH and ammonium as markers 
of inflammation should be used in future gene therapy trials as they are cheap, 
quick and simple to perform 
Using clean techniques free from contamination, no proteins are repeatedly 
detectable in EBC using highly sensitive SELDI techniques.  This technique 
reflects the highest sensitivity of any available proteomics instrument and 
therefore until new technologies become available, it would be incorrect to 
assay any proteins in EBC.  
The induced sputum proteomics study identified 38 independent markers of CF 
lung inflammation  Therefore, sampling by collection of induced sputum should 
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be used in gene therapy trials.  The endpoints should be assessed by a 
combination of SELDI as an endpoint and by ELISA where this is available.   
The marker Calgranulin is likely to report on neutrophil recruitment to the lung.  
It is anticipated that this will be a sensitive marker of inflammation in the lung 
and it also has the potential to report on successful of gene transfer as it is 
raised in heterozygote carriers as well as homozygotes with CF. 
Therefore, the non-invasive technique induced sputum coupled to proteomic 
analysis would have the ability to reflect the level of inflammation in CF subjects 
and may also report on CFTR function. 
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Statement of Hypothesis 
Markers of inflammation in Cystic Fibrosis Lung Disease are measurable in samples 
collected non-invasively, and can be developed into clinically useful assays. 
These assays would have the ability to reflect the level of 
1. Inflammation in the CF lungs. 
2. CFTR function – this would be sensitive enough to detect improvement 
following administration of gene transfer agents.
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
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1.1 Cystic Fibrosis Lung Disease – An Outline 
Cystic Fibrosis (CF) is the most common, fatal single gene defect in the Caucasian 
population.  It is an autosomal recessive condition caused by a mutation of the CF gene 
on chromosome 7.  The CF Gene encodes for the cell membrane ion transport protein 
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).  Individuals of 
Northern European origin have the highest incidence of CF with about 1 in 2500 new-
born children affected and a carrier frequency of 1 in 25.  There are approximately 
70,000 affected individuals in the world, with 7500 living in the UK. The commonest 
mutation is the ΔF508 mutation – a 3 base pair DNA deletion that results in the deletion 
of phenylalanine at position 508 in the protein.  Cystic Fibrosis affects the respiratory, 
alimentary and reproductive tracts.  CF heterozygotes are considered phenotypically 
normal.  The disease is much less common in African and Asian populations, where 
carrier frequencies of 1/100 to 1/200 have been estimated.  Precise incidence in the 
developing world is not known due to high infant mortality rates and limited survival of 
CF homozygotes (Greening, 2000). 
Median life expectancy for affected individuals has improved from 2 years in 1940, to 
30 years in 2000, as shown compared to average life expectancy (Figure 1).  It has been 
predicted that with current rates of improvements in therapies, affected children born in 
the year 2000 have an average life expectancy around 40 years.  
1.1.1 CF Pathology – Clinical overview 
Cystic Fibrosis is a multisystem disorder.  The major cause of morbidity and mortality 
is CF Lung Disease.  Subjects can also suffer significant pathology of the alimentary 
and reproductive tracts.   
1.1.2 Cystic Fibrosis Lung Disease 
Since the cloning of the CF gene, it has become accepted that many of the 
pathophysiological abnormalities are related to abnormal ion transport (Riordan et al., 
1989, Quinton, 1999). 
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Figure 1. Life expectancy of Cystic Fibrosis patients.  
Red bar denotes CF subjects and Blue bar non-CF subjects. Data derived from UK 
census data. (Dodge et al., 2007) 
Improvement in life expectancy for subjects with cystic fibrosis (red) as compared to 
the increase in life expectancy in non-CF subjects from 1940 to 2000 in the UK. 
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In Cystic Fibrosis neonates, the lungs appear pathologically normal (Sobonya and 
Taussig, 1986).  Early infection with pathogenic bacteria is evident. The first step in this 
process is not entirely clear.  It may be that abnormal mucociliary clearance along with 
reduced Airway Surface Liquid height and mucus hypersecretion is enough to permit 
the colonisation and impaired clearance of pathogenic bacteria.  Others have argued that 
the initial defect is inflammation prior to infection, evidencing this with studies of 
bronchoalveolar lavage fluid from the lungs of neonates where proinflammatory 
cytokines and inflammatory cells were detected in the absence of any detectable 
pathogenic bacteria (Balough et al., 1995). 
Consequent to the presence of pathogenic bacteria and impaired bacterial clearing, 
patients develop persistent suppurative lung disease.  Small airways obstruct with 
viscous mucus, pathogenic organisms and inflammatory cells.  This results in air 
trapping and then widespread fibrosis and bronchiectasis.  Long-term suppuration and 
bronchiectasis lead to a decline in lung function. The lung function marker, forced 
expiratory volume in 1 second (FEV1) is a predictor of prognosis. The organisms 
Haemophilus influenzae, Staphylococcus aureus, Pseudomonas aeruginosa, 
Stenotrophomonas Maltophilia and Burkholderia Cepacia are pathogenic bacteria that 
colonise the airways of patients with CF.  
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1.1.3 Progression of CF lung disease 
Initial pathology is of blockage of bronchioles with mucus, bacteria and neutrophils.  
Progressive fibrosis and bronchiectasis cause a decline in lung function.  As the disease 
worsens, there are changes of colonising organisms.  With milder lung disease such as 
Haemophilus Influenzae and Staphylococcus Aureus are found.  Later organisms which 
cause more severe morbidity such as Pseudomonas aeruginosa, Stenotrophomonas 
Maltophilia and Burkholderia Cepacia may appear.  (Figure 2)  Pseudomonas 
aeruginosa is one of the most significant pathogens in CF, causing acceleration in 
decline of lung function and increased subsequent morbidity and mortality (Jacques et 
al., 1998).  The changes of fibrosis and bronchiectasis can be seen radiologically 
(Figure 3).  
1.1.4 Cystic Fibrosis pathology – non-respiratory disease 
The major cause of mortality in Cystic Fibrosis is lung disease.  Cystic Fibrosis 
pathology in other organs does contribute to significant morbity (Table 1). 
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Figure 2. The rising percentage of CF patients who are colonised with 
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Figure 3. Chest X rays of normal and CF subjects 
The lower chest x ray panel demonstrates the upper lobe fibrosis and bronchiectatic 
changes typical of CF lung disease compared to healthy control subject (upper X ray 
panel). 
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Sweat Duct High sodium and 
chloride secretion 
Salt depletion in heat 






Late—fibrous and fatty 
replacement, and loss 






Meconium plug, distal 





Liver Reduced bile salt 
secretion, increased 
circulating bile salt 
concentration 
Early—bile duct 
hyperplasia, plugging of 
intrahepatic bile ducts, 
focal biliary cirrhosis 
Late—multilobular 
cirrhosis 
Gallbladder Reduced bile salt pool, 
lithogenic bile 
Cystic duct occlusion, 
hypoplastic gallbladder, 
gallstones 







Table 1. Non respiratory pathological changes of Cystic Fibrosis 
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1.2 CFTR Defect 
1.2.1 The CF Gene and CFTR Protein 
CF Gene  
The CF gene was identified  in 1989 (Riordan et al., 1989).  Earlier linkage analysis 
identified the putative CF locus to be on the long arm of chromosome 7 (Tsui et al., 
1985), and to the band 7 cen-q22 (Wainwright et al., 1985), as shown in the following 
schematic (figure 4).  Cloning and characterisation studies revealed the CF gene to be 
approximately 6500 base pairs long (the putative protein having a membrane bound 
component and an ATP binding domain) as well as revealing the commonest CF 
mutation, the deletion of phenylalanine at amino acid 508.  The gene encodes the Cystic 
Fibrosis Transmembrane Regulator protein, which has 1480 amino acids (Riordan et al., 
1989).   
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Figure 4. The location of CFTR gene in the long arm of chromosome 7 (cen-q22) is 
shown. 
The black band represents CFTR, on the long arm of chromosome 7. 
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1.2.2 CFTR Protein 
CFTR protein shows sequence homology with ATP-Binding Cassette (ABC) 
transporters (Riordan et al., 1989).  Such ATP dependant ABC transporters have been 
identified as being cross membrane transporters of molecules (Hyde et al., 1990).  
CFTR is composed of five domains: two membrane-spanning domains (MSDs), two 
nucleotide-binding domains (NBDs), and a regulatory (R) domain (Sheppard and 
Welsh, 1999).  Artistic impressions of the protein have been drawn (figure 5), and 
attempts to assess CFTR structure using recombinant protein and X ray crystallography 
have predicted that it forms a heterodimer in the membrane to form a pore (figure 6).  
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Figure 5. Artistic representation of CFTR protein  
This artist’s impression shows the regulator R domain lying below the ion pore (Welsh 
and Smith, 1995). 
 
Figure 6. X ray crystallographic representation of CFTR dimers  
The figure shows two CFTR protein molecules together spanning the cell membrane to 
form an ion pore (Hung, 1998). 
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1.2.3 CFTR gene mutation/protein defect 
To date there are 1542 different genetic mutations recorded as being associated with the 
disease (Cystic Fibrosis Mutations Database - http://www.genet.sickkids.on.ca/cftr/).  
The most common CF mutation is delta F508, which accounts for approximately 70% 
of worldwide CF mutations. A group of 12 further mutations are common and 
collectively amount for another 15% of the total.  The remaining mutations are all 
individually rare, many having been observed in only one or a few closely related 
families. The mutations can be put into different classes and defects may occur at 
different sites within the cell (Figure 7).  There is some correlation between phenotype 
(i.e. clinical symptoms) and genotype. 
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Figure 7. Diagram representing sites of CFTR mutation Class I-V.   
Cartoon representation of the different sites within the cell where mutant CFTR 
protein defect occurs (Greening, 2000, Riordan et al., 1989). 
• Class 1: Defective protein production. 
• Class 2: Defective trafficking. 
• Class 3: Defective regulation of CFTR. 
• Class 4: Altered/defective conduction of Cl- channel. 
• Class 5: Reduced synthesis of functional CFTR. 
• Class 6: Altered stability of mature protein. 
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1.2.4 CFTR Function 
The main function of CFTR protein is established as being an ATP dependant chloride 
channel situated in the apical membrane of epithelial cells (Riordan et al., 1989).  
Chloride channel activity is not the only possible function of CFTR.  Other potential 
CFTR functions are that it acts as a bicarbonate channel (Choi et al., 2001b), that it 
interacts with the sodium channel ENaC (Stutts et al., 1997), and that it interacts with 
inflammatory mediators (Balough et al., 1995) and bacteria (Zar et al., 1995).  Despite 
considerable effort, there is no unifying hypothesis, which explains the link between 
CFTR protein dysfunction and the pathological changes of Cystic Fibrosis lung disease. 
1.2.4.1 CFTR as a chloride channel. 
Evidence that Cystic Fibrosis was a disease of an ATP dependant chloride channel was 
first shown using sweat duct perfusion studies – abnormally low Cl- permeability in 
cystic fibrosis sweat ducts led to poor Na+Cl- reabsorption. Such electrophysiological 
evidence predates the cloning of the gene (Quinton, 1983, Schoumacher et al., 1987). 
This was later confirmed along with the identification of the requirement for cAMP 
dependant protein kinase activity (Hwang et al., 1989). After discovery of the CF gene, 
within a year, proof of principle for retroviral gene therapy correction of the chloride 
defect was obtained in vitro (Drumm et al., 1990). 
Confirmatory evidence that CFTR acts as a chloride channel are studies showing 
reduced chloride conductance in the human CF nose which can be detected by nasal 
potential difference (PD) (Knowles et al., 1995). 
1.2.4.2 CFTR as a bicarbonate channel. 
Acidification of secretions in Cystic Fibrosis was first identified in 1987.  Researchers 
investigating sweat pH found it to be reduced in CF subjects, but this was thought to 
reflect rate of sweat production, and passive reabsorption of bicarbonate (Bijman and 
Quinton, 1987).  CFTR functioning as both a chloride and a bicarbonate pore in the 
pancreas was then detected (Durie, 1992).  Later, confirmation of diminished 
bicarbonate secretion in porcine airway was found, and this reduction in bicarbonate 
secretion was attributed to submucosal gland CFTR dysfunction (Ballard et al., 1999). 
When a correlation between pancreatic function and CFTR bicarbonate secretion was 
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found, the authors proposed that diminished bicarbonate secretion might in fact be the 
defect causing CF pathology.  They argued that acidic secretions of CF subjects would 
cause increases in mucus viscosity and bacterial binding, leading to CF lung disease 
(Choi et al., 2001a, Choi et al., 2001b, Reddy and Quinton, 2001).  Reasoning that 
defective bicarbonate secretion could be the basic defect came with the discovery that 
CF airway cells failed to react to an acid load being applied to the ASL, whereas wild 
type airway cells rendered the ASL alkaline in response (Coakley et al., 2003). 
1.2.4.3 CFTR interaction with the Sodium channel ENaC. 
Potential difference measurements revealed not only chloride channel activity, but 
evidence that the basal rate of sodium absorption was raised in CF polyps, when 
compared with control tissues.  Increased sodium absorption was found to be due to the 
epithelial sodium channel (ENaC), confirmed by blocking the activity with amiloride 
(Boucher et al., 1986). The presence of CFTR in the membrane made it more likely that 
the ENaC pore would not be open. Therefore, it has been established that in CF cells, 
through loss of the direct interaction of CFTR with ENaC at the level of single channel 
gating, the sodium channel pore remains open and sodium hyperabsorption occurs 
(Stutts et al., 1997, Zar et al., 1995). 
1.2.4.4 CF and increased bacterial binding 
Patients with Cystic Fibrosis have a predilection for infection with the organisms 
Staphylococcus aureus, Haemophilus influenzae and Pseudomonas aeruginosa.  The 
interaction between CFTR and Pseudomonas aeruginosa has been most studied and 
best defined.  Adherence of Pseudomonas aeruginosa to epithelial cells from patients 
with CF was found to be greater than adherence to the cells of control subjects and 
heterozygotes (Zar et al., 1995).  This increased adherence was found to be related to 
activation of the asialoglycoprotein receptor asialo GM1, whose expression is increased 
in regenerating epithelial cells, which functions as a Pseudomonas aeruginosa pilin 
receptor.  It was postulated by this group that Cystic Fibrosis cells would undergo 
increased epithelial repair, and that it is the repair event itself which in turn exposes the 
asialoGM1 receptor, allowing increased pseudomonas binding (Bryan et al., 1998, de 
Bentzmann et al., 1996, Balough et al., 1995, Konstan and Berger, 1997). 
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1.2.4.5 CF and inflammatory mediators 
The argument that the initial abnormality in Cystic Fibrosis could be inflammation prior 
to bacterial infection was evidenced by Bronchoalveolar Lavage (BAL) studies of 
neonates.  These studies revealed that inflammatory cells and proinflammatory 
cytokines could be detected before evidence of bacterial colonisation/infection (Balough 
et al., 1995, Konstan and Berger, 1997), suggesting that the initial inflammation may be 
the causative factor in CF lung disease, rather than as a response to pathogenic bacteria.  
It has, however, been noted that markers of CF lung damage such as FEV1 correlate 
with bacterial infection, but not with proinflammatory cytokine levels (Nixon et al., 
2002). 
1.2.4.6 Interaction with modifier genes 
It has been argued that the lung disease associated with CF reflects the interaction 
between CFTR protein and other genes and proteins.  This interaction could be the basic 
defect, or alternatively the severity of CFTR dysfunction may be modified by other 
genes and proteins.   
One particularly compelling argument is centred on the clinical heterogeneity of CF 
subjects, as each genotype poorly correlates with disease phenotype with regard to lung 
disease. It may, therefore, be that Cystic Fibrosis lung disease is not related to an ion 
channel defect, but rather CFTR effects on other “modifier” genes and proteins.   
Further evidence for genetic “modifiers” is the discordance in lung function in dizygotic 
twins, and greater concordance in lung function seen in monozygotic twins, suggesting 
CF lung disease severity is modified by an inherited gene component in addition to the 
CFTR gene itself (Mekus et al., 2000). The concept of modifier genes and protein 
products that interact with CFTR is currently gaining momentum with the investigation 
of the CFTR interactome, i.e. the set of proteins that interact with CFTR and determine 
net function in an organ specific fashion. 
The best evidence for such interactions is the discovery of proteins that interact with the 
intracellular components of the C terminus of CFTR.  Molecules such as 
EBP50/NHERF1 and ezrin have been shown to interact with the C terminus.  Whilst 
their function is poorly understood, it is known that these molecules then interact with 
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other intracellular proteins such as actin (Haggie et al., 2004).  It is conceivable 
therefore, that a function unrelated to Chloride channel efflux may well lead to CF lung 
disease.  Other examples of genes implicated with CFTR function are mannose-binding 
lectin, glutathione-S-transferase, transforming growth factor-beta1, tumor necrosis 
factor-alpha, beta2-adrenegic receptor, and HLA class II antigens (Merlo and Boyle, 
2003).  
1.2.4 Correction of CFTR function 
As the cellular ramifications of how CFTR dysfunction leads to CF lung disease have 
not yet been clearly established, the best potential for development of novel therapies 
may lie in inserting “healthy” Wild Type CFTR into the cell membrane, by CF Gene 
Therapy.  
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1.3 CF Lung Disease and Airway Surface Liquid 
1.3.1 Evolution of lung disease 
The clinical course of Cystic Fibrosis lung disease varies greatly between individuals.  
The genotype does not accurately predict the severity and prognosis of CF lung disease.  
Some individuals may present soon after birth with CF pathogens in the lung, whereas 
other individuals with the same genotype may present in adolescence and adult life, 
reflecting differing environmental exposure, path of care as well as genetic factors. 
The major pathology is exhibited in the airway lumen - airway obstruction with 
blockage by mucus, neutrophils and bacteria (Figure 8).  Analysis of the Airway 
Surface Liquid (ASL) in this lumen could therefore be used for discovery of biomarkers 
of CFTR function and of CFTR related inflammation. 
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Figure 8. Obstruction of Bronchiole in CF lung disease (different magnification) 
These images are of histological sections through a normal lung (upper image) and CF 
lung (lower image).  The lumen of the largest bronchus in the CF subject can be seen to 
be distended and obstructed – by mucus, neutrophils and bacteria. 
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1.3.2 Alterations to the Airway Surface Liquid 
The airway surface liquid in Cystic Fibrosis is altered for at least two reasons:  
• Altered mucus composition as a direct consequence of the ion channel defect. 
• In response to the infective and the inflammatory component of CF. 
Alterations in mucus composition 
The basic defect of reduced chloride efflux and increased sodium influx into the cell has 
given rise to two theories as how the chloride channel defect might precipitate lung 
disease. 
1.3.2.1 The hydration hypothesis (low ASL volume hypothesis) 
This hypothesis (Boucher, 2003, Boucher, 2004, Matsui et al., 1998, Tarran et al., 2001) 
proposes that the most important control for Airway Surface Liquid height is the 
absorption of sodium ions.  This is accompanied by the diffusion of chloride ions into 
the cells via tight junctions. In CF, the sodium absorption is accelerated and chloride 
efflux defective, leading to an increased rate of water absorption. Reduced water in the 
ASL would lead to depletion of a specific compartment of the ASL - the periciliary 
liquid (PCL). This would then lead to defective ciliary clearance and reduced ciliary 
beat frequency, reducing the efficacy of the mucociliary escalator in clearing mucus 
from the lung. Subsequent to PCL depletion, mucus adheres to airway surfaces and 
persistant mucin secretion generates the formation of "thickened" mucus plaques and 
plugs.  These plaques and plugs would be a nidus for persistent bacterial colonisation.  
In the case of Pseudomonas aeruginosa, these bacterial plaques allow formation of 
mucoid colonies in a biofilm, conferring bacterial resistance to both host defences and 
standard antibiotic regimens. The most compelling data supporting this hypothesis are 
the images from Air Liquid Interface cultures and electron microscopy showing 
shortening of the PCL height in cultures of CF epithelial cells from CF patients 
(Boucher, 2003, Boucher, 2004).  
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1.3.2.2 The high salt hypothesis 
This hypothesis postulated that in normal ASL the fluid would be hypotonic and in CF 
the ASL would be isotonic.  The increased salinity of CF ASL would have a detrimental 
effect on activity of antibacterial proteins such as defensins, lysosymes, cathelicidins 
and lactoferrin.  This relies on the premise that the epithelium is impermeable to water 
and that tight junctions do not allow absorption of water, whilst transport of sodium and 
chloride continue actively through CFTR and ENaC.  This theory suggests that CFTR 
regulates chloride transport across the apical membrane of epithelial cells, as confirmed 
by air-liquid interface cultures (Uyekubo et al., 1998).  Therefore, as this regulation is 
deficient in Cystic Fibrosis, chloride levels would be raised in the extracellular fluid in 
CF.  The evidence for this theory relies on the findings that CF ASL sodium and 
chloride levels were increased and that bacterial killing by CF ASL was impaired 
(Smith et al., 1996).  Since then however, contradictory reports have shown that high 
salt does not diminish the antibacterial activity of ASL, partly invalidating the high salt 
ASL hypothesis (Bals et al., 2001, Matsui et al., 1998, Travis et al., 2000). 
1.3.2.3 Difficulties in assessing ASL ion composition 
Confirming whether the low salt or the isotonic salt hypothesis is correct depends upon 
in vivo assaying of sodium and chloride levels of ASL, but this is technically difficult. 
Sampling of airway surface liquid by conventional bronchoalveolar lavage would affect 
the levels of ions due to dilution effect and the use of isotonic sodium chloride solution 
for the lavage. Sampling using filter paper and bead approaches to absorb ASL have 
instead been used.  There is no consistency in the results of the approaches used, 
perhaps reflecting methodological variations in collection of ASL.  These variations 
could include mixing of periciliary liquid, mucus, secretions from submucosal glands 
and perhaps active secretion of ions and fluid - as insertion of filter paper etc. onto the 
airway may not be entirely inert. Investigators have found results, which generally 
support their hypothesis with regard to low salt and isotonic salt.  Knowles et al found 
no differences in ASL ion composition (Knowles et al., 1997), whereas Quinton’s group 
found ASL to be hypotonic, but isotonic in Cystic Fibrosis (Joris et al., 1993). 
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The compelling evidence of Boucher’s group showing images of reduced ASL height in 
CF airway cells cultured on air-liquid interface casts doubt on the validity of the low 
salt hypothesis (Boucher, 2003).
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1.4 Gene Therapy for Cystic Fibrosis 
Improvements in conventional therapies have lead to an increase in life expectancy, 
with predictions that a child born in 2007 has a median life expectancy of 
approximately 40 years. However, there is clearly a need for more effective therapies 
and since the isolation of the cystic fibrosis (CF) gene in 1989 (Kerem et al., 1989), the 
potential for gene therapy to correct the basic defect of this disease has been 
investigated. 
1.4.1 Barriers to successful CF gene therapy 
As the major cause of mortality is CF lung disease, the primary target for gene therapy 
is the respiratory epithelium of the lung.  This target for gene therapy offers several 
advantages and disadvantages (Table 2). 
1.4.2 The ideal gene transfer agent 
The ideal gene transfer agent would be deliverable topically using an inhaled delivery 
device, exhibit a high level of transfection efficiency, transfect the putative stem cell 
population of the lung, have low toxicity and cause long term expression of wtCFTR at 
levels similar to exogenous levels. No currently available gene transfer agents or 
clinical protocols achieve all of these ideals.
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Advantages of CF Gene Therapy Disadvantages of CF Gene Therapy 
Lung epithelium accessible to topical 
delivery 
Respiratory epithelium evolved to 
resist exogenous DNA 
Lung is the target organ Stem cell population of lung 
inaccessible/unknown 
Gene transfer in vitro corrects 
chloride channel defect 
Detection of effective therapy is 
difficult 
5% transfection efficiency may be 
satisfactory 
Mucus and inflammation may block 
transfection in the adult population 
(the initial treatment population) 
Mouse models demonstrating 
electrophysiological abnormality can 
be studied 
No animal model demonstrates CF 
lung disease (pathology) 
Corrects the primary CFTR defect Most pathology represents 
secondary disease/damage, not the 
primary CFTR defect 
Table 2. Advantages and disadvantage of CF Gene Therapy
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1.4.3 Proof of Principle for transfection 
Within a year of identification of the CF gene, proof of principle that gene therapy 
could correct the ion channel defect was shown in cell lines, and patch clamping 
showed correction of anion efflux (Drumm et al., 1990). Prolonged correction of the 
genetic defect was performed in proliferating cells using retrovirus (Olsen et al., 1992). 
Transfer of human CF gene to the mouse airway was first demonstrated in 1992 
(Rosenfeld et al., 1992). Topical delivery of recombinant adenovirus was used in non 
human primates and transgene transfection was detected particularly in alveolar cells 
(Engelhardt et al., 1993). Lack of repeatable delivery of viral gene therapy was 
identified as a problem due to both T cell immunity and the presence of neutralising 
antibodies (DeMatteo et al., 1997, Yang et al., 1995). Recent gene therapy trials have 
used AAV2 and have shown reduction in induced sputum interleukin 8 at 30 days 
(Moss et al., 2004). Despite modulation of the vector and the immune response, no viral 
gene therapy agent has been shown to have the ability to deliver cDNA to the airway 
epithelium repeatedly. 
Evidence for functional gene transfer in the CF mutant mouse using liposomes rather 
than viruses was first demonstrated in 1993 (Alton et al., 1993, Hyde et al., 1993).  
Subsequently, phase I clinical trials were performed in the human nose (Caplen et al., 
1995, Gill et al., 1997, Porteous et al., 1997) and in the human lung (Alton et al., 1999). 
Delivery of liposomal gene therapy to the nose and lung of adults produced evidence of 
correction of the chloride defect, as well as a reduction in bacterial adherence (Alton et 
al., 1999).  These studies provided evidence of correction of the ion transport defect in 
some patients, however this correction was short lived.  Subsequent improvements in 
efficacy and repeatability would be required for clinical benefit. 
1.4.4 Target Cell Population 
Potential targets for gene therapy in the airway include ciliated, non-ciliated and goblet 
cells in the surface airway epithelium as well as submucosal glands.  As yet, the stem 
cell population of the lung has not been identified, but if/when, it is identified, it would 
be the ideal target cell population for transfection, as potentially lifelong gene 
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transfer/expression could occur. At present, however, it is unclear which cellular targets 
are most relevant with regard to gene therapy.  
1.4.4.1 Ciliated epithelial cells of the conducting airways 
Cystic Fibrosis presents as a small airway disease.  It is therefore plausible that airway 
epithelial cells in the conducting airways are the most relevant target for CF Gene 
Therapy (Jiang and Engelhardt, 1998). CFTR expression in the distal conducting 
airways is higher than in the proximal bronchi.  It is apically localised in epithelial cells 
(Engelhardt et al., 1994). Access to epithelial cells of the conducting airways is possible 
topically through aerosol-inhaled delivery.   
The Engelhardt study used in situ hybridization and immunohistochemistry to quantify 
CFTR expression in the distal conducting airways – high levels of expression were 
found in the airway cells spanning the terminal bronchioles and respiratory bronchioles 
(Engelhardt et al., 1994). These cells are likely to be most abundant at the 15-25th 
generation of division of the airway (Figure 9). 
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Figure 9. CFTR expression in the distal conducting airways (Engelhardt et al., 
1994) 
This figure is taken from the publication by Engelhard (Engelhardt et al., 1994) showing 
the expression of CFTR was greatest in the terminal and respiratory bronchiole i.e. the 
distal bronchial tree with a marked fall in expression of CFTR mRNA in the alveoli.  
The implication of this figure is that the most appropriate target for CFTR gene transfer 
would be in the terminal and respiratory bronchiole.  Clara cell 10kDa protein (CC10) 
expression was compared as a control as it was most abundant in the proximal 
bronchioles. 
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1.4.4.2 Submucosal Glands 
Work has shown high levels of CFTR expression in the submucosal glands and that 
their secretions are the principal contributor to the ASL of the porcine trachea (Ballard 
et al., 1999).  They suggested that submucosal gland CF dysfunction leading to 
dehydrated viscous mucus is the main contributor to CF lung disease. However, as 
submucosal glands are only present to the level of cartilaginous rings (i.e. first few 
generations of airway – to approximately 3.5mm in diameter), and CF lung disease 
starts in the small conducting airways which are more distal (Sobonya and Taussig, 
1986) submucosal glands cannot contribute to the site of initial pathology.   
The ciliated and non-ciliated cells of the distal conducting airways have been chosen as 
the primary target of CF gene therapy by the UK Cystic Fibrosis Gene Therapy 
Consortium.   
1.4.4.3 Stem Cell population of the lung 
Other successful gene therapies (e.g. in human Severe Combined Immunodeficiency 
(SCID)) have targeted bone marrow stem cells using viruses and have brought about 
long term correction of the genetic defect (Hacein-Bey-Abina et al., 2002). 
The stem cell population of the lung has not yet been identified (Cardoso and Williams, 
2001).  The stem cell population may migrate from the marrow during epithelial repair 
or may be present in the lung from the stage of embryogenesis.  Attempts have been 
made to identify these cells in female sex-mismatched bone marrow transplant 
recipients, by assessing percentage of epithelial cells with Y-chromosomes.  However 
no such population of epithelial cells was found (Davies et al., 2002).   
The relevance of the stem cell is that potentially lifelong gene correction would be 
possible, but that a topical delivery approach is less likely to target this population of 
cells. 
1.4.5 Gene Therapy for CF 
The identification of the CFTR gene in 1989 has made gene therapy for CF possible.  
Within 4 years of cloning of the gene, the first gene therapy trials were completed. 
Since then, there have been 12 human trials of gene transfer agents.  At present the 
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largest limiting factor appears to be low levels of delivery of GT agents (especially non-
viral GT agents) and therefore presumably little production of CFTR protein.  At 
present, there are no techniques to quantify CFTR protein. This is important because 
once the barrier of delivery is overcome, the potential toxicity of overexpression of 
CFTR will need to be investigated. 
Gene therapy vectors fall into two categories – viral and non-viral gene transfer agents.  
This thesis is linked to the work of the UK CF Gene Therapy Consortium, whose focus 
is on non-viral gene transfer with the objective of developing a well-tolerated practical 
protocol that achieves clinical benefit upon repeated application. 
1.4.5.1 Gene Therapy Vectors 
A gene therapy vector is any agent that transfers nucleic acid in a functional form to the 
appropriate cell type. 
1.4.5.1.1 Naked DNA 
Naked DNA can transfect cells however, it is not stable by nebulised delivery methods, 
and could be degraded by endogenous or exogenous DNase in the ASL.  If these 
hurdles could be overcome, it is an attractive candidate as it is easily formulated and 
manufactured.  
1.4.5.1.2 Non-viral gene therapy vectors 
1.4.5.1.2.1 Cationic Liposomes 
Cationic liposomes are positively charged and are attracted to the negatively charged 
surface membrane of the cell.  They can be complexed with DNA and cause compaction 
of the DNA.  Liposomes can be monovalent or polyvalent.  Examples used by the 
UKCFGTC include DOTAP, lipofectin, lipofectamine, PEI and GL-67. The mode of 
entry to the cell is most likely to be via the endosome, and release from the endosome is 
a significant barrier to these GTAs (Zabner et al., 1995, Zhou and Huang, 1994). 
1.4.5.1.2.2 Compacted DNA 
Compacted DNA, otherwise known as nanoparticles could assist gene transfer, as 
nanometre sizes would allow diffusion in to the nucleus.  DNA can be compacted using 
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polyethylene glycol-substituted poly-L-lysine, forming unimolecular DNA particles 
(nanoparticles) (Ziady et al., 2003a, Ziady et al., 2003b, Ziady et al., 2002). 
1.4.5.1.3 Viral gene therapy vectors 
1.4.5.1.3.1 Adenovirus. 
Adenovirus is the most commonly used viral gene transfer agent for CF gene therapy.  
Its mode of action is the best characterised of the gene therapy vectors. Adenovirus is a 
double-stranded linear DNA virus that posses a natural tropism for respiratory cells and 
has the ability to transfect non-dividing cells.  As viral DNA can integrate into the host 
genome (especially during cell division), there is an association with neoplasia (e.g. by 
insertion of viral promoters in front of human proto-oncogenes). 
1.4.5.1.3.2 Adeno-associated Virus 
Adeno-associated virus (AAV) is a modified parvovirus and delivered in CF GT trials 
to adults and children in the US (Moss et al., 2004).  AAV offers good transfection 
efficiency and limited immunogenicity, whilst its ability to integrate into host genome 
has been reduced compared with adenovirus.  Indeed it has been reported that human 
CF GT lung studies with AAV2 have shown a reduction in interleukin 8 - suggesting 
partial correction of the inflammatory status of the CF subjects airways.  There is no 
convincing evidence of success of delivery after repeated dosing, and neutralising 
antibodies have been detected in BAL after AAV delivery.  The neutralising antibodies 
may inactivate AAV, or may, after repeated dosing cause an immune response leading 
to inflammation and toxicity.  Loss of efficacy after repeated dosing has been suggested 
with rises in interleukin 8 levels to initial levels within 3 doses (Moss et al., 2004).  
1.4.5.1.3.3 Sendai Virus 
Sendai virus (SeV) belongs to the paramyxoviridae family and the mouse is its natural 
host.  SeV efficiently transfects human epithelia, through multiple mechanisms. 
Attachment and cytoplasmic entry is mediated by two envelope glycoproteins, 
haemagglutinin-neuraminidase (HN) and fusion protein (F) which interact with 
cholesterol and sialic acid respectively.  This mode of transfection is very efficient.  
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However these proteins are markedly immunogenic, and repeated delivery of SeV has 
not been possible due to neutralising antibodies. 
1.4.5.2 Target Transfection efficiency 
Cystic Fibrosis is an autosomal recessive disease.  Since heterozygotes, who have 50% 
of WT CFTR protein, do not develop CF lung disease, transfection of 50% of cells may 
not be necessary.  
Evidence from multiple sources has lead to the proposal that the required transfection 
efficiency needed may be as low as 5% of cells.  Mixing experiments in cell lines 
showed correction of the electrical defect by adding as few as 6-10% corrected cells to 
an epithelial sheet (Johnson et al., 1992).  Subjects with mild CF mutations such as 
R117H, retaining only 2% of estimated activity, are pancreatic sufficient and have mild 
lung disease, suggesting that even low rates of gene transfer may confer some 
protection against CF lung disease. 
Intercrossing of CF and non-CF mutant mice is possible and leads to modulation of 
expression of CFTR.  5% of normal allele expression revealed a disproportionately 
large correction of the chloride ion transport defect (50% of normal) and essentially 
complete rescue of the intestinal disease (100% survival) (Dorin et al., 1996).  Therefore 
it follows that even modest levels of transgene expression and only partial correction of 
CFTR channel activity may have a significant clinical impact. 
Transfection efficiency of 5% is an achievable endpoint using viral GT agents, and 
maybe achievable using non-viral GT agents coupled with repeated delivery. 
1.4.6 United Kingdom Cystic Fibrosis Gene Therapy Consortium. 
The UK CF Gene Therapy Consortium combines the efforts of three centres within the 
UK with a wealth of experience and a long-term commitment to developing gene 
therapy - Oxford, Imperial College, London and Edinburgh.  It has the specific aim of 
developing effective gene therapy for delivery to patients.  The CF Trust, UK, supports 
the work of the UK CF Gene Therapy Consortium (UKCFGTC).  Original and 
additional support comes from the Medical Research Council, Wellcome Trust, Chief 
Scientists Office, Scotland and others. 
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The gene therapy products developed will need to demonstrate gene transfer, protein 
production, functional correction, and efficacy and have the ability to be delivered 
repeatably for the lifetime of the CF subjects.  The work of this thesis is to develop and 
validate assays that would reflect improvements in CF inflammation in the lungs of 
stable CF subjects and to develop surrogate markers of CFTR function. 
The website for the UK gene therapy consortium is http://www.cfgenetherapy.org.uk/  . 
Non-invasive assays are advantageous since they avoid the problems of invasive 
procedures like bronchoscopy.  Such problems include lack of repeatability and safety 
issues in subjects with respiratory failure.  It is hoped that non-invasive assays would be 
better tolerated, enabling repeated testing of individual subjects.  Therefore data could 
be generated in a longitudinal manner e.g. throughout cycles of infective exacerbation, 
or at multiple times in the weeks and months following gene therapy deliver. 
Established assays of chloride efflux such as nasal potential difference (PD) require 
electrical contact with epithelium, therefore non-invasive techniques will not be able to 
assess chloride efflux directly (as would be possible using a bronchoscope).  Instead of 
direct measure of changes in PD, the intention is to use surrogate markers of CFTR 
function.  In addition, we anticipate assay of cytokines and chemokines will be useful to  
report on the inflammatory state of each individual. 
1.4.6.1 Trial Design to optimise detection of Gene Transfer 
It would be difficult for Gene Therapy studies commencing in children to be approved 
by the UK Gene Therapy Advisory Committee, who are the government body to advise 
on the ethical acceptability of gene therapy trials.  They have evolved the ethical 
principle that children can be studied if only there is no possibility of relevant study in 
adults and if they, as individuals, are likely to benefit.  This leads to difficulties as 
children are likely to be the group who respond best to gene therapy in that they would 
not have the high bacterial loads and severity of established lung damage that the adult 
group would have.  Therefore, it is necessary that the adult group must first be studied.  
Although safety not efficacy is the sole objective in a phase 1 trial, to ensure approval of 
Phase 2/3 studies in children it is likely that efficacy as well as safety will have to be 
demonstrated in adults. Adults will have more severe lung disease, as by nature it is 
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progressive.  They are more likely to have the characteristic thick tenacious sputum 
present when bronchiectasis is present.  This tenacious sputum has long been known to 
reduce gene transfer efficiency.  Consequently, adults recruited for GT trials are less 
likely to show demonstrable efficacy of gene transfer and therefore to gain clinical 
benefit.  As gene transfer will not reverse bronchiectatic pathology (i.e. inflammatory 
pathology), markers of CFTR function are necessary alongside markers of 
inflammation.  Steps to improve study design and increase likelihood of demonstrating 
efficacy would be to use patients with milder phenotype (e.g. FEV1 50-80%) and have a 
scaled introduction for older children once initial safety has been proven e.g. after first 6 
months, recruit 12-16 year old to the study.
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1.4.6.2 Assays of inflammation for Gene Therapy trials 
At present, the optimal gene therapy vectors are being developed concurrently with the 
development of assays of efficacy.  This makes both the assessment of different vectors 
and the assessment of assays of efficacy difficult. Assays that evaluate the inflammation 
of CF lung disease are necessary, as the inflammatory response in CF appears 
upregulated.  It is anticipated that the inflammatory response will be downregulated 
with gene transfer.  Proofs of principle of this theory have been demonstrated in both 
non-viral and viral gene therapy trials with reduction in interleukin 8 levels in airway 
surface liquid (Alton et al., 1999).  Evaluation of novel inflammatory mediators would 
also be helpful, as there is overlap between CF and non-CF interleukin 8 levels. Novel 
biomarkers demonstrating a clear separation of CF and non-CF groups would improve 
likelihood of GT efficacy being detected.  
Electrical measurements provide a functional end-point assay. However, it remains 
unclear how the electrical defect is related to disease pathology.   Therefore, it may be 
more relevant to have assays that correlate better with disease processes and 
pathophysiology.  For example, assays that correlate with lung function, reflect 
mucociliary clearance, inflammation and bacterial adherence may be more suitable to 
evaluate gene transfer efficacy.  
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1.5 Non-invasive sampling techniques in lung disease 
Non-invasive sampling techniques to investigate airway inflammation are those which 
collect airway surface liquid (ASL), avoiding the sedation and/or anaesthesia required 
for bronchoscopy and bronchoalveolar lavage.  Sampling ASL (using invasive 
techniques) is performed routinely during the clinical care of patients with respiratory 
problems and is known to be useful in monitoring severity and progress of many 
diseases (Nicolai, 2001).  It can be performed by fibreoptic bronchoscopy (FOB), with 
either sedation and local anaesthesia or a general anaesthetic.  Bronchoalveolar lavage 
(BAL) sampling can take place using this invasive sampling technique, and is generally 
performed alongside bronchial brushings and biopsies.  This technique is reasonably 
well tolerated in children but is rarely used in the majority of CF adults, as 
bronchoscopy should not be performed in subjects with respiratory failure.  The two 
non-invasive techniques investigated in this thesis are the collection and analysis of 
Exhaled Breath Condensate and Induced Sputum.   
The potential to sample ASL without using an invasive procedure such as FOB is 
attractive in that it would allow a wider range of patients to be investigated e.g. those 
with respiratory failure.  The EBC and Induced Sputum collection technique offers the 
potential to be safe, simple to perform and repeatable in each individual (Table 3).  If 
successful, these techniques would allow ASL analysis to be applied on a large scale 
and longitudinally to clinical studies of CF .
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Table 3. Comparison of three techniques to sample ASL
 Bronchoalveolar Lavage Exhaled Breath 
Condensate 
Induced Sputum 
Time 40 minutes including 
bronchoscopy 
5 minutes 30 minutes 
Safety Unsafe in respiratory failure Safe Can cause wheeze and 
↓ FEV1 
Simplicity No Yes Yes 
Easily 
repeatable 
No Yes – within minutes Yes - After 24 hours 
Reproducibility Yes Not known Not known 
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1.5.1 Exhaled Breath Condensate 
The potential of Exhaled Breath Condensate to be used as a research tool was first 
realised by Russian researchers (Iakovleva et al., 1987, Kurik et al., 1987, Sidorenko et 
al., 1980).  This original work focused on the viscosity of “exhaled airway humors”.  
Independently, is was found that more than 200 compounds were present in exhaled air 
(Manolis, 1983) and exhaled breath condensate (Scheideler et al., 1993).  Thereafter, 
groups started to investigate EBC principally to investigate changes to pulmonary 
surfactants, but also for other compounds such as acetylcholine, serotonin, and 
histamine (Goncharova et al., 1989).  Such compounds, being non volatile in nature 
(albeit at very low concentrations) imply that EBC is comprised of more than just 
condensed volatile gases.  This important observation has fueled further research in this 
field, as EBC may therefore contain components of Airway Surface Liquid (ASL) 
(Scheideler et al., 1993). 
Initial research using EBC focused on the common respiratory disease, asthma 
(Goncharova et al., 1989).  Biological mediators have been investigated, with particular 
focus on chemokine and cytokine mediators and their metabolic end products 
(Khyshiktyev et al., 1994). 
Markers of oxidative stress have generated interest as they are thought to reflect the 
oxidative burst in cells and hence inflammatory responses.  Markers of nitrative stress, 
also reflect components of the inflammatory process.   
Strong evidence of a non volatile component to EBC has been published.  Detection of 
ion, protein and lipid components have taken place (Effros et al., 2002, MacGregor, 
2004, Montuschi et al., 1999).   
Mass spectrometry is a sensitive technique to analyse multiple compounds using their 
molecular weights.  It was first used to analyse the lipid component of EBC in 1997 
(Iatsenko et al., 1997, Jobsis et al., 1997). 
With regard to cystic fibrosis, several markers of inflammation have been investigated, 
including the exhaled gas nitric oxide and EBC nitrite and hydrogen peroxide (Hacein-
Bey-Abina et al., 2002, Ho et al., 1999, Ho et al., 1998a, Ho et al., 1998b).  The work of 
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this thesis is an evolution of these studies, specifically applied to CF in the context of 
gene therapy. 
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1.5.2 Induced Sputum 
Induced sputum has been established as a research tool evolved from collection and 
analysis of spontaneous sputum.  As sputum contains fluids expectorated from the lung, 
it is likely to contain Airway Surface Liquid. 
Induced sputum is a technique which was developed to diagnose Pneumocystis carinii 
pneumonia in immunocompromised patients and is used for this purpose routinely in 
hospital care (Pitchenik et al., 1986). The technique involves asking subjects to inhale 
hypertonic saline solution for a set period of time and then they are asked to expectorate 
sputum. This sputum is used for further analysis. 
It is possible that induced sputum samples fluid from the airway at a point more distal to 
that of spontaneous sputum as the inhaled saline nebuliser delivers saline to the 
conducting and distal airways. Ultrasonic nebulisers offer a larger particle size (5.58µm) 
that standard “Jet” nebulisers (3µm).  This has an advantage in that a higher proportion 
of the particles deposit in the conducting airways (i.e. the target region where we would 
like to sample ASL) compared to the alveolar region (Rau, 2002). 
1.5.3 Induced Sputum collection technique 
Induced sputum collection techniques have been standardized to a greater extent than 
EBC collection.  It is established that ultrasonic nebulisers should be used, with 
percentage of saline and the duration of delivery being the only variable to be 
standardized.  Investigation of induced sputum has taken place in COPD, asthma and 
lung cancer (Khajotia et al., 1991, Ordonez et al., 2003, Pin et al., 1992, Sterk, 1997, 
Suri et al., 2003, Tsoumakidou et al., 2003).  
Investigation of sputum has taken place in cystic fibrosis research for many years, with 
sputum microbiology being a mainstay of clinical care. Induced sputum protocols have 
been developed and established as safe in CF, to obtain ASL from patients who are too 
young to expectorate spontaneously (De Boeck et al., 2000).  
As induced sputum contains cells along with a liquid phase, a greater number of 
investigations can be performed on the sample.  The cell phase can be used to assess the 
inflammatory cell infiltrate in the airway and the differential proportion of each type of 
inflammatory cell is a good discriminator between diseases and has been shown to be 
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useful in asthma and COPD.  The liquid phase of induced sputum has also been the 
subject of interest, with raised interleukin 8 and total protein being found (Sagel et al., 
2001). 
The method for induced sputum used in this thesis is derived from those of the initial 
investigators (Pin et al., 1992) and adapted by others (Pizzichini et al., 1996).  Other 
investigators have extensively analysed induced sputum for inflammatory mediators in 
subjects with Cystic Fibrosis and have revealed that these in particular have investigated 
the differential cell counts, protein levels and inflammatory cytokine interleukin 8 
(Ordonez et al., 2003, Sagel et al., 2001, Sagel et al., 2002, Suri et al., 2003).  
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1.6 Markers of Inflammation in CF Lung Disease 
The various markers of inflammation can be broken down into their chemical 
subcomponents.   An understanding of the immune response is necessary to identify the 
relevance of the various potential markers of inflammation to CF lung disease.  
1.6.1 Inflammatory response 
The inflammatory response can be broken down into two main types – the innate and 
adaptive immune responses.   
The innate immune response acts via pathogen recognition receptors (PRRs).  
Molecular patterns, which are highly conserved on large groups of microbes, are termed 
pathogen associated molecular patterns and are recognised by toll-like receptors (TLR).  
Examples include lipopolysaccharide (TLR2/4), lipoteichoic acid (TLR2) and bacterial 
unmethylated cytosine-guanosine dinucleotides in DNA (TLR9). PRRs are present on 
all antigen presenting cells, dendritic cells and macrophages. Once pathogens are 
recognised, these receptors induce Nuclear Factor Kappa B production, leading to 
transcription of a wide range of inflammatory and immune-response genes such as TNF 
alpha, interferon gamma, Interleukin 1 Beta and interleukin 6.  
The adaptive (acquired) immune response is activated via antigen presenting cells - 
dendritic cells and macrophages in the lung. They signal recruitment of immature 
dendritic cells and macrophages to the lung. This response is amplified by the innate 
immune response and TNF alpha and Interleukin 1 beta production. Macrophages are 
recruited from the circulation and activated via TNF alpha, Interferon gamma and 
Interleukin 1 beta. They secrete chemokines such as interleukin 8 (neutrophil attractant) 
and RANTES (eosinophils attractant) inducing humoral immunity with neutrophil 
influx and immunoglobin secretion.  
1.6.1.1 Neutrophil response 
Neutrophils are manufactured in the bone marrow, travel through the circulation and 
adhere to venular endothelium (including the capillary endothelium in the lung) 
awaiting a chemotactic signal – particularly interleukin 8, but also to leukotriene B4. 
They respond by diapedesis through the vascular wall, migrate to the site of 
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inflammation to phagocytose and destroy microbes and other foreign material. 
Phagocytosis is signalled as part of both the innate and adaptive immune responses. The 
neutrophil membrane envelops microbes and other particles forming a membrane bound 
vacuole. Neutrophil cytoplasmic granules contain a variety of bacterial inactivating and 
killing proteins including myeloperoxidase, elastase, lactoferrin, lysozyme, proteinase 3, 
cathelicidins, gelatinases and defensins (Borregaard et al., 2001, Wagner and Roth, 
2000). 
Killing and digestion occurs by fusion of toxic granules to the vacuole, and generation 
of the enzyme NADPH oxidase.  This enzyme passes electrons from NADPH in the 
cytoplasm to molecular oxygen within the vacuole.  Superoxide is generated by this 
oxidative (or respiratory) burst.  A chain reaction occurs leading to rapid consumption 
of molecular oxygen, and generation of a variety of reactive oxygen and nitrogen 
species. Superoxide is converted into hydrogen peroxide, which in turn reacts with 
myeloperoxidase to generate hypochlorous acid and chloramines, both potent 
disinfectants (Nauseef, 1999). 
1.6.1.2 Apoptosis and necrosis in the CF airway 
Apoptosis is programmed cell death with organised disassembly. Uncontrolled cell 
death is termed necrosis. Cell membrane integrity is lost, leading to lysis, release of cell 
contents and an inflammatory response.  The macrophage detects cell lysis products and 
releases proinflammatory mediators such as TNF alpha, IL8 and thromboxane B2. 
Apoptotic cells express phosphatidylserine receptors leading to ordered cell death and 
clearance. CF airway fluid cleaves the phosphatidylserine receptor leading to 
unprogrammed cell death, necrosis and exacerbation of the inflammatory response in 
the CF airway (Vandivier et al., 2002). Therefore, as cell necrosis occurs in the CF 
airway, various inflammatory mediators involved in the inflammatory processes may be 
released into the ASL of CF subjects. 
1.6.2 Potential Biomarkers of inflammation to be investigated 
1.6.2.1 Oxidative stress 
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The oxidative burst of the neutrophil is responsible for the generation of an excess of 
reactive oxygen species, necessary for bacterial killing.  It has been established that 
oxidative stress occurs in Cystic Fibrosis and a correlation between the lung function 
parameter FEV1 and serum levels of lipid hydroperoxides has been shown (Brown and 
Kelly, 1994, Brown et al., 1996).  Detection of a variety of surrogate markers of 
oxidative stress such as carbon monoxide and 8-isoprostane is possible and will be 
investigated. 
1.6.2.2 Nitrative stress 
As end products of oxidative stress are generated by the oxidative burst of neutrophils, 
products of nitrative stress are generated by reactive nitrogen species i.e. Nitric Oxide, 
peroxynitrite, Nitrite and Nitrotyrosine. NO is generated in two ways.   
• Inducible nitric oxide synthetase (NOS 2) expression can be induced by 
proinflammatory cytokines (Latzin et al., 2002).  However this induction may 
not occur in CF as iNOS is less abundant by immunohistochemical detection in 
CF lungs compared to other respiratory pathologies (Meng et al., 1998).  This 
reduction in iNOS in CF is confirmed to be at the RNA level in epithelium 
(Zheng et al., 2004). In addition, using FABP mice, the iNOS reduction appears 
to be site specific (iNOS levels low where CFTR is not expressed in nasal 
epithelium, but higher in the gut where CFTR was expressed (Steagall et al., 
2000, Widdicombe, 2000, Zheng et al., 2003).  This important finding suggests 
that products of iNOS could be low in CF and that it may be useful to report on 
success of CFTR GT.  
• Additionally, NO is released from glutathione nitrated products (s-nitrosothiols). 
The majority of NO released from the airway (70-90%) is as a product of s- 
nitrosothiol release (Stamler et al., 1992). Importantly glutathione is low in the 
adult CF airway (Roum et al., 1993, Zaman et al., 2001) and cell line studies 
suggest it may be secreted through the CFTR channel (Kogan et al., 2003). 
1.6.2.3 Lipid mediators 
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The predominant lipid mediators available are those involved in the arachidonic acid 
pathways generating leukotrienes and prostaglandins (Baraldi et al., 2003, Montuschi 
and Barnes, 2002a). 
1.6.2.4 Ions 
Ion changes are potentially interesting as changes in Na+, Cl-, K+, pH and ammonium 
may reflect the basic CFTR function defect, changes in acid/base status or changes in 
capillary leakiness due to inflammation.  
1.6.2.5 Proteins 
Many proteins are involved in the inflammatory response.  These fall into two general 
categories – the chemokines/cytokines e.g. interleukins and the killing/defence proteins 
e.g. elastase and defensins. 
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1.6.3 Proteomics and Novel Protein discovery 
The biomarkers dicussed previously are known and have been used to investigate 
inflammatory diseases in previous studies.  An alternative approach is to attempt to 
discover novel biomarkers of disease.  Proteomics methodologies could be applied for 
this purpose. 
Proteomics is the genome wide study of proteins.  The completion of the working draft 
of the human genome sequence signalled the key point in the evolution of the field of 
proteomics (Lander et al., 2001).  Since then, work on the predicted human proteome 
(identification of the protein “complement” of gene expression) has begun.  The 
proteome is much more complex than the corresponding genome as around 500,000 
proteins are generated from some 30,000 genes. Most genes are subject to differential 
splicing which is cell type specific.  After translation, the majority of proteins are then 
modified e.g. by glycosylation, phosphorylation and cleavage. The correlation between 
mRNA expression and protein function is consequently weak.   
Differences in protein expression between diseased and healthy subjects may vary 
greatly.  The human proteome is a highly complex and dynamic protein network and is 
generated from a static genomic blueprint. The field of study has evolved in two ways. 
Gel electrophoresis techniques have been established for many years (the first available 
reference investigating human samples was in 1968 (Cudny and Wald, 1968), and more 
recently very sensitive Mass Spectrometry techniques have been established.  These 
techniques offer highly sensitive detection of proteins, and when coupled to gel 
electrophoresis techniques and human proteomic databases, we can identify the majority 
of proteins of interest. 
Characterisation of the Human Proteome has just begun, with the focus on serum, 
plasma and liver samples initially.  There are large-scale collaborative plans to complete 
study of the proteome of all biological fluids. There are no immediate plans to 
investigate the Airway Surface Liquid. 
The investigation of the proteome of ASL in normal control subjects and in Cystic 
Fibrosis subjects is of interest as it is the ASL where CF lung disease is exhibited and 
proteins are the downstream product of gene regulation.  By investigating the proteome 
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of CF lung disease, we may find markers of inflammation, protein products of modifier 
genes as well as surrogate protein markers of CFTR function. 
As exhaled breath condensate is a dilute biological fluid, the nanogram sensitivity of gel 
electrophoresis may not be enough to detect protein biomarkers of CF lung disease.  A 
highly sensitive mass spectrometry technique is an alternative - Surface Enhanced Laser 
Desorption/Ionisation (SELDI).  This technique offers attomolar sensitivity, generating 
semi quantitative data with the advantage of removing interfering compounds such as 
salts and DNA.  Analytical software allows differential expression analysis and 
recognition of patterns of different proteins in each sample.  These techniques will be 
discussed further in Chapter 6. 
In this thesis, polyacrylamide gel electrophoresis and SELDI mass spectrometry are 
both applied in an attempt to detect and validate novel markers of inflammation in EBC 
and Induced Sputum.
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1.7 Introduction - Summary 
This introduction has outlined Cystic Fibrosis lung disease, its progression and the need 
for CF gene therapy.  For clinical trials of CF GT, biomarkers of CFTR function and of 
inflammation are needed to assess successful delivery.  Non-invasive sampling 
techniques such as EBC and Induced Sputum could report usefully on the inflammatory 
state of the CF airway and could potentially also report on surrogate markers of CFTR 
function. 
The work of this thesis will focus on the development and validation of such biomarkers 
for use in future gene therapy trials. 
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2.1 The Ideal Marker 
2.1.1 Hypothesis 
Markers of inflammation for Cystic Fibrosis Lung Disease are measurable in samples 
collected non-invasively, and can be developed into clinically useful assays. 
These assays would have the ability to reflect the level of 
1. Inflammation in the CF lungs  
2. CFTR function, in the context of gene transfer 
2.1.2 The Optimal Biological Sample 
2.1.2.1 The optimal biological sample would be 
1. Repeatable in each subject 
2. A sample the Airway Surface Liquid 
3. Non – invasive 
4. Well tolerated 
5. Simple to collect and to analyse 
2.1.3 The non-invasive samples assessed in this thesis were 
1. Exhaled Breath Condensate 
2. Induced Sputum 
Where possible these samples were compared to the “gold standard” ASL sampling 
technique – fibreoptic bronchoscopy and the collection of bronchoalveolar lavage fluid.  
Cellular analysis of the nasal epithelium was used to validate markers identified. 
Sampling constraints have meant that collection was limited for multiple reasons.  The 
simplest collection technique – exhaled breath condensate, was collected locally and 
assessed with the majority of assays (in adults at the Western General Hospital, 
Edinburgh). Collaboration with other research groups within and without the UK CF 
Gene Therapy Consortium yielded further samples particularly with regard to paediatric 
EBC samples from Dr Steve Cunningham (Royal Hospital for Sick Children Hospital, 
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Edinburgh) and bronchoalveolar lavage fluid (Dr Tom Hilliard, Brompton Hospital, 
London).  Induced sputum was collected locally in adults at the Western General 
Hospital, Edinburgh.  
2.1.4 The Ideal Biomarker 
The ideal marker would show clear separation between groups and be both repeatable 
and reproducible.  Such a marker would be both highly sensitive and specific for the 
disease being assessed. 
2.1.4.1 Rationale of biomarkers studied 
To find biomarkers, a dual approach was taken.  Firstly, established markers of lung 
inflammation were assessed to see if they were useful in assessing inflammation in the 
Cystic Fibrosis lung.  These markers were identified in the scientific press as being 
useful in assessment of inflammation in other respiratory diseases including COPD, 
asthma and bronchiectasis.  Secondly, an unbiased search for potential protein 
biomarkers using mass spectrometry was performed in the hope that novel markers of 
inflammation and of CFTR function could be identified.  
We anticipated that individual biomarkers might not meet all of the required criteria, but 
by combining a “battery” of the best markers, the general hypothesis would be proven 
and a practical multimarker assay developed. Combining different tests requires 
multivariate statistical analysis techniques, and these were applied where possible 
throughout the thesis. 
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2.1.5 Subjects 
The majority of patients recruited were adults attending the Adult Cystic Fibrosis 
Service in Edinburgh.  Children attending the Paediatric CF clinic were also recruited 
where possible.  Control subjects were recruited from staff at the Adult Centre and 
children attending the fracture clinic in the Paediatric Centre.   
CF patients were assessed as “stable” (usual clinical condition, with no change in 
symptoms, lung function or sputum production) or “exacerbation” (combination of 3 or 
more of the following plus a clinical decision to treat with antibiotics. 
1. Increased cough. 
2. Increased sputum production. 
3. Increased breathlessness. 
4. Increased white count. 
5. Decreased lung function (FEV1). 
6. Reduced exercise tolerance. 
7. New pyrexia. 
Written informed consent was obtained from Adults in the study and from the parents of 
children recruited.  Verbal consent was obtained from each child.  All studies were 
approved by the Lothian NHS Research Ethics Committee. 
The subjects were recruited over a three-year period. Due to the limitations of small 
sample volumes of EBC, it was not possible to perform multiple assays in each 
individual sample.  Most assays were validated initially with adult control samples, then 
adult CF samples and for the most robust assays samples from children were also used.  
An advantage of using both adult’s and children’s samples is that as CF lung 
inflammation is progressive, the levels of inflammation are more severe in the adult 
population.  By comparing children’s samples with adult samples, we could gain more 
information about how the potential markers may relate to the development of lung 
disease.
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2.2 Sample collection techniques 
2.2.1 Exhaled Breath Gas analysis 
Exhaled Breath Gas sampling techniques to assay exhaled carbon monoxide (CO) and 
nitric oxide (NO) have been established and validated.  The techniques used in this 
thesis are as published in Thorax by my predecessor in the unit, Dr Ling Pei Ho (Ho et 
al., 1998a). A Logan Sinclair Research (Model LR2000; Logan Research, Rochester, 
UK) NO and CO analyser was used.  It contains a combination of an electrochemical 
cell and chemiluminescence sensors.  Subjects were asked to exhale through a 
mouthpiece, at expiratory flow rate of 50 ml per second for one complete breath (vital 
capacity).  The plateau value read at the end of expiration was taken and the procedure 
was performed in triplicate and the mean +/- SD of the three values was used. 
2.2.2 Exhaled Breath Condensate collection 
2.2.2.1 Introduction 
Exhaled Breath Condensate research is an evolving field and established and validated 
methods for collection at time of this research had not been published.  Since the period 
of research was completed guidelines have been published jointly by the European 
Respiratory Society and the American Thoracic Society (Horvath et al., 2005).  These 
guidelines represent a consensus view on optimal collection techniques, and are the 
same as used in this thesis. As yet, EBC is being used primarily as a research tool and 
has not been established in the clinical management of patients.  It is hoped that in the 
future EBC sampling and the use of established assays would be used in clinical 
practice.  Therefore, robust and repeatable sampling methods need to be established. 
Exhaled breath condensate could conceivably contain compounds from anywhere in the 
respiratory tract from the mouth to the alveoli.  There is a large water component, as 
evidenced by the low concentration of molecules assayed compared to serum, and also 
potentially dissolved volatile compounds and microdroplets of airway surface liquid. 
Components of EBC which may be useful for biomarker analysis are:- 
• Dissolved volatile compounds from the respiratory tract 
• Microdroplets of Airway Surface Lining Fluid 
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2.2.3EBC Collection Devices 
2.2.3.1 EBC Collection technique 
The exhalation of the different components may vary with respiratory maneuvers 
particularly with changes in respiratory flow rate.  As the concentration of “solutes” in 
EBC is undoubtedly low, any techniques to increase microdroplet concentration would 
be useful.  
2.2.3.2 Variables affecting EBC solute concentration 
Exhaled breath condensate is collected by exhaling over a cooled surface.  The potential 
variables in design of EBC collection device are of 
1. Variation in condensing surface area. 
2. Variation in condensing surface temperature. 
3. Variation in condensing surface chemistry. 
4. Alteration in respiratory pattern of exhalation. 
• Respiratory flow 
• Respiratory volume (i.e. minute ventilation) 
2.2.3.3 Exhaled Breath Condensate – Methods 
Two techniques were used for collection of EBC.  The first, using PFA tubing in ice 
was used at commencement of this work, and later a commercially available system, 
Ecoscreen from Jaeger-Toennies (Jaeger-Toennies, Germany) was used.
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2.2.3.4 PFA tubing Sample Collection technique 
Perfluoroalkane (PFA) tubing was submerged in ice at approximately -4oC.  Tubing 
dimensions were 4mm diameter, 1.5m long.  The narrow bore of the tubing was chosen 
to facilitate closure of the soft palate, reducing nasopharyngeal contamination of EBC. 
The tubing was cooled for at least 15 minutes in the ice, before use.  Patients were asked 
to rinse their mouths with tap water and then asked to exhale through the tube for 
approximately 5 minutes (figure 10).  The sample was collected into a Universal 
container at the other end of the tube. After 5 minutes of exhalation through the tube, 
approximately 1 ml of Exhaled Breath Condensate (EBC) was collected. 
2.2.3.4.1 Disinfecting Teflon Perfluoroalkoxy (PFA)  Tube 
Some of the biomarkers of interest were products of reactive species generated by the 
respiratory burst.  The disinfection agents used to clean EBC collection equipment 
contain reactive species such as reactive chlorine and reactive oxygen species.  
Therefore, it was important to remove the disinfecting agents thoroughly after they have 
contacted the equipment, to avoid false oxidation and nitration of EBC samples. 
The technique used Virkon, a chlorine based disinfecting solution (Antec, USA).  PFA 
tubing was submerged for 30 minutes, then flushed through with warm tap water for 10 
minutes and finally flushed with distilled water.  For drying, high flow oxygen was 
piped through the tubing to flush out any water.  Both ends of the tubing were capped 
with parafilm to reduce contamination before use.
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Figure 10. PFA tubing apparatus 
The PFA tubing was submerged in ice and the exhaled breath condensate was collected 
into a polypropylene pot. 
 
Figure 11. Patient using PFA tubing apparatus. 
This figure demonstrates a patient exhaling through the PFA tubing apparatus.
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
 Chapter 2 – Sample collection and preparation 73 
2.2.4 Jaeger Toennies Ecoscreen EBC collection device 
A commercially available collection device, the Ecoscreen (Jaeger-Toennies, Germany) 
was investigated when it became commercially available in 2001. 
Using a system of valves, patients are able to exhaled through a metal condensing 
chamber kept at -20oC.  The valve system allows the patient to breath tidally without 
having to remove their mouth from the mouth piece. 
2.2.4.1 Jaeger Sample Collection Technique  
This system comprises a mouthpiece and valve system attached to a cooled metal alloy 
sleeve.  A polypropylene pot collects EBC, and a saliva trap collects saliva to prevent 
contamination of the EBC (Figure 11, 12 and 13).   
The mouthpiece/valve manifold was inserted into cooling unit and allowed to chill for a 
minimum of 15 minutes.  Patients were asked to rinse their mouths with water and then 
use nose clips.  Patients were then asked to breathe “normally” through the mouthpiece 
for 5 minutes i.e. tidal breathing.  Once sample collection was complete, the metal 
condensing chamber and polypropylene pot were spun for 30 seconds at 2000rpm to 
miminise sample loss in the alloy sleeve.  The sample was then transported on ice to the 
laboratory for analysis and/or storage.  
2.2.4.2 Disinfection of the Jaeger Ecoscreen collection device 
Removal of disinfection agents was performed by flushing with water afterwards.  The 
technique used was to use a dilute Virkon solution.  The mouthpiece and collecting 
system was then soaked for 20 mins before rinsing with warm water tap and flushed for 
2 hours.  Afterwards the entire system was flushed with distilled water, air dried and 
then stored in a clean sealable bag until use. 
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Figure 12. Diagrammatic representation of cooling system from Jaeger device. 
The direction of exhaled breath through the breathing tube is indicated. It is cooled on 
metal alloy (shaded black).  As a result of cooling, the exhaled breath condenses and is 
collected in a polypropylene container (shaded grey). 
 
Figure 12. Jaeger Mouthpiece and EBC collection chamber and subject breathing 
through device. 
 
Subject breathing through Jaeger collection device.  Note noseclips are used and subject 
is breathing tidally.
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2.2.5 Which sampling technique to use 
When the Jaeger EcoScreen was initially used on CF subjects, it was clear that they 
preferred breathing tidally to the Teflon tubing (forced exhalation) method and 
commented that it was far less tiring. 
As we were primarily interested in collecting microdroplets of ASL, we compared the 
EcoScreen with the Teflon tubing method (in healthy control subjects) and found that 
total protein concentrations using the EcoScreen were reproducible, and within a tight 
range (0.5 – 25.5micrograms/ml).  We found the majority of sample collected using the 
Teflon tubing to be below the level of detection of the assay (0.5micrograms/ml) and no 
sample gave a figure as high as the median EcoScreen level of total protein.  Therefore, 
we chose to use the EcoScreen due to patient preference and enhanced detection of ASL 
microdroplets. 
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2.3 Induced Sputum Collection 
The technique of collecting of Induced Sputum has been established and validated (Pin 
et al., 1992, Pizzichini et al., 1996).  I am grateful to Deborah Parker and Ian Pavord of 
the Department of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, 
Leicester for teaching me the clinical and laboratory techniques required for induced 
sputum collection and analysis. These techniques are derived from those used in the 
clinic at Glenfield hospital. 
2.3.1 Induced sputum collection technique 
The nebuliser used was a Devilbiss Ultra-Neb large volume ultrasonic nebuliser 
(Devilbiss, USA) and the nebuliser solution used was 3% (hypertonic) saline (Tayside 
Pharmaceuticals, UK). 
Initially a saliva sample was collected into a “universal” container. Baseline spirometry 
was recorded – FEV1  and FVC.  Then 5mg of Salbutamol was administered.  
Spirometry was then repeated. 
Patients were asked to blow their nose and rinse their mouth with water before 
proceeding with the 3% saline inhalation.  Patients were requested to breathe normally 
with the nebuliser mask in place.  Any secretions coughed were collected into a sterile 
container, labelled for each inhalation period.  At the end of each inhalation – 4 minutes, 
patients were instructed to blow their nose and rinse their mouth with water, and then be 
encouraged to cough to produce sputum.  Then FEV1was again recorded. If FEV1 fell 
by > 20% post nebulisation then the sputum induction process was discontinued.  The 
inhalations were repeated 3 times to a total of 12 minutes. The collected sample was 
then processed within 2 hours of collection. 
2.3.2 Induced Sputum Processing 
The mucus plugs were separated from saliva by applying the induced sputum to a Petri 
dish which was then rotated to separate saliva from the mucus plugs.  Then the plugs 
were removed using curved forceps and transferred to another Petri dish and mixed 
using curved forceps. 
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Mucus plugs were reduced using DTT by transferring the plugs to a preweighed 10 ml 
falcon tube.  0.1% DTT was added, vortexed for 15 seconds and then mixed on a 
sample rotator for 15 minutes.  The fluid volume was doubled with Dulbeccos PBS. 
The sample was filtered through pre-wetted nylon gauze (45µm). To separate the 
cellular and soluble components, the sample was centrifuged at 800g for 10 minutes 
(4oC). The supernatant was aspirated and stored at – 80oC until further analysis. 
The cell pellet was resuspended to approximately 1x 10 4cells/ml.  Cytospins were 
prepared (400 rpm for 5 minutes), and slides were fixed using methanol for 10 minutes.  
Haematoxylin and eosin staining for 10 minutes was performed at a later stage to assess 
differential cell counts.
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
 Chapter 2 – Sample collection and preparation 78 
2.4 Bronchoalveolar Lavage fluid collection 
Bronchoalveolar lavage fluid was kindly supplied by Dr Tom Hilliard of the Royal 
Brompton Hospital as part of the UKGTC collaboration. 
2.4.1 Subjects 
Children, in whom, bronchoscopy was being performed for clinical reasons were 
recruited.  BAL was performed in 34 children with CF and 30 non-CF children.  
Samples were collected from patients undergoing bronchoscopy as part of their routine 
respiratory care.  Therefore the majority of the non-CF group had inflammatory lung 
conditions.  The majority of subjects had recurrent lower respiratory tract infection (18) 
or primary ciliary Dyskinesia (6). Two subjects had cardiac disease, one under 
investigation for haemoptysis and one had left lower lobe bronchiectasis. 
Ethical approval for these studies was granted by Royal Brompton & Harefield NHS 
Trust and National Heart and Lung Institute Ethics Committee, and the Riverside 
Research Ethics Committee. 
2.4.2 BAL processing technique 
Bronchoscopy was performed under general anaesthesia.  The fibreoptic bronchoscope 
was wedged in the middle lobe.  8 x 30ml aliquots of 37oC normal saline were instilled 
and then immediately aspirated.  The aspirated (lavage) sample was put onto ice.  The 
sample was filtered through gauze to remove debris.  The cells were spun off (10 mins 
at 4oC – 1000 rpm).  The supernatant was stored at -80oC in polypropylene eppendorfs. 
2.4.3 BAL TCA precipitation technique for 2D gels 
For polyacrylamide gel electrophoresis, it was necessary to remove interfering 
compounds such as salts from the sample.  Trichloroacetic acid precipitation was used 
for this.  One ml of BAL fluid was added to an eppendorf.  30% trichloroacetic acid 
(TCA) in acetone containing 60mM DTT was added and left at room temperature for 1 
hour.  The sample was spun at 13000rpm for 15 minutes.  The supernatant was 
discarded and the remaining pellet with cold acetone containing 20 mM DTT.  Again 
the sample was spun at 13000 rpm for 5 minutes and washed with acetone/DTT 
(repeated twice).  The sample was air dried - by incubating at 37 oC for 10 minutes.  The 
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sample pellet was resuspended by adding a small aliquot of ultrapure water and SDS 
sample buffer.
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2.5 Freeze Drying 
Freeze drying was necessary in various part of the thesis due to low concentrations of 
solutes in EBC.  Freeze-drying is the process of removing water from frozen material 
through sublimation.  Ice sublimates directly to vapour when the pressure is lower than 
6.11 mbars.  We used a Christ Alpha (Christ, Germany) freeze dryer that operates under 
partial vacuum up to 0.25 mbars.  This gives a miminum drying temperature of -34oC. 
2.5.1 Pre-freezing 
Pre-freezing of samples is necessary as the freeze drying technique rapidly cools the 
sample to – 30oC and causes a vacuum within seconds. If the sample is not pre-frozen, 
trapped oxygen in the sample expands in the vacuum, causing the sample to bubble and 
spill.  When samples are pre-frozen (30 minutes in -80 oC freezer or 10 minutes in a dry 
ice/ethanol bath at atmospheric pressure), no loss of sample occurs.  
2.5.2 Freeze Drying Pressure 
As EBC is predominately water, its eutectic (freezing) point should be 0oC.  The 
minimum temperature for drying is 10oC below the eutectic temperature, to avoid the 
sample melting and evaporating.  The sample temperature is controlled by the vacuum.  
Therefore, the drying vacuum used was 2.560 mbars giving a drying temperature of -
10oC. 
2.5.3 Main Drying 
Once the freeze drier reaches the appropriate temperature and pressure, the sample 
begins drying.  This removes the majority of the water.  It takes approximately 4 hours 
to dry the sample.  Then the pressure is reduced for final drying to remove any 
remaining cristallic bound water for a further 30 minutes. 
2.5.4 Freeze Drying Technique 
The samples were checked every four hours until freeze drying was complete. 
2.5.5 Calculation of percentage of sample reconstituted 
Once the sample had been freeze-dried, very small quantities of powder were visible 
along the side and bottom of the well. 
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For assay purposes, the dry powder sample needs to be reconstituted in either ultrapure 
water or an assay specific buffer. For EBC analysis, samples were freeze dried from 
1ml and reconstituted using 10µL of appropriate sample buffer.  Reconstitution of such 
small volumes is difficult as some of the dry powder sample may fail to resolubilise 
back into solution. 
2.5.6 Validation of Freeze Dying/Reconstituting as applied to EBC and Nitrite 
40 mls of exhaled breath condensate was collected, by prolonged sampling using the 
Jaeger EBC system, from 3 healthy control subjects.  This EBC was pooled and spiked 
with sodium nitrite at a known concentration (10µM). The spiked breath condensate 
was freeze dried in 40x 1ml aliquots and reconstituted in 100µL of ultrapure water.  
From the 40 samples processed, a return of 88% (range 86-91%) was achieved with 
nitrite. 
Sample recovery was at a high level (88%) and is likely to represent the high water 
solubility of sodium nitrite as this is an ion.  It should be considered that reconstitution 
of other compounds which are not as highly soluble such as proteins may not give as 
high a percentage of recovery and therefore losses in the reconsitiution process should 
be anticipated to be higher than with sodium nitrite.
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2.6 Statistical Analysis 
2.6.1 Sigma Stat 2.03 and Sigma Plot 2001 (SPSS) 
These statistical software packages allow analysis of data using standard statistical 
testing methods.  As the majority of data generated were non-parametric, the statistical 
test used was Mann Whitney Rank Sum with Bonferroni correction for multiple 
analyses.  Correlation coefficients were calculated using Pearson’s correlation 
coefficient.  Sigma stat was used to calculate linear regression equations and Microsoft 
Excel used to extrapolate such data.  Graphical representation of the data was generated 
as box plots using sigma plot (Figure 15). 
Data were expressed as median and as an interquartile range (IQR) i.e. 25th and 75th 
quartiles. 
The further statistical software to analyse SELDI data will be discussed in chapter 6.
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Figure 15. Box plot representation of data. 
The majority of data generated in the studies were non-parametric. Therefore box plots 
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2.7 Bioinformatics tools used 
2.7.1 Laboratory Protocols Online 
This laboratory reference website is a reference tool to search for laboratory protocols. 
http://www.protocol-online.org/ 
2.7.2 NCBI (National Centre for Biotechnology Information). 
This website (http://www.ncbi.nlm.nih.gov/Entrez) was used to access many databases, 
particularly Pub Med. http://www.ncbi.nlm.nih.gov/Entrez 
2.7.3 SWISS PROT and TrEMBL 
Swiss-Prot is a “protein knowledgebase”and TrEMBL is a computer-annotated 
supplement to Swiss-Prot.  This searchable database offers multiple proteomics tools on 
one website.  It offers the proteomics sequences derived from the human genome 
project (along with other taxonomies). http://us.expasy.org/sprot/ 
2.7.4 ProFound 
The Rockefeller University Profound website contains a powerful search engine to 
assist with identification of proteins from the mass of their peptide digested fragments - 
http://129.85.19.192/prowl-cgi/ProFound.exe 
2.7.5 MASCOT 
This database was used to confirm the identity proteins from MALDI sequences 
generated by fragmented peptides. 
http://www.matrixscience.com/search_form_select.html 
2.7.6 Association of Biomolecular Research Facilities - Delta Mass Database 
This website contains a concise database of posttranslational modifications and the mass 
shift effect they have on proteins. 
http://www.abrf.org/index.cfm/dm.home?AvgMass=all  
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2.8 Assay Techniques – Chapters 3 - 6 
Many of the assays applied in this thesis have been used and validated by others using 
samples such as plasma and serum. 
Exhaled Breath Condensate is a dilute biological fluid when compared to serum and 
therefore assays need to be suitably sensitive to measure the compounds of interest. 
As the assay techniques applied are varied, the methodology, results and discussion for 
each assay techniques have been combined and are detailed in the following chapters. 
Chemical assays         Chapter 3 
• CO and NO 
• Nitrite and Total Protein 
Enzyme Immunoassays      Chapter 4 
• ELISA – Interleukin 8 
• EIA – Leukotrienes, Isoprostane and Nitrotyrosine 
Ion analysis        Chapter 5 
• pH  
• Ion selective electrodes – Ammonium, Na+, Cl- and K+ 
Proteomic analysis        Chapter 6 
• Polyacrylamide Gel Electrophoresis 
• Surface Enhanced Laser Desorption/Ionization
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3.0 – Chemical Assay Techniques 
3.1 Chemical assays 
The chemical assays applied in this thesis are used to quantify the exhaled gases carbon 
monoxide and nitric oxide, the ion nitrite and total protein. 
 
3.1.0 Exhaled Carbon Monoxide 
3.1.1 Rationale 
Exhaled carbon monoxide has been proposed as a marker of oxidative stress.  The 
expression of the enzyme haemoxygenase can be induced by oxidative stress and as CO 
generation reflects haemoxygenase activity (Horvath et al., 2001), it may be used as a 
surrogate marker of oxidative stress activity in the lung.  Haemoxygenase is the enzyme 
which catabolises haemoglobin (biliverdin) to bilirubin, releasing CO and iron in the 
process. 
This marker has been established as being raised in stable Cystic Fibrosis subjects 
(Paredi et al., 1999). It has been shown to be raised further during infective exacerbation 
(Antuni et al., 2000). 
3.1.2 Methods 
A Logan Sinclair Research NO and CO analyser was used.  It contains a combination of 
an electrochemical cell and chemiluminescence sensors, with the electrochemical cell 
measuring CO levels.  Subjects were asked to exhale through a mouthpiece, at 
expiratory flow rate of 50 ml per second for one complete breath (vital capacity).  Three 
replicates were performed in each subject and the average was used. 
Subjects 
The subjects included in this study were 15 healthy control subjects (adults) and 30 
stable CF adults. 
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3.1.3 Results 
There was no difference in CO between stable CF subjects (n=30, Median 4.2 (IQR 4.0-
5.2) and non-CF subjects (n=15, Median 4.0 (IQR 3.5-6.1) p=0.754.  See Figure 16. 
3.1.4 Discussion 
Exhaled CO is not different between stable CF subjects and non-CF subjects.  
Therefore, eCO cannot be used to discriminate between CF and non-CF individuals.  
Because of this, its role for gene therapy trials would be limited to reporting on 
significant toxicity. 
It is not clear why these results were different from those previously reported. The 
median was similar to previously reported (Antuni et al., 2000, Paredi et al., 1999), but 
the range of data in this study was wider, particularly in the control group. One factor 
that could confound the study is that eCO is raised in smokers, therefore we were 
dependant on the study subjects reporting honestly about smoking habit.  All subjects 
recruited denied smoking.  However, two of the control subjects and one of the CF 
subjects had an eCO >10ppm, which was higher than would be anticipated in any non-
smoker.
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Figure 16. Exhaled CO levels in controls and CF. 
Box plot of data in adults. Exhaled CO levels are not different between control and CF 
subjects.
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3.2 Nitric Oxide 
3.2.1 Rationale 
Nitric Oxide is a gaseous product of nitrative stress. Its production could reflect reactive 
oxygen species generated in the tissues, inducible nitric oxide synthetase (NOS 2) 
activity (induced by proinflammatory cytokines and potentially by CFTR) or by release 
from glutathione nitrated products (s-nitrosothiols).  
It is exhaled in the gas phase and therefore can be measured in exhaled breath.  It has 
been shown to be no different between CF subjects than controls (Ho et al., 1998a, Ho 
et al., 2000). Indeed, some studies investigating children with CF have suggested than 
NO levels are lower in CF individuals, in particular of exhaled breath (Balfour-Lynn et 
al., 1996, Elphick et al., 2001, Grasemann et al., 1997) and nasal air (Dotsch et al., 
1996). 
3.2.2 Methods 
As with eCO measurements, a Logan Sinclair Research NO and CO analyser was used, 
utilising the chemiluminescence analyser.  Again, subjects were asked to exhale through 
a mouthpiece, at expiratory flow rate of 50 ml per second for one complete breath (vital 
capacity). 
Subjects 
The subjects included in this study were 15 healthy control subjects (adults) and 30 
stable CF adults. 
3.2.3 Results 
Exhaled Nitric Oxide was not different between stable CF subjects (n=30, Median 
2.1(IQR 1.8-3.4)) and controls (n=15, Median 2.7 (IQR 2.0-4.6)) p=0.214. The median 
CF level is lower than in the control group, at just above the 25th quartile of the control 
group (see Figure 17). 
3.2.4 Discussion 
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There is no significant difference between the control and CF group data.  Due to the 
level of inflammation in the CF subjects airways, even when stable, it would have been 
anticipated that they would have higher than normal levels of eNO.   
The median exhaled NO was lower in Stable CF subjects than controls. These data are 
consistent with previous reports of lower NO measurements in Cystic Fibrosis children.  
The difference was not significant in adults due to the wider range of spread of data are 
seen in adult subjects.   
In CF lung disease, the low median NO could be explained by the three following 
mechanisms. 
1. iNOS production and activity is reduced in CF,  via the Signal Transducers and 
Activators of Transcription pathway (STAT).  A direct link between between 
iNOS and CFTR expression has been shown in cell line and mouse studies 
(Steagall et al., 2000, Zheng et al., 2004). In this study, levels of iNOS reflected 
CFTR activity in CFTR null and wild type mice.  Where tissue specific 
promoters of CFTR were used (FABP),  iNOS levels were normal in that tissue 
(intestinal tract).  This raises the prospect that successful CFTR gene transfer 
may cause a rise in iNOS and eNO levels. 
2. The majority of NO is released from s-nitrosothiols. BAL from adults with CF 
have demonstrated lower glutathione levels than control subjects (Roum et al., 
1993).  Whether this is a direct consequence of the CF mutation or due to 
infection and inflammation cannot be ascertained but it has been postulated that 
CFTR may enhance glutathione efflux.. 
3. eNO can be consumed by denitrifiying bacteria, present in the airways of Cystic 
Fibrosis subjects.  Pseudomonas aureginosa can metabolise nitric oxide through 
assimilatory and dissimilatory pathways (Gaston et al., 2002). 
Although eNO in stable CF is not different from control subjects, the marker could still 
be useful in gene therapy trials as the levels could rise due to successful CFTR GT.  
Successful CFTR expression could cause an increase in iNOS expression and an 
increase in CFTR enhanced glutathione levels generating greater quantities on eNO.
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Figure 17. Exhaled NO levels in controls and CF stable subjects. 
eNO levels were not different between control and CF subjects.  The median eNO in the 
CF subjects can be seen to be lower than control subjects - at 25th quartile level of 
control subjects.
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3.3 Nitrite 
3.3.1 Introduction 
Nitrite is a stable end product of NO metabolism (van der Vliet et al., 1999). This end 
product has previously been shown to be raised in CF (Ho et al., 1998b) and in CF 
children (Cunningham et al., 2000), and has been confirmed as being raised in patients 
with severe asthma, cystic fibrosis and COPD, but not in smokers or patients with mild 
asthma (Corradi et al., 2001). 
3.3.2 Methods 
The reaction used to quantify Nitrite (and nitrate) is the Greiss reaction and this has 
previously been modified and validated for use in EBC analysis in CF subjects.  This 
protocol requires that the EBC sample be assayed as soon as possible after collection as 
decay in the nitrite signal has been reported to occur. 
The reagents used were 2% sulphanilamide in 4% orthophosphoric Acid and 0.2%-1-
Napthyl-ethylenediamide dihydrochloride (NED), Sodium Nitrite standard solution 
100mM.  A standard curve was generated - 0.00, 0.5, 1, 2, 4, 6, 8, 10µM, and run in 
triplicate.  Duplicate samples were used. 100µL of sample or standard was added per 
well.  The sulphanilamide solution and NED were mixed in a Petri dish, and 25µL 
added to all wells. The microtitre plate was then stored in the dark for 15 minutes before 
reading plate at 540nm in a Spectrophotometre microtitre plate reader.  Quantitative 
data were derived using sigma stat software and linear regression analysis.  
To determine whether nitrite assays could be performed on stored samples of CF 
Exhaled Breath Condensate – 200µl aliquots were assayed immediately using Greiss 
reaction and others frozen at –80oC and stored for 7 days before assaying. There was no 
difference between samples assayed immediately and after 7 days (n=6, p=0.899).   
Subjects 
The subjects included in this study were 33 healthy control subjects (adults) and 29 
stable CF adults. 
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3.3.3 Results - Nitrite 
We found no difference in nitrite between stable CF adults (n=29, Median 3.43 (IQR 
2.58-5.00)) and control subjects (n=33, Median 3.80 (IQR 2.00-5.59)), p=0.911.  See 
Figure 18. 
3.3.4 Discussion 
There was no difference in nitrite between CF and control subjects.  This result differs 
from previous published data which was generated using the same analysis techniques 
(greiss reaction) (Ho et al., 1998b).  The only methodological difference was that our 
sampling technique used the Jaeger EcoScreen and tidal breathing rather than forced 
exhalations via PFA tubing.  This may have influenced the outcome. 
As nitrite is a stable end product of eNO metabolism, these nitrite data support the 
previous eNO data.  The argument that successful CFTR gene therapy transfer could 
cause a rise in eNO levels therefore also applies to nitrite.  The possible reasons are via 
reduced iNOS expression, reduced glutathione efflux or increase metabolism by 
Pseudomonas aeruginosa.  As with eNO, successful correction of CFTR by gene 
therapy could lead to a rise in nitrite by inducing iNOS expression or by increasing 
glutathione efflux.  As it is a simple and easy marker to measure, it should be included 
in the battery of non-invasive tests performed in GT trials.
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 3 – Chemical assay techniques 95 
 
Figure 18. EBC Nitrite levels in controls and CF stable subjects. 
EBC Nitrite levels are not different between control subjects and stable CF subjects.
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3.4 Total Protein 
3.4.0 Quantification of EBC protein concentration using bicinchoninic acid assay 
3.4.1 Introduction  
Total protein of EBC has been proposed as a reporter of inflammation as it was found to 
be raised in smokers compared to non smokers (Garey et al., 2004).  
CF inflammation leads to an inflammatory infiltrate into the ASL, as well as capillary 
leak of serum proteins through loosening of the tight junctions between epithelial cells.  
These pathophysiological processes could lead to an increase in ASL (and therefore 
EBC) total protein concentrations. 
Total Protein has also has been proposed as an internal standard against which other 
markers could be compared (Effros et al., 2002).  This would allow interpretation of 
results, by correcting for variation in the number of microdroplets of ASL collected. 
3.4.2 Methods  
Previous publications in analysis of EBC have used the Pierce BCA assay to quantify 
Total Protein concentration (Effros et al., 2002). Using EBC collected from CF and Non 
CF subjects, the limit of detection of this assay was just above the levels in EBC 
(5µg/ml).  Therefore, the microBCA technique was used to quantify proteins in this 
work as this was 10 fold more sensitive (lower limit of detection 0.5µg/ml). 
The bicinchoninic acid (BCA) assay relies on the reaction of the peptide bonds between 
amino acids and copper.  The reduction of copper leads to the formation of a purple 
complex with BCA.  The microtitre plate assay was read on a spectrophotometer at 
540nm. Interfering compounds can affect this assay (including H2O2, ascorbic acid, uric 
acid, lipids, and iron and reducing sugars). 
A linear standard curve was generated from 0.5 to 200µg/ml using bovine serum 
albumin in ultrapure water, r=0.999.  The reaction requires 150µL of EBC sample and 
is incubated for 2 hours in the BCA solution. 
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 3 – Chemical assay techniques 97 
The standard curve also generated in acidified solutions at pH 4,5 and 7 (using 
hydrochloric acid) to ensure that differences in EBC pH would not have any effect on 
total protein detection (no pH effect was found). 
Subjects 
The subjects included in this study were 11 healthy control subjects (adults) and 9 stable 
CF adults. 
 
3.4.3 Results  
Total Protein (µg/ml) was raised in CF subjects (n=9, Median 16.15 (12.78-20.95)), 
compared to controls (n=11, Median 3.07 (11.08-13.40)), p=0.027. See Figure 19. 
3.4.4 Discussion 
Total protein was raised in CF subjects and therefore could be used as an end-point in 
future gene therapy trials. 
The total protein concentrations detected in this study were within the wider range 
quoted in previous publications (Ballard et al., 1999, Effros et al., 2002, Scheideler et 
al., 1993, Simpson et al., 2005).  The range of total protein in our sample group was 
narrower, but the reasons for this are not clear.  One possibility is that our sampling 
technique to collect EBC reduced intersubject variation by using the Jaeger EcoScreen 
system using tidal breathing was used rather than using forced exhalations as with the 
PFA tubing technique. 
The reason why total protein concentration is raised in CF subjects is not evident, but 
may reflect either a marked rise a single protein or an rise in multiple proteins.  
Presumably these protein changes would be as a consequence of inflammation or CFTR 
dysfunction (or both).  Further analysis of the different proteins contained within EBC 
(the EBC proteome) was therefore warranted, as more sensitive and specific markers of 
CF lung disease could be identified.  The results of these studies are included in the 
proteomics chapter (Chapter 6). 
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Figure 19. EBC Total Protein levels in controls and CF stable subjects. 
EBC Protein levels are different between control subjects and stable CF subjects.  The 
median value in the CF subjects was higher than any of the control subjects.
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3.5 Chemical Assays - Discussion 
The exhaled gases did not prove to have the ability to discriminate between CF and Non 
CF subjects.  It could be argued that eCO should be included in a panel of markers as it 
could potentially report toxicity – due to increased oxidative stress.  However, the 
toxicity would have to be considerable to change group median data and therefore 
should not be used in future trials. 
The two nitritative stress markers, NO and nitrite were also not different between 
controls and CF subjects.  As CFTR function seems linked through iNOS regulation and 
also through glutathione transport, it may be that we should anticipate a rise in either 
NO or nitrite during CF gene therapy trials. Therefore either of these tests should be 
considered for use in future trials despite the lack supporting data in this thesis. 
Total protein was found to be raised in the EBC of CF subjects.  This interesting finding 
may reflect proinflammatory proteins in the CF airway or indeed direct markers of 
CFTR function.  These data led the direction of this thesis towards further assay of 
proteins.  A dual approach was used, using previously published cytokines and 
chemokines aswell as taking an unbiased proteomic approach to identify further 
biomarkers of CF lung disease.
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4.0 – EBC - Enzyme Immunoassay Techniques 
4.0.1 Enzyme Linked Immunosorbant Assay Techniques 
4.1 Proteins 
4.1.1 Interleukin 8 
Interleukin 8 is a potent cytokine responsible for neutrophil recruitment into the lung.  
As it is a proinflammatory chemokine, it may be a sensitive marker of the neutrophil 
influx of CF lung disease.  To this end, it would be of importance to assay interleukin 8 
using non-invasive techniques. IL-8 is produced in the lung predominately by 
macrophages, but also by epithelial cells, fibroblasts and stimulated monocytes.  
Bronchoalveolar lavage studies have focussed on interleukin 8 revealing that BAL IL8 
levels were 100 fold higher in CF infants when compared to non CF infants (Armstrong 
et al., 1995). Moreover, IL8 has been shown to be sensitive enough to detect an 
improvement after adenoassociated viral (aaV) gene therapy in BAL as levels fell 30 
days after delivery to humans.  This efficacy was lost after 30 days however, perhaps 
reflecting aaV neutralisation by antibodies (Moss et al., 2004).  It has previously been 
detected in EBC from subjects with CF (33% of subjects) using standard ELISA 
techniques (Cunningham et al., 2000), therefore efforts were made to improve 
sensitivity of detection. 
4.1.2 Methods 
As interleukin 8 release is an important proinflammatory pathway leading to neutrophil 
recruitment, a major component of the work of this thesis was on validating an assay for 
it. Interleukins 6, 10, 1β and TNF α were the other cytokines identified for investigation.  
For all five cytokines, an ultrasensitive Enzyme Linked Immunosorbant Assay (ELISA) 
was used.  These assays allow detection of very low quantities of compounds.  For IL 8, 
the ultrasensitive ELISA from Biosource (Biosource International, USA) is sensitive to 
0.39pg/ml in serum and cell culture supernatants.  Using this assay, combined with 10 
fold concentration by freeze drying techniques, it is theoretically possible to detect IL 8 
at the femptogram level (39 fg/ml). 
4.1.2.1 Biosource ultrasensitive ELISA – Interleukins 8, 6, 10, 1β and TNF α,  
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A kit based sandwich assay was used.  The antibody (e.g. to Human Interleukin 8) was 
coated to a microtitre plate.  A standard curve (in ultrapure water) using recombinant 
standard was generated (IL 8 - 0.39pg/ml to 25pg/ml).  Samples were added to wells on 
the same microtitre plate (100µl of sample).  The plate was then incubated at 37oC for 2 
hours to bind antibody to antigen.  Next, the plate was washed 4 times and a secondary 
biotinylated antibody added and incubated for 1 hour. The plate was again washed 4 
times. Next streptavidin-horseradish peroxidase was bound to the biotinylated antibody 
for 30 minutes and washed 4 times. This complex was detected by the addition of 
chromogen to generate a blue colour (15-45 minutes).  After stopping the reaction with 
hydrochloric acid, a yellow colour was generated, and the plate read in a 
spectrophotometer at 450nm.  Data were extrapolated using sigma stat to perform linear 
regression from the standard curve. 
4.1.2.1.1 Standard Curve diluents 
The recommended diluent for serum and cell line assays was the Biosource diluent 
buffer.  The contents of this diluent are not in the public domain but are likely to contain 
serum and detergents. Often cell line and serum samples require dilution to be in the 
middle of the detection range of the ELISA, and are diluted using the recommended 
diluent. EBC has a low protein concentration, cannot be diluted, and therefore the 
standard curve used for ELISAs was validated to ensure that appropriate extrapolation 
of data was performed. 
The data published on EBC interleukins have protein levels at (or below) the limit of 
detection of most ELISAs.  The methods with regard to standard curves were not stated 
in these publications (Bucchioni et al., 2003, Carpagnano et al., 2002a, Shahid et al., 
2002). 
4.1.2.1.2 Methods 
Pooled EBC from healthy volunteers collected using the Jaeger Ecoscreen was used for 
validation of the standard curve.  Biosource diluent and pooled EBC were compared by 
spiking with different concentrations of recombinant interleukin 6 and 8 (500, 250, 125, 
62.5, 31.2, 15.6 and 7.8 pg/ml) to yield a standard curve. See figure 20 and 21.  
4.1.2.1.3 Results 
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The figures show higher OD readings for any given quantity of interleukin 6 and 8 
when using Biosource diluent rather than EBC.  This means that when Biosource buffer 
is used to generate a standard curve, any extrapolated protein concentrations will be 
falsely low as EBC appears to have a negative effect on IL8 detection.  The effect is less 
marked with interleukin 6.  See  Figures 20 and 21.
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Figure 20. Interleukin 8 Standard curve with EBC and Biosource buffer as 
diluents. 
Lower OD readings were generated when EBC was used instead of biosource buffer, 
meaning than when EBC is used, samples compared to a standard curve in biosource 
buffer would give false high results.  
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Figure 21. Interleukin 6 Standard curve with EBC and Biosource diluent.  
The difference between OD reading using EBC and Biosource buffer were not as great, 
meaning that results compared to Biosurce buffer standard curve would be less 
inaccurate than with interleukin 8. 
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4.1.2.1.4 Discussion 
These data are important as they imply that using the recommended assay diluent will 
give false low levels of interleukin 6 and 8 in EBC.  The reason for this is that linear 
regression analysis will be performed on incorrect OD readings.  One reason the OD 
readings may be higher in the Biosource diluent group is that it is likely to contain 
protein and therefore there will be more non-specific binding. This would not be a 
problem for serum and cell lines as these are diluted in assay diluents and are at higher 
points on the curve, however EBC is not diluted as it would then be below the level of 
detection of the assay.  
The difference in OD readings was not so great with IL6, and therefore the importance 
of using an appropriate standard curve would seem to be less significant with IL6.  
Presumably the difference is due to the binding characteristics of the ELISA epitopes 
selected for the two assays, and differences in non-specific binding of these two 
epitopes.   
Errors in extrapolation from an inappropriate standard curve does not explain why some 
groups detected in interleukins in EBC (see 4.1.2.3.3 for explanation). and why these 
data have not been repeatable in our hands.  It also does not explain the significant 
difference between diseased and non diseased groups that other groups have found e.g. 
interleukin 4 and 6 raised in disease groups compared to controls (Bucchioni et al., 
2003, Carpagnano et al., 2002a, Shahid et al., 2002).  It is not clear therefore whether 
these data reflect a real difference in cytokine levels or if they reflect another difference 
e.g. non specific binding of other proteins.
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4.1.2.3 Attempts to identify an appropriate buffer. 
In an attempt to find a more suitable diluent compared to EBC, interleukin 8 was 
reconstituted into different buffers.  The different buffers may have different advantages 
as listed. 
The buffers tested were 
• Ultrapure H20 – Theoretically the most similar to EBC as EBC is reported to 
have very low ion concentrations. 
• 0.9% Na Cl – Physiological level of saline solution. The theoretical advantage of 
isotonic saline would be that protein folding of cytokines would be 
physiological, therefore potentially exposing the binding site which the ELISA 
monoclonal antibody was raised against. 
• PBS – may have the advantage of being appropriate buffer to allow protein 
refolding to expose appropriate epitope (in the same way as 0.9% Na Cl). 
• Biosource Buffer – Serum based buffer supplied with Interleukin 8 kit.  
Appearance would be in keeping with serum based buffer with added detergents, 
formulation not in public domain. 
• KPL Buffer – Commercially available buffer, formulation not in public domian. 
This buffer was clear rather than pink (biosource buffer) and therefore its colour 
would not have any effect on OD readings 
• EBC – Pooled EBC collected from healthy subjects for comparison 
4.1.2.3.1 Methods 
The above listed substances were compared as buffers by spiking with different 
concentrations of recombinant interleukin 8 (250, 125, 62.5, 31.2, 15.6, 7.8 and 3.75 
pg/ml) to create a standard curve. 
4.1.2.3.2 Results 
The buffers all gave different OD reading for any given quantity of interleukin 8.  
Biosource buffer was most similar to EBC, but all buffers used gave higher OD 
readings than EBC. (Figure 22) 
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Figure 22. Interleukin 8 with different diluents. 
EBC is seen to give the lowest OD reading for any given concentration of interleukin 8.
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4.1.2.3.3 Discussion 
These data show that assays of spiked interleukin 8 are less sensitive using EBC as the 
diluent than in any other buffer tested.  As the concentrations of cytokines in EBC are 
low, it is necessary to add larger volumes of EBC to an ELISA than necessary for more 
concentrated biological fluids e.g. serum or BAL.  EBC appears to have an inhibitory 
effect on ELISA detection as this experiment shows, and therefore it is vital that an 
appropriate standard curve is used.   
The explanation for EBC giving lower OD readings than other diluents could be due to 
interleukin 8 degradation by EBC,  IL8 epitopes for ELISA antibodies being masked by 
substances in EBC or that compounds in EBC interfere with the ELISA technique.  As 
multiple washing steps are in place after allowing 2 hours of initial binding of 
interleukin 8 in the sample to the well, it seems more likely that degradation of IL8 or 
inhibition of the binding process are the more relevant factors rather than non-specific 
binding (which should remove non-IL8 proteins).  
Importantly the difference in OD reading between EBC, biosource buffer and ultrapure 
water could potentially explain why other groups found detectable levels of interleukins 
which were not repeatable in our hands.  If the standard curve is generated in biosource 
buffer and EBC is lyophilised and resuspended in ultrapure water, any extrapolation 
from the standard curve will give a false high level of interleukin in the samples.  As 
lyophilisation and resuspension in water was the technique applied in other studies, this 
would be a potential explanation for other groups results (Edme et al., 2008, Bayley et 
al., 2008, Bodini et al., 2007, Sack et al., 2006, Carpagnano et al., 2003, Carpagnano et 
al., 2002b).  In addition this shift in OD reading would explain why all data generated in 
these studies are at the lower limit of detection of ELISAs. 
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4.1.3 Compounds to optimise ELISA signal  
These results suggest a detrimental of EBC effects on IL8 detection.  The postulated 
mechanisms were degradation of IL8, inhibition of binding of IL8 or non specific 
binding to IL8. The first two were addressed by addition of chemicals listed below and 
the later by adding protein in the form of bovine serum albumin. 
4.1.3.1 Compounds to prevent IL8 degradation. 
A number of different protease inhibitors and phosphatase inhibitors were added to 
EBC in an attempt to avoid degradation of Interleukins.  Previous work has shown that 
this strategy works for induced sputum, increasing the detection of interleukin 5 by at 
least 60 fold using an ELISA (Kelly et al., 2001). In cystic fibrosis sputum, there is an 
imbalance between protease and antiprotease activity, with a particular excess of 
neutrophil elastase and proteinase 3 (Witko-Sarsat et al., 1999).  Therefore, it is 
conceivable that there is unopposed protease activity in the EBC of CF subjects. 
The following Protease inhibitors were tested – AEBSF, Aprotinin, Leupeptin, Bestatin, 
Pepstatin A, E- 64 and EDTA. 
The following Phosphatase Inhibitors were tested - Microcystin LR, Cantharidin, P-
bromotetramisole, Sodium Vanadate, Sodium Molybdate, Sodium Tartrate and 
Imidazole. 
As EBC has a very low protein and bicarbonate concentration, it has fewer biological 
buffers than serum or plasma (most ELISA kits are designed for Serum/Plasma). Two 
biological buffers were used in an attempt to improve IL8 detection. 
The buffers tested were  Bovine Serum Albumin and HEPES. 
4.1.3.1.1 Compounds to enhance binding by improving epitope exposure 
The sputum produced in CF has a relatively high quantity of DNA (Henke et al., 2007), 
this can bind to interleukin 8 and therefore may mask the epitope for binding to the 
antibody and microtitre plate.  Previous studies in sputum have shown that adding 
DNase can enhance the IL8 signal (Perks and Shute, 2000, Shah et al., 1996). 
Additionally, actin may bind and mask the IL8 epitope.  Gelsolin can be used to cleave 
actin and lead to increased epitope exposure (Perks and Shute, 2000). 
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The enzymes tested were DNase 1 and Gelsolin. 
4.1.3.1.2 Methods 
The above listed substances were compared by adding to standard curves with different 
concentrations of recombinant interleukin 8 (250, 125, 62.5, 31.2, 15.6, 7.8 and 3.75 
pg/ml).  The two buffers compared were EBC and ultrapure water to clarify whether 
there was any effect on EBC. Pooled EBC collected from healthy subjects was used to 
generate the EBC standard curve. 
4.1.3.1.3 Results of studies to optimise interleukin 8 assay 
Aprotinin and BSA caused increased OD readings.  PBS, EDTA and HEPES caused 
reduction in OD readings.  These changes were the same in both EBC and ultrapure 
water.  No other compounds listed above altered OD readings. 
4.1.3.1.4 Discussion 
No compound had a differential effect on OD readings in EBC.  As there was no 
difference between water and EBC, this implies that there is no benefit in using these 
chemical agents to improve detection i.e. any effects are on the assay rather than an 
effect on EBC. No method caused a reduction in IL8 degradation or improved binding 
of IL8. 
In support of non-specific binding to the ELISA well, the addition of the proteins 
aprotinin and BSA will give higher OD readings, an effect similar to that seen using 
Biosource buffer.   
4.1.4 Freeze Drying - with spiked samples 
When directly assaying patient samples for IL8 in EBC, all results are below the level 
of detection of the assay.  Freeze-drying allows concentration of the sample from 1ml to 
100µl – i.e. a 10-fold increase in concentration.   
4.1.4.1 Methods 
To assess detection of interleukin 8 after  freeze drying and after concentration, spiking 
experiments were performed.  Pooled EBC was collected from healthy volunteers.  
Recombinant interleukin 8 was added to freshly collected EBC to a concentration of 
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20pg/ml.  This was then split into 3 groups.  1 aliquot was frozen and assayed 24 hours 
later (frozen), 1 aliquot freeze dried and reconstituted in its original volume using 
ultrapure water and assayed 24 hours later (FD-original volume), and the third aliquot 
was freeze dried, reconstituted in 1/10th of its original volume using ultrapure water (10 
fold concentration) and assayed 24 hours later (FD-1/10th volume). 
4.1.4.2 Results 
From the 20pg/ml fresh spike, in the sample frozen and assayed 24 hours later, the 
median return was 0.789pg/ml (3 replicates, range 0.719 – 1.09).  In the samples which 
were freeze dried and then reconstituted back to their original volume the median return 
was 1.399pg/ml (10 replicates, range 1.384-1.431). The highest return was with freeze 
drying and reconstitution in 1/10th of original volume and the return was 3.49pg/ml (10 
replicates, range 3.38-3.49).  The maximum return from the 20pg/ml spike was less than 
3.82 pg/ml, which is only 19% of the original quantity of IL8 added to the EBC (figure 
23). 
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Figure 23. 20 pg spike of interleukin 8 in EBC, fresh sample, freeze dried sample 
and freeze dried and concentrated 10 fold sample. Data are expressed in pg/ml. 
Pooled EBC was collected and divided into 1ml aliquots.  20pg of recombinant 
interleukin 8 was added to each sample.  Then the samples were processed in three 
different ways:- 
1. Sample frozen immediately and thawed 24 hours later and then assayed (frozen). 
2. Sample freeze-dried immediately and then stored until assay 24 hours later then 
reconstituted in 1ml of ultrapure water i.e. to original volume (“FD 1X recons” 
in figure). 
3. Sample freeze-dried immediately and then stored until assay 24 hours later then 
reconstituted in 100µl of ultrapure water i.e. 1/10th of original volume (“FD and 
10X conc” in figure). 
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4.1.4.3 Discussion 
The highest return on the original 20pg of recombinant interleukin 8 was less than 20% 
when using the freeze drying and concentrating method.  This technique did show good 
reproducibility between samples (n=10), however return was poor. Therefore, 
recombinant interleukin 8 does not appear to be stable in EBC despite freeze drying 
techniques, although some improvement in detection was made.  Methods to try to 
reduce interleukin 8 degradation, unmask IL8 epitope and remove interfering 
compounds were unsuccessful. 
As no optimal method giving full return was identified, the method chosen for EBC 
collection of clinical samples was freeze-drying and 10 fold concentration.  The choice 
of diluent after lyophilisation is a subject for debate.  As other groups had used 
reconstitution in ultrapure water with success, we chose to do the same (Edme et al., 
2008, Bayley et al., 2008, Bodini et al., 2007, Sack et al., 2006, Carpagnano et al., 2003, 
Carpagnano et al., 2002b).  However after interpreting the previous experiments, we 
chose to also make up the standard curve in ultrapure water to ensure appropriate 
extrapolation of data. 
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4.2 EBC IL 8 in CF vs Control Adults. 
Introduction. 
Despite best efforts, an optimal assay to measure IL8 levels in EBC was not identified. 
As an IL8 assay would be beneficial, the method which gave the best results  (i.e. 
highest return on previous experiment) was chosen for testing with CF and control 
EBC. 
Methods 
The technique used was to snap freeze 1ml of EBC immediately after collection, then 
freeze dry and concentrate then sample in 1/10 of original volume (by reconstituting in 
100µl of ultra pure water), and assay using a Biosource ultrasensitive ELISA, with the 
standard curve made up in ultrapure water. Ultrapure water was used as diluent and 
standard curve to ensure appropriate extrapolation of end-data.  
Subjects. 
The subjects included in this study were 8 healthy control subjects (adults) and 7 stable 
CF adults and 10 CF adults during infective exacerbation.  1 ml of EBC was collected 
from each subject for this assay. 
4.2.1 Results  
Interleukin 8 was detectable in 36% of samples at very low levels (all less than 3pg/ml) 
and was not detectable i.e. below the level of detection of the assay in the other 64% of 
samples. See Figure 24. 
There was no difference in interleukin 8 levels between control and CF subjects.  We 
found no difference in interleukin 8 between stable CF adults (n=7, Median 0.00 (IQR 
0.00-1.08)) and control subjects (n=8, Median 0.15 (IQR 0.00-0.59)), p=0.694.  There 
was no difference CF adults during exacerbation (n=10, Median 0.00 (IQR 0.00-0.67)) 
and control subjects (n=8, Median 0.15 (IQR 0.00-0.59)), p=0.688.  
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Figure 24. EBC IL8 levels in control vs CF stable vs CF exacerbation data after 
freeze drying and concentrating 10 fold. 
As the majority of the CF samples were below the limit of detection of the assay (64%), 
individual data are plotted.  There were no differences in the data from control and CF 
subjects. The limit of detection of the assay was 0.39pg/ml.
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4.2.1 Discussion 
These data are in agreement with a previous paediatric study. which found interleukin 8 
to be detectable in one third of samples (Cunningham et al., 2000).  By using an 
ultrasensitive ELISA (10 fold more sensitive) and concentrating sample 10 fold, our 
assay should have been more sensitive.   
As the positive samples were all at the lower end of detection by ELISA, a more 
sensitive detection technique was needed to ensure that the positive results were 
genuine. Despite best efforts it was not possible to stabilise interleukin 8 in EBC, and it 
was only detectable in just over one third of samples.  Therefore these analysis 
techniques did not prove to be robust enough to be recommended for use in future gene 
therapy trial.  More sensitive analysis techniques were sought, and the chosen route was 
to used proteomics techniques for further analysis of EBC.
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4.3 Other Cytokines 
4.3.1 Interleukins 6 
Interleukin 6 has both pro and anti-inflammatory effects. It is known to be raised in CF 
BAL (Bonfield et al., 1995).  Interleukin 6 may be useful in monitoring toxicity of CF 
gene therapy in that it has previously been raised after dosing with viral gene therapy 
vectors and predicted clinical deterioration (Ben-Gary et al., 2002, Reix et al., 2002). 
4.3.2 Interleukin 10 
Interleukin 10 is an anti-inflammatory cytokine, and it has been shown to be reduced in 
mouse and human CF BAL (Bonfield et al., 1995). It has been postulated that 
interleukin 10 polymorphisms correlate with different disease phenotypes, are important 
in defence against bacterial and fungal colonisation (Casaulta et al., 2003, Virella-
Lowell et al., 2004) and are an inhibitors of inteleukin 8 secretion (Tabary et al., 2003). 
4.3.3 Interleukin 1 beta and Tumour Necrosis Factor alpha (TNF α) 
These cytokines are released after exposure to bacterial exotoxins and endotoxins and 
are therefore relevant to CF lung disease where there is chronic colonisation by bacteria 
(Staugas et al., 1992). Their relevance is that they form part of the proinflammatory 
profile of cystic fibrosis lung disease and have been shown in vitro to cause a reduction 
in reporter gene  (Bastonero et al., 2005). 
4.3.4 Interferon gamma (INF γ) 
This cytokine is secreted in response to stimulation with bacterial LPS, and this 
response has been shown to be reduced in CF cell lines and to have variable results in 
CF nasal biopsies (Moss et al., 2000, Wojnarowski et al., 1999). 
4.3.5 Methods 
Ultrasensitive ELISAs from Biosource were used and 100ul of EBC from 14 healthy 
controls and 10 subjects with Cystic Fibrosis were used for each assay. 
4.3.6 Results for cytokines -  IL6, IL10, IL1-beta, INF gamma and TNF alpha   
All CF (n=10) and control (n=14) EBC samples had results below the limit of detection 
of the assay. 
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4.4 Discussion about ELISA 
No cytokines were reproducibly detectable in EBC.  After concentration using freeze-
drying techniques, interleukin 8 was sometimes detectable.  However, even using this 
technique only 36% of samples had detectable levels of interleukin 8.  Assays of 
interleukin 6, interleukin 10, interleukin1-beta, interferon gamma and tumour necrosis 
factor alpha were unsuccessful.  More sensitive and specific analytical tools were 
needed to assay proteins in EBC.  Accordingly attempts to analyse proteins were made 
using more sensitive techniques.  A proteomics approach was made using mass 
spectrometry. See chapter 6. 
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4.5 Competitive Enzyme Immunoassay (EIAs) 
4.5.1 Lipid mediators 
4.5.1 Introduction 
Leukotrienes are synthesised from arachidonic acid.  LTB4 is a potent mediator.  It 
causes chemotaxis and chemokinesis in human polymorphonuclear leukocytes at 
subnanomolar levels.  At higher concentrations, it leads to neutrophil aggregation and 
degranulation as well as superoxide anion production. LTB4 is present and rises after 
withdrawal of steroids in asthma patients in exhaled breath condensate.  LTE4 is 
generated predominately by mast cells and eosinophils and causes mucus secretion and 
airway smooth muscle contraction . LTE4 levels in CF spontaneous sputum 
correlate(Leff, 2000) with disease severity (FEV1) (Montuschi et al., 2000). It is most 
predominant leukotriene present in CF sputum (75%) whereas LTB4 is predominant in 
asthmatic sputum (65%) (Montuschi and Barnes, 2002b). 
4.5.2 Competitive Enzyme Immunoassay- LTB4 and LTE4 
These assays are similar to ELISA in that binding to antibody is required.  Unlike 
ELISA they use a competitive technique whereby the analyte competes with a tracer 
chemical for binding to assay well. This technique is used for assay of leukotrienes B4 / 
E4, 8-isoprostane and nitrotyrosine. 
This technique was used to assay LTB4 and LTE4. A kit based enzyme immunoassay 
(EIA) was used (Cayman Chemicals, USA).  The technique is the same for each assay, 
and will be described for LTB4. The LTB4 assay is a competitive assay based on the 
competition between LTB4 and an LTB4-acetylcholinesterase conjugate (LTB4 tracer) 
for a limited amount of LTB4 antiserum.  Because the concentration of LTB4 varies, 
the amount of LTB4 tracer that is able to bind to the LTB4 antiserum will be inversely 
proportional to the concentration of LTB4 in the well.  This antibody-LTB4 complex 
binds to a mouse monoclonal anti-rabbit antibody that has been previously attached to 
the well.  The plate is washed to remove any unbound reagents and then Ellman’s 
Reagent (which contains the substrate to anticholinesterase) is added to the well. The 
product of this enzymatic reaction has a yellow colour and can be read on a microplate 
reader at 420 nm (actual peak 412nm).  The intensity of OD reading is proportional to 
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 4 – Enzyme Immunoassay techniques 121 
the amount of LTB4 tracer bound to the well, and this is inversely proportional to the 
amount of free LTB4 present in the well during the incubation. Linear regression 
analysis is used for data extrapolation, and negative correlations between Optical 
Density (OD) readings and concentration of standards.   
As the assay used was a commercially available kit using competitive binding 
techniques, attempts to optimize the standard curve (as with interleukin 8) were not 
possible. 
Subjects 
The subjects included in this study were 6 healthy controls where fresh EBC was 
collected immediately before assay (all within 1 hour).  The remainder of the sample 
was stored for 1 week at -80oC and the assay was then repeated.   
EBC samples were also collected over a 3 month period from 20 healthy control 
subjects and 20 CF subjects.  These samples were stored at minus 80oC until being 
assayed. 
4.5.3 Results 
Leukotrienes were detectable in fresh EBC median 27.4 pg/ml (n=6, IQR 15.4-39.1). 
When assayed after storage of 1 week in the minus 80oC freezer, LTB4 was not 
detectable in any of the samples.   
When analysis stored samples, 3 of the 40 samples showed LTB4 at the lower limit of 
detection of the assay, and the remaining 37 were below limit of detection of the assay.  
Therefore statistical analysis was not performed due to failure of detection. 
4.5.4 Discussion 
Although LTB4 was detectable in fresh breath of healthy control subjects, it was not 
detectable after being stored for 1 week.  This means that LTB4 was not stable and 
would have required immediate assay. This would have been prohibitively expensive 
both in assay costs (one assay kit per day) and in staff time to perform the assay. 
Therefore, it was not possible to run large numbers of fresh samples, and no further 
investigation of LTB4 was performed. 
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4.6    8-Isoprostane assay 
8 - Isoprostane is a member of the eicosanoid family.  It is produced by oxidation of 
tissue phospholipids by oxygen radicals. It is a potent pulmonary vasoconstrictor and 
has been implicated as a causative mediator in pulmonary oxygen toxicity.  8-
isoprostane has been proposed as a marker of oxidative stress and has been shown to be 
raised in the EBC of Cystic Fibrosis and asthmatic subjects (Montuschi et al., 2000, 
Zanconato et al., 2004).  As a marker of oxidative stress, it has several advantages in 
that it is chemically stable, is formed in vivo at sites of free radical activity, and is 
specific for lipid peroxidation. 
4.6.1 Methods 
An EIA supplied by Cayman Chemicals (Ann Arbour, USA) was used.  This was a 
competitive assay where 8-isoprostane in the sample competed with an 8-isoprostane 
tracer compund.  Butylated Hydroxytoluene was added to the samples to prevent ex-
vivo oxidation after the sample was collected. 
Test samples of EBC collected from 6 healthy volunteers were used to optimise the 
assay.  The results were at the lower limit of detection, and therefore freeze-drying was 
used to concentrate the samples ten fold. 
Samples were collected from 9 control subjects and 18 adults with cystic fibrosis when 
they were deemed clinically stable. Samples were also assayed from 8 subjects who 
were in-patients with an infective exacerbation of cystic fibrosis. 
4.6.2 Results 
We found no difference in 8-Isoprostane levels between stable CF adults (n=18, Median 
2.65 (IQR 1.80-4.20)) and control subjects (n=9, Median 3.13 (IQR 2.38-8.52)), 
p=0.258.  There was no difference CF adults during exacerbation (n=8, Median 2.75 
(IQR 2.02-3.75)) and control subjects (n=9, Median 3.13 (IQR 2.38-8.52)), p=0.386 or 
CF stable subjects p=0.978. See figure 25. 
4.6.3 Discussion 
There were no differences between the study groups.  Numerically the 8-isoprostane 
levels were lower in the CF groups, which is contrary to the hypothesis that it can be 
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used to report on the increased oxidative state of the CF lung.  The assay used was a 
competitive assay and therefore EBC could be having a detrimental effect on binding of 
the reporter chemical, giving a false positive signal.  
Another technique would be to employ gas chromatography mass spectrometry as a 
more sensitive (and potentially more specific) technique than the EIA used here.  GC 
MS techniques were not available, and the data from this study would suggest that 
further research using EIA techniques to assay isoprostanes in EBC are not warranted in 
the context of Cystic Fibrosis gene therapy trials. 
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Figure 25. EBC 8 Isoprostane levels in control subjects vs CF stable subjects vs CF 
exacerbation subjects. 
The levels of 8-isoprostane were not different between the groups.
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4.7 Nitrotyrosine 
Nitrotyrosine is a stable end product of the reaction between the amino acid tyrosine 
and reactive nitrogen species. It could therefore be used as a stable end product assay of 
nitrative stress.  It has been investigated in EBC and has previously found to be raised in 
stable steroid naive asthmatics (Hanazawa et al., 2000), after cigarette smoking (Balint 
et al., 2001a) and in Cystic Fibrosis (Balint et al., 2001b). In the studies in this thesis the 
markers of nitrative stress, eNO and Nitrite have not been raised, despite results of 
previous studies.  It was hoped that the marker nitrotyrosine would reflect the increased 
nitrative stress in the CF lung and therefore was studied in our CF population.  
4.7.1 Methods 
An EIA supplied by Cayman Chemicals was used.  The technique employed was again 
a competitive assay where nitrotyrosine in the sample competed with labelled 
nitrotyrosine for a set quantity of antibody.   
Samples were collected from 13 control subjects and 9 adults with cystic fibrosis when 
they were deemed clinically stable. Samples were also assayed from 8 subjects who 
were in-patients with an infective exacerbation of cystic fibrosis. 
4.7.2 Results  
There was no difference in EBC nitrotyrosine levels between stable CF adults (n=9, 
Median 4.46 ng/ml (IQR 1.84-6.23)) and control subjects (n=13, Median 4.16 ng/ml 
(IQR 1.84-6.23)), p=1.000.  There was no difference CF adults during exacerbation 
(n=8, Median 3.93 ng/ml (IQR 2.05-7.39)) and control subjects (n=13, Median 4.16 
ng/ml (IQR 1.84-6.23)), p=0.800 or with CF stable patients. See Figure 26. 
4.7.3 Discussion 
No difference in nitrotyrosine was found between any of the groups and therefore this 
assay will not be of use in future gene therapy trials.  As this was a competitive assay, 
the concerns about EBC having a negative effect on the binding of antibody to antigen 
in the well apply i.e the levels of nitrotyrosine reported may be a false positive result. 
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It is interesting to note that all three markers of nitrative stress eNO, EBC nitrite and 
EBC nitrotyrosine cannot differentiate between subjects with cystic fibrosis and healthy 
control subjects.  This raises the possibility that either there is no difference between 
controls and cystic fibrosis subjects (true negative result) or that the available 
techniques were unable to detect a difference (false negative studies).  There is a need 








Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 4 – Enzyme Immunoassay techniques 127 
 
Figure 26. EBC Nitrotyrosine levels in controls, CF stable subjects CF 
Exacerbation subjects. 
There were no differences in EBC nitrotyrosine levels in patients with CF compared to 
controls.
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4.8 Enzyme immunoassay techniques – ELISA and EIA 
4.8.1 Discussion 
The use of ELISA and EIA techniques to discriminate between CF and controls subjects 
was unsuccessful.  Despite a significant effort to try to optimise ELISA for assay of 
cytokines in breath, in particular interleukin 8, it was not successful.  Concerns around 
degradation of sample, compounds masking epitopes or substances interferening with 
binding of sample to antibodies remain.  The most significant concern is that any signal 
detected was always at the lower end of detection of ELISA and therefore confidence 
about detection was not possible.  At best interleukin 8 was only detected in 36% of 
samples and did not differentiate between CF and control groups.  Other cytokines were 
not detectable. 
EIA proved more successful in detection, with nitrotyrosine and 8 isoprostane detected 
in all subjects. However the results did not discriminate a cystic fibrosis subject from a 
control subject.  Also the results were positive at low levels.  Concern about the 
competitive nature of the assay raised questions about the genuine presence of these 
compounds in EBC.  There seemed to be a rather narrow spread of data in all subjects, 
and it might be concluded that the results were false positives.  
The positive results reported other groups could not be repeated.  The main issue with 
other studies were the possible use of inappropriate standard curves for ELISAs, leading 
to extrapolation that compounds were present at levels higher than reality (i.e. false 
positive results).  Interpretation of data in previous studies appeared potentially flawed 
in that if no compound was detected, a fictitious level was given to those samples.  
Despite these concerns, there does not appear to be an explanation as to why researchers 
found differences between disease groups, and therefore it would be appropriate to 
conclude that their studies were measuring real differences but the techniques have 
proven to be unrepeatable. 
As there were no differences detected between CF and control subjects, these assays 
should not be used for EBC analysis in future gene therapy trials.  More sensitive and 
specific analytical tools are needed to assay compounds in EBC.  In view of the raised 
total protein in EBC, proteomic techniques were investigated (chapter 6). 
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5.0 EBC - Ion Measurements 
5.1 pH  
5.1.1 Introduction 
The pH of exhaled breath condensate was found to be low in asthmatic subjects when 
compared to controls (Hunt et al., 2000).  This is taken as reflecting severity of airways 
inflammation, since the pH normalizes with treatment of the exacerbation.  The 
reduction in pH may be attributed to an increase either in an as yet unidentified 
inflammatory acid, or by diminished buffering capacity of EBC. 
An increase in acidity of biological fluids in response to a proinflammatory stimulus is 
recognised to occur (in humans)  In chronic suppuration such as in bacterial infection of 
the pleural cavity (empyema), a lowering of fluid pH is seen (Chavalittamrong et al., 
1979).  The lowering of pH in empyema is thought to be due to leukocyte phagocytosis 
and bacterial metabolism (Sahn et al., 1983).  
In cystic fibrosis there is chronic suppuration with bacterial colonisation and neutrophil 
inflammation, and through these mechanisms the ASL pH may be lower than that of 
controls.  In addition, as CFTR has been proposed as a bicarbonate channel, the ASL in 
CF may be further acidified due to reduced levels of bicarbonate (Ballard et al., 1999). 
It was ,therefore, hypothesised that the pH of EBC in cystic fibrosis subjects may be 
lower than healthy controls.   
5.1.2 Methods 
Patients were recruited at the Paediatric and Adult Cystic Fibrosis services in 
Edinburgh. Control subjects were recruited from staff at the Adult Centre and children 
attending the fracture clinic in the Paediatric Centre. 
Two types of pH meter were used in this work.  Initially a glass electrode was used 
(Orion pH probe, USA) with a pH millivolt meter.  This was capable of measuring the 
pH in 650µl of EBC accurate to 0.01pH.  As this is a large volume of EBC, a solid-state 
electrode system was tested.  This required 50µl of EBC (pH Boy, Camlab, UK) which 
was sensitive to 0.1 pH point (figure 27).  Both systems required two-point calibration 
before each use and required a stable temperature of sample before analysis as 
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temperature affects conductivity, therefore samples were allowed to warm to room 
temperature.
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Figure 27. pH Boy ion selective electrode. 
50µl of EBC is sufficient to cover both electrodes of the pH boy.  This technique was 
sensitive to 0.1 pH point.  The arrow shows a meniscus of EBC covering the electrodes. 
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5.1.2.1 Deaeration of samples 
A difference in methodologies between this CF study and previously published asthma 
studies was performed (Hunt et al., 2000). Hunt chose to deaerate the samples and assay 
them later after freezing. The purpose of this was to remove dissolved CO2 
(bicarbonate).  In CF studies, the importance of assaying bicarbonate is that it is 
secreted by CFTR and therefore may report on CFTR function. In this thesis, the 
samples were assayed immediately (without deareation) in the hope that bicarbonate 
would be held in solution by surface tension and therefore would contribute to EBC pH.  
To test whether deaeration affected pH of EBC, 6 samples were tested - three from 
healthy controls and three from subjects with stable cystic fibrosis attending clinic.  
Although dereation changed the numerical value of pH, the order of results between all 
subjects was identical and there was a strong correlation between pH before and after 
deaeration (r=0.67, p=0.000048). 
5.1.2.2 pH Boy vs Standard pH meter 
The two pH meters were compared with EBC from 6 subjects - three from healthy 
controls and three from subjects with stable cystic fibrosis attending clinic.  A strong 
correlation was noted (r=0.999, p=<0.0001, n=6).  Therefore, the pH boy was chosen as 
the preferred method of analysis as 50 µl of sample was required as compared to 650 µl 
(standard pH meter). 
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EBC pH was lower in stable CF adults when compared to their age matched control 
group: (CF Stable – n=26, Median 5.84,IQR 5.48-6.16 vs Control – n=14, Median 6.1, 
IQR 5.9-6.21) p=0.047. (Table 4) (figure 28) 
EBC collected at time of exacerbation had a lower pH in adults with CF when compared 
to controls: (CF Exacerbation – n=14, Median 5.37, IQR 4.96-5.66 vs. Control – n=14, 
Median 6.1, IQR 5.9-6.21) p=<0.001. (Table 4) (figure 28) 
EBC pH was not lower during infective exacerbations compared to the stable CF 
patients in adults: (CF Exacerbation – n=14, Median 5.37, IQR 4.96-5.66) vs. (CF 
Stable – n=26, Median 5.84,IQR 5.48-6.16) p=0.005. (Table 4)(Figure 28) 
 
Children’s data. 
EBC pH was not lower in stable CF children when compared to their age matched 
control group: (CF Stable – n=12, Median 5.9, IQR 5.50-6.15 vs. Control – n=20, 
Median 5.9, IQR 5.8-6.25) p=0.546. (Table 5)  (figure 29) 
EBC collected at time of exacerbation had a lower pH in children with CF when 
compared to controls: (CF Exacerbation – n=8, Median 5.35, IQR 5.15-5.75) vs. 
(Control – n=20, Median 5.9, IQR 5.8-6.25) p=0.007. (Table 5) (figure 29) 
EBC pH was not lower during infective exacerbations compared to the stable CF 
patients in children: (CF Exacerbation – n=8, Median 5.35, IQR 5.15-5.75) vs. (CF 
Stable – n=12, Median 5.9, IQR 5.50-6.15) p=0.028. (Table 5)(Figure 29) 
 
Combined adults and children’s data. 
Combined adult and childrens data EBC pH was not lower in stable CF patients (n=38, 
5.90 median, IQR 5.48-6.16, p=0.064) compared to controls (n=34, 6.03 median, IQR 
5.80-6.21). (Table 6) 
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Combined adult and childrens data EBC pH was lower in those with an exacerbation 
(n=22, 5.37 median, IQR 5.00-5.70 p=<0.001) compared to controls (n=34, 6.03 
median, IQR 5.80-6.21). (Table 6) 
 
In each subject group (controls, CF stable, CF exacerbation), there was no difference in 
EBC pH when adults were compared to children (Control p=0.401, CF Stable p=0.950 
and CF Exacerbation p=0.394) although the data for each childrens group had wider 
interquartile ranges than the adults.
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Table 4 – EBC pH – Adults data 
Table 5 – EBC pH – Children’s data 








Subject n= Median Interquartile range (IQR) 
Controls 34 6.03 5.80-6.21 
CF patients (Stable) 38 5.90 5.60-6.20 
CF Patients (Exacerbation) 22 5.37 5.00-5.70 
Subject n= Median Interquartile range (IQR) 
Controls 14 6.1 5.90-6.21 
CF patients (Stable) 26 5.84 5.48-6.16 
CF Patients (Exacerbation) 14 5.37 4.96-5.66 
Subject n= Median Interquartile range (IQR) 
Controls 20 5.9 5.80-6.25 
CF patients (Stable) 12 5.9 5.50-6.15 
CF Patients (Exacerbation) 8 5.35 5.15-5.75 
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Figure 28. Adults - EBC pH levels in controls, CF stable subjects and CF subjects 
with exacerbation.   
EBC pH was lower in both stable CF subjects (p=0.047) and CF subjects with 
exacerbation (p=<0.001) and CF subjects with exacerbation had lower EBC pH than 
stable CF subjects (p=0.005). 
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Figure 29. Children - EBC pH levels in controls, CF stable subjects and CF 
subjects with exacerbation.   
EBC pH was not lower in stable CF subjects (p=0.546), but was lower in CF subjects 
with exacerbation (p=0.007) 
.  
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5.1.4 Discussion 
Discussion of these results can be found in combination with EBC ammonium data after 
the EBC ammonium section.
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5.2 Ammonium 
5.2.1 Introduction 
Ammonium is one of the major biological buffers (the others being bicarbonate and 
proteins).  Levels of Ammonium have been found to be reduced in the EBC of 
asthmatic subjects (Hunt et al., 2002). Lowering of Ammonium has been attributed to 
inhibition of the acid/base homeostatic enzyme Glutaminase.  Glutaminase converts 
glutamine to glutamate with the formation of ammonium.  Its expression can be induced 
in respiratory epithelial cells by an acid environment (Hunt et al., 2002).  Ammonium is 
a weak buffer with a pKa of 9.0, and therefore when generated will neutralise any free 
acid.  However, glutaminase expression, and thereby ammonium production, can be 
inhibited by proinflammatory cytokines including TNF alpha and Interferon gamma.  
Therefore, in the CF airway these cytokines could affect ammonium production (Gaston 
et al., 2002). 
 
Another further possible source of Ammonium in the CF airway is production by 
denitrifying bacteria such as Pseudomonas aeruginosa (pseudomonas generates 
ammonia gas from nitrites), generating ammonium ions via reaction with CO2 and H2O 
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5.2.2 Methods 
5.2.2.1 Ion selective electrodes 
Ion selective electrodes allow the assay of different ions at very low levels.  Their 
general application is to assay purity of drinking water, and they can assay down to 0.01 
parts per million. 
An ammonium electrode was used in this work to quantify ammonium in EBC.  
Sodium, Chloride, Potassium were also assayed using this technique and will be 
discussed later in the chapter.  The Ammonium electrode (Jenway, UK) was attached to 
a sensitive millivolt meter (Jenway 3345 Ion meter, UK).  As the volume of EBC was 
limited, a technique of inverting the electrode was used (figure 30).  Then 130µl of EBC 
was applied to the surface (being held on by surface tension) (See figure 30). 
The electrode functions by allowing the selective diffusion of the appropriate ion 
through a semi permeable membrane.  The conductivity through this membrane was 
measured using a millivoltmeter.  Because the relevant ion diffuses through the 
membrane to create the voltage, the voltage generated reflected diffusion kinetics, i.e. a 
linear change in voltage would reflect an exponential change in ion concentration. 
A standard curve for extrapolation was made using serial dilution of ammonium 
standard.  With every 10 fold dilution of ammonium standard, the voltage dropped in a 
linear fashion.  When the voltage change became non-linear the limit of sensitivity was 
reached.  For ammonium the voltage became non-linear at 0.01ppm and so the lower 
limit of detection was 0.1ppm (figure 31). 
As with measurements of pH, temperature affects conductivity (and diffusion).  As 
diffusion occurs from the sample, and solute concentrations are low in EBC, some 
drifting of voltage was seen.  This may be due to progressive loss of ions through the 
membrane, altering the concentration.  To avoid artefact due to this, the voltmeter 
recording was always taken at 10 seconds. 
Calibration using solutions of ions at 1000, 100, 10, 1 and 0.1 parts per million were 
used as the standards.  
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5.2.1.2 Coefficient of variation 
If many samples were assayed at once, a new standard curve was generated every 20 
samples.  To calculate coefficient of variation of Ammonium assay, 100 standards were 
assayed at 10 (550µM) and 100 ppm (5500µM).  Coefficient of variation for this 
analysis technique was 0.7% and 1.3% respectively. 
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Figure 30. Jenway Ion selective electrode.  
This image shows the quantitation of ammonium in 120µl of EBC.  The electrode was 
inverted (turned upside down) and then fluid was applied to the tip (arrow shows EBC 
onto of tip) and this was held in place by surface tension.  
 
Figure 31. Generation of standard curve for regression analysis (Ammonium 
Chloride) 
As ion diffusion across a membrane obeys nernstian kinetics, regression analysis of the 
standard curve to moles is non-linear (exponential). 
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EBC Ammonium was lower in stable CF adults when compared to their age matched 
control group: (CF Stable – n=10, Median 160,IQR 40-230 vs Control – n=18, Median 
536, IQR 380-1030) p=0.002. (Table 7)(Figure 32)  
EBC collected at time of exacerbation had a lower Ammonium in adults with CF when 
compared to controls: (CF Exacerbation – n=14, Median 70, IQR 56-200 vs. Control – 
n=18, Median 536, IQR 380-1030) p=<0.001. (Table 7)(Figure 32) 
Ammonium was not lower during infective exacerbations compared to the stable CF 
patients in adults: (CF Exacerbation – n=14, Median 70, IQR 56-200) vs. CF Stable – 
n=10, Median 160, IQR 40-230) p=0.519. (Table 7)(Figure 32) 
 
Children’s data. 
EBC Ammonium was lower in stable CF children when compared to their age matched 
control group: (CF Stable – n=12, Median 230, IQR 205-520 vs. Control – n=44, 
Median 428, IQR 276-638) p=0.040. (Table 8)(Figure 33) 
EBC collected at time of exacerbation had a lower Ammonium in children with CF 
when compared to controls (CF Exacerbation – n=7, Median 290, IQR 180-415) vs. 
(Control – n=44, Median 428, IQR 276-637) p=0.070. (Table 8)(Figure 33) 
Ammonium was not lower during infective exacerbations compared to the stable CF 
patients in children: (CF Exacerbation – n=7, Median 290, IQR 180-415 vs. CF Stable – 
n=12, Median 230, IQR 205-520) p=0.583. (Table 8)(Figure 33) 
 
Combined data. 
Combined adult and childrens data EBC Ammonium was lower in both stable CF 
subjects (n=22, 220µM median, IQR 150-330µM, p=<0.001) and those with an 
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 5 – Ion Measurements 145 
exacerbation (n=20, 140µM median, IQR 60-350µM p=<0.001) compared to controls 
(n=62, 480 µM median, IQR 311-730µM) (Table 9). 
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Table 7 – EBC ammonium -  Adult data 
 Table 8 – EBC ammonium – Children’s data 
 Table 9 – EBC ammonium - Combined adults and children’s data 
Subject n= Median 
µM 
Interquartile range (IQR) 
µM 
Controls 62 480 311-730 
CF patients (Stable) 22 220 150-330 
CF Patients (Exacerbation) 20 140 60-350 
Subject n= Median 
µM 
Interquartile range (IQR) 
µM 
Controls 44 428 276-637 
CF patients (Stable) 12 230 205-520 
CF patients (Exacerbation) 7 290 180-415 
Subject n= Median 
µM 
Interquartile range (IQR) 
µM 
Controls 18 536 380-1030 
CF patients (Stable) 10 160 40-230 
CF Patients (Exacerbation) 14 70 56-200 
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Figure 32. EBC ammonium in control and CF adults. 
EBC ammonium was lower in stable CF adults (p=0.003) and during exacerbation 
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Figure 33. EBC ammonium in control and CF children. 
EBC ammonium was lower in stable CF children (p=0.040) and during exacerbation 
(p=0.070) when compared to controls. 
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5.3 Discussion – pH and ammonium data combined. 
This study shows that pH of EBC in stable adults with Cystic Fibrosis is reduced 
compared to controls.  In stable children with CF, in contrast, there was no difference in 
pH compared to controls.  This difference between adults and children raises the 
possibility that the adult CF airway is more inflamed, even when clinically well, than 
that of CF children.  
The lower pH detected during exacerbation is likely to be reflect inflammation as EBC 
pH of both CF adults and children was lower during exacerbation. This would be 
consistent with a worsening of lung inflammation causing a reduced EBC pH, as 
occurred in subjects with Asthma, COPD and bronchiectasis (Hunt et al., 2000, 
Kostikas et al., 2002). 
When we looked at the buffer ammonium, in adults and children EBC ammonium was 
reduced, even when stable, and did not drop any further during exacerbation.  
Interestingly stable CF children had a lower EBC ammonium than controls, unlike EBC 
pH.  It is possible that this reflects a type 2 error as the number of stable CF children 
recruited was lower than CF adults, more data would be needed to address this question. 
This lower ammonium was not different between the CF stable and CF exacerbation 
groups.  This implies that the low pH seen in all CF subjects during exacerbation may 
reflect an increase in an “inflammatory” acid (or reduction in other buffer) rather than a 
reduction in ammonium. 
It could be postulated that pH and ammonium are present in equilibrium (i.e as pH falls 
the ammonium buffer would fall).  If this is the case, the data would imply that 
ammonium would fall before pH (as ammonium, but not pH is low in CF children).  It 
is likely that only after the buffering capacity of EBC is used up (e.g. with a high 
quanitity of an “inflammatory”acid), the pH would fall. Both a low pH and ammonium 
would then reflect a higher levels of inflammation, potentially as seen in adults with CF.  
There was no correlation between pH and Ammonium in any disease group or age 
group which may reflect the fact that ammonium is low in all CF subjects.  Also there 
was no correlation with % Predicted FEV1, bacterial colonisation, cigarette smoking or 
genotype. 
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In each subject group the level of pH was not altered by age, as there were no statistical 
differences between adult and child data.  A wider spread of data was noted for children 
and the wider spread of data was seen in control and CF subjects. This wider range 
potentially reflected variations in sample collection, but it is possible that in the CF 
subjects there was a wider variation in inflammation in children.  However, ammonium 
was lower in the adult CF population compared to the CF children, and this may reflect 
the greater severity of inflammation present in the stable CF adult compared to the 
stable CF child. 
EBC Ammonium is lower in the CF population when compared to healthy controls. 
One possible mechanism being the action of proinflammatory cytokines on glutaminase 
expression. This would also partly provide an explanation for the reduced EBC pH.  
Methodological differences account for the difference in pH between these data and 
those previously reported by previous investigators (Hunt et al., 2000, Kostikas et al., 
2002). We chose not to deaerate our samples with Argon, and measured pH 
immediately after sample collection.  When tested, a strong correlation between the two 
methodologies, with and without argon, was noted.  The reason for the difference was 
as an attempt to indirectly assay bicarbonate.  By rapidly measuring pH without 
deaeration we hoped to hold bicarbonate in suspension due to surface tension.  We 
anticipated that EBC pH would thereby reflect CFTR function/dysfunction.  The finding 
that EBC pH in CF stable children was not different from their controls implies that we 
are not assaying any differences in bicarbonate in EBC pH in CF subjects. A difference 
in EBC pH in CF stable adults therefore is more likely to reflect an increase in 
inflammation rather than any CFTR dysfunction reflected in low bicarbonate.  
Interestingly, there was no relationship between EBC pH and Ammonium.  This is 
contrary to previous data in asthma (Hunt, Erwin et al. 2002) and implies changes in the 
acid/base status of EBC, which are not related to ammonium.  Kostikas found a 
difference in EBC pH in bronchiectatics colonised with pseudomonas, compared to non 
pseudomonas bronchiectatics (Kostikas et al., 2002). In CF subjects there was no 
difference in EBC pH or Ammonium with colonising organism, implying that 
production of Ammonium by denitrifying bacteria such as pseudomonas does not affect 
EBC pH or ammonium to a detectable extent in CF EBC.   
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A reduction in ASL pH could lead to detrimental effects on the CF airway such 
increasing mucous viscosity (Bhaskar et al., 1991, Holma, 1985), decreasing ciliary beat 
frequency (Clary-Meinesz et al., 1998) and directly altering the integrity of the 
respiratory epithelium (Giddens and Fairchild, 1972).  In spite of this we found no 
correlation with FEV1.  FEV1 is an insensitive measure of “short term” changes in 
inflammatory state of the airway in CF.  Instead it reflects predominantly a lifetime of 
lung damage and deterioration, which is multifactorial in causation. 
One potential source of ammonium is the mouth.  No change in either EBC pH or 
ammonia was detected when control subjects were asked to hyperventilate.  Indeed, as 
CF patients have poor dentition due to the high energy diet and mineralization defect of 
teeth, we would expect higher levels of ammonia than controls, as production of 
ammonia gas by assimilating bacteria would increase.  This was not the case.  
It has not been established as to which components of ASL are present in EBC.  We 
hypothesised that we are collecting the aerosolised particles of the periciliary liquid 
layer of ASL, rather than the more viscous mucus layer which lies on top.  There are 
two supporting pieces of evidence for this. Firstly, nasal ASL pH is not lower in CF 
subjects compared to controls (McShane et al., 2003), suggesting we are not measuring 
the same material.  It may be possible that as the nasal epithelium is not a good model 
of lung inflammation or that EBC pH reflects a volatile gas, but it is also possible that 
EBC pH reflects a subcomponent of the ASL.Topical application of pH electrode to the 
airway would be measuring the resistance of the top mucus layer of ASL, and not the 
periciliary liquid layer beneath, whereas EBC would be sampling the microdroplet 
components of ASL which can aerosolise.  Secondly, it has previously been shown that 
CF sputum has higher levels of ammonium (produced by pseudomonas) than non CF 
sputum (from children with neurogenic respiratory failure) (Gaston and Hunt, 2002). If 
EBC was sampling the entire ASL, we should expect EBC ammonium levels to be high 
in CF (as in CF mucus where pseudomonas exists in biofilms). However if the viscous 
mucus layer was resistant to aerosolisation, the periciliary layer of ASL would be the 
major contributor to EBC.  The periciliary microenvironment of airway epithelial cells 
is one of the last lines of defence against invading organisms and therefore it is 
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conceivable that it is here that the three proton pumps responsible for acidifying ASL 
(Na+/H+ exchange, H+ ATPase and an H+, K+ ATPase) exhibit their greatest effect. 
In conclusion, these data would suggest that EBC pH is low in stable CF adults and is 
further reduced in adults and reduced in children with CF during infective 
exacerbations.  Ammonium is reduced in all CF subjects.  These endpoints have the 
potential to be used as surrogate markers of the inflammatory status of CF patients.  In 
this study, the collection and analysis of EBC proved simple and safe to perform in 
subjects as young as 6 years of age. For future trials of new therapies in Cystic Fibrosis, 
the differences between pH and Ammonium in CF subjects could be utilised.  As a 
surrogate marker of inflammation, EBC pH is most likely to be useful in detecting any 
deterioration from a stable baseline in both adults and children, since the pH during CF 
exacerbation was highly different from the stable CF EBC pH level.  EBC Ammonium 
may be more useful when detecting any improvement from a stable CF baseline i.e. 
drug trials or gene therapy trials designed to improve the steady state of the patient 
towards that of healthy controls, since Ammonium levels were greatly reduced 
compared to the levels of healthy controls. Further studies of these surrogate markers of 
inflammation are warranted to assess their potential application in the clinical 
management of CF patients.
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5.4 Sodium, Chloride, Potassium (and Lactate) Ions 
CF is characterised by an apically localised, ATP dependant chloride channel.  
Therefore assay of chloride in the airway surface liquid in a non-invasive manner would 
be a good way to assess CFTR function.  ENaC dysfunction is also associated with 
CFTR dysfunction and measurement of sodium may also be helpful.   
In vivo analysis ASL sodium and chloride is difficult and most data are available for 
nasal measurements only.  Using in vivo micro-dialysis in mice, no difference in CF 
nasal ASL sodium and chloride levels was found, but potassium levels were higher in 
CF mice (Grubb et al., 2002).  In human studies using filter paper absorption to assay 
sodium and chloride, no difference was found between CF subjects and controls 
(Knowles et al., 1997).  This field of research remains controversial as methodological 
arguments as to which techniques truly assay ASL have been made (since ASL has a 
mucus and periciliary liquid layer, topical and adsorptive techniques may not be 
assaying entire liquid). 
Therefore, as EBC offers the potential to sample the ASL, albeit in dilute form, we 
chose to investigate Na+, Cl- and K+ levels in EBC. As there is a dilution factor (by 
exhaled water and variations in shedding of microdroplets) the three ions and their 
ratios were investigated to see if there is a CF non - CF difference. 
Lactate has been suggested as the fourth main ion in EBC (Effros et al., 2002) and may 
be raised in cystic fibrosis due to pseudomonas metabolism of pyruvate and has been 
postulated to be raised in the saliva of CF subjects (Bardon, 1987, Eschbach et al., 
2004).   
5.4.1 Methods 
Ion selective electrodes for sodium, chloride and potassium were tested.  The subjects 
were children who were either healthy controls (who had been attending fracture clinic) 
and children with CF attending clinic (stable).   
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As well as assaying the absolute values of different ions, the ratios between them were 
also.  This was an attempt to use the different ions as internal standards to compensate 
for the dilution effect that EBC would have on droplets of ASL. 
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5.4.2 Results 
There was no difference detected with any of the ions, nor of the ratio between ions. 
Sodium - No difference between CF (n=19, Median 0.8µg/l (IQR 0.5-1.2)) and Non CF 
(n=19, Median 1.0 (IQR0.6-3.6)) p=0.307 (Table 10)Figure – 34/A 
Potassium - No difference between CF (n=19, Median 0.2µg/l (IQR 0.17-0.32)) and 
Non CF (n=19, Median 0.3 (IQR 0.19-0.42-)) p=0.307 (Table 12) Figure – 34/B 
Chloride - No difference between CF (n=19, Median 0.1µg/l (IQR0.08-0.3)) and Non 
CF (n=19, Median 0.2 (IQR 0.1-0.3)) p=0.161 (Table 11)Figure – 34/C 
Lactate – Majority of samples below limit of detection of assay. (Table 13)Figure – 
34/D 
The ratio between ions was tested and no difference was found between the control and 
CF population. The ratios were Na/K – p=0.110, Na/Cl p=0.221, K/Cl p-0.161. There 
was no difference in the total ion count of CF and control EBC Na+K+CL p=0.225. See 
figure 35/A-D. 
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Table 10. EBC Sodium levels in control and CF subjects. No difference between the 
groups. P=0.307 
Table 11. EBC Chloride levels in control and CF subjects. No difference between the 
groups. P=0.161 
Table 12. EBC Potassium levels in control and CF subjects. No difference between the 
groups. P=0.307 
Table 13. EBC Lactate levels in control and CF subjects. No difference between the 
groups. P=0.109 
 
Subject n Median µg/l Interquartile range (IQR) 
Controls 19 1 0.6-3.6 
CF patients 19 0.8 0.5-1.2 
Subject n Median µg/l Interquartile range (IQR) 
Controls 19 0.2 0.1-0.3 
CF patients 19 0.1 0.08-0.3 
Subject n Median µg/l Interquartile range (IQR) 
Controls 19 0.3 0.19-0.42 
CF patients 19 0.2 0.17-0.32 
Subject n Median µg/l Interquartile range (IQR) 
Controls 19 0.0 0.00-0.15 
CF patients 19 0.0 0.00-0.05 
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 Figure 34/  
A. EBC ions Sodium - No difference between CF and controls. 
B. EBC Potassium - No difference between CF and controls. 
C. EBC Chloride- No difference between CF and controls. 
D. EBC Lactate- No difference between CF and controls. Lactate below 
limit of detection in majority of samples. 
No difference between controls and CF for Sodium, Potassium, Chloride or lactate.
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Figure 35/  
A. EBC ion ratios – Total Sodium + Potassium + Chloride - No difference 
between CF and controls 
B. Ratio of Sodium to Potassium - No difference between CF and controls 
C. Ratio of Potassium to Chloride - No difference between CF and controls 
D. Ratio of Sodium and Chloride in control and CF subjects. - No difference 
between CF and controls 
No difference between controls and CF for ratio of ions Sodium, Potassium and 
Chloride. 
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5.4.3 Discussion 
No differences in ions or ratios of ions were found.  Ranges of ion levels were noted.  
Sodium and chloride correlated strongly in each individual in both the CF and the 
control group (Na/Cl r=0.66, p=0.000005), implying that the assay techniques were 
successful.  Therefore, the levels are likely to reflect the genuine ion concentration in 
EBC of CF and Non CF subjects.  From these data, there is no suggestion that CF EBC 
(and therefore potentially ASL) contains higher or lower concentrations of salts.   
Until know, there has been controversy around whether the CFTR function affects 
hydration of ASL (hydration hypothesis (Boucher, 2003, Boucher, 2004)) or salt 
tonicity in ASL (low salt hypothesis (Smith et al., 1996)).  According to the hydration 
hypothesis, in the normal state, sodium controls ASL height via the ion channel ENAC, 
which in turn is controlled by CFTR.  However in CF, ENAC is permanently open, 
sodium absorption is accelerated into the cell.  By osmosis, water and any extracellular 
chloride would then be absorbed through leaky tight junctions, leading to a depleted 
isotonic ASL.  Therefore in the hydration hypothesis, there should be no difference in 
the ion composition of CF ASL (and EBC)  compared to control subjects.  In the low 
salt hypothesis, it is postulated that the normal ASL is hypotonic, and stems from the 
finding that CF ASL had higher salt level than control in cell culture (air liquid 
interface) (Smith et al., 1996).  This was explained by CFTR controlling chloride 
absorption into cells (as well as ENAC controlling sodium) and tight junctions stopping 
any influx of water.  This would lead to an hypotonic ASL.  In CF, chloride and sodium 
absorption would not be controlled and therefore ASL sodium and chloride would be 
isotonic (by osmosis). Therefore if the low salt hypothesis is correct, we should see 
more sodium and chloride in the ASL (and EBC) of CF subjects. If EBC is directly 
sampling ASL (dissolved in exhaled water vapour) then these data are potentially very 
important and would suggest that the hydration hypothesis is correct (Knowles et al., 
1997).  This would have particular importance for CF gene therapy as it would imply 
that tight junctions are leaky resulting in improved transfection efficiency. 
EBC data should not be used to comment on whether ASL is hypotonic or isotonic as 
we do not know the dilution effect of exhaled water vapour.   
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With regard to the purpose of this thesis, to detect markers of CFTR, it was not possible 
to distinguish CF from control subject using the measurement of Na+, Cl- and K+ ions in 
EBC.  Therefore it will be necessary to use surrogate markers of CFTR function rather 
than direct measures. 
Assay of Na+, Cl- and K+ ions in EBC cannot be used to distinguish CF from non-CF 
subjects and therefore does not have a role in CF GT trials.
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5.5 Analysis of combination of EBC Biomarkers 
5.5.1 FEV1 
5.5.1 Introduction 
The gold standard non-invasive marker is the lung function marker forced expiratory 
volume in 1 second. The FEV1 is the best discriminator used in clinical practice.  Its 
main disadvantage is that it reflects a lifetime of deterioration and damage.  This 
deterioration is multifactorial in causation, reflects age of onset of pseudomonas 
colonisation, compliance with treatments, social class, and has a poor correlation with 
genotype.  For FEV1 day-to-day variability is significant (200ml) and it is relatively less 
sensitive to short term changes in lung inflammation e.g. during infective exacerbation. 
The FEV1 of our subjects was measured for comparison and was the gold standard 
marker to which all biomarkers would be compared.   
5.5.2 Methods 
The sensitivity and specificity of FEV1 can be calculated using tree based algorhithms.  
This was used as a way of assessing how good a discriminator FEV1 was (of CF). 
Pattern recognition software was used to calculate the true and false positive and true 
and false negative predictive value of FEV1.(Ciphergen, USA)  
Subjects. 
Adults who were either healthy control subjects or CF subjects whilst stable performed 
spirometry. 
5.5.3 Results 
Lung function (FEV1) was significantly lower in CF subjects (n=28, Median 2.0 (IQR 
1.1-2.9)) compared to controls (n=15, Median 3.7 (IQR 3.2-4.3)) p=<0.001.  Using 
pattern recognition software - the predicted sensitivity was 65% and specificity 95%. 
See figure 36. 
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Figure 36. Lung function parameter – FEV1 in controls and CF subjects. 
FEV1 is significantly lower in CF subjects when compared to healthy controls, p<0.001. 
 
FEV1 
Sensitivity - 65% 
Specificity - 95% 
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 5 – Ion Measurements 163 
5.5.3 Discussion 
FEV1 is a good discriminator of CF compared to controls.  As FEV1 drops gradually 
through a patients lifetime, it is more to reflect a life long deteriorations rather than 
reflecting well-being in recent weeks and months.  For this reason it may be that a 
significant imorovement in FEV1 will not be attainable by successful gene therapy..   
As a minimum target for biomarkers of CF, significance should be p=<0.001 and 
sensitivity at least 65% sensitive, to be comparable to FEV1. 
5.6 Comparison of all markers against FEV1 
5.6.1 Introduction 
None of the individual breath markers investigated so far in this thesis gives a 
sensitivity as high as FEV1.  Therefore it is necessary to combine more than one marker 
to optimise discrimination.  The technique used was to generate a decision tree to 
optimise discrimination between CF and non-CF subjects.  This way all markers could 
be tested in a combined way.  
5.6.2 Methods 
A statistical package was used to identify patterns within the data set which could be 
used to discriminate CF from control groups (Ciphergen pattern recognition software, 
USA). Sensitivity and specificity were also calculated.  A data table of all previous EBC 
and EB gas data was generated.  Complete data sets for the markers eCO, eNO, EBC 
nitrite, pH and ammonium were collected from adults with CF (n=28) and healthy 
control subjects (n=15).  This dataset represents a mixture of CF subjects who were 
stable and during exacerbation. 
5.6.3 Results 
A discriminatory tree was generated which used the EBC markers ammonium, pH, and 
nitrite as well as eNO (figure 37).   
Sensitivity and specificity were calculated as 67% and 92% respectively. 
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Figure 37. Biomarker decision tree for combination of markers. 
Diagrammatic representation of biomarker decision tree.  This dendrogram represents 
the discriminatory levels of a combination of EB gas and EBC markers. Therefore, in a 
new sample initial discrimination starts with EBC ammonium (at the top).  As can be 
seen from the decision tree, if the ammonium level in less than 11.7µm then the sample 
is likely to be CF.  If the ammonium level is not low (>25.5µm) but the eNO level is 
low (<2.95ppm) then the sample is likely to be CF.
FEV1 
Sensitivity - 67% 
Specificity - 92% 
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5.6.4 Discussion 
By combining EBC data, it was possible to discriminate between CF and Non CF better 
than by using FEV1. The combined tree showed slightly higher sensitivity and much 
higher specificity than FEV1. As these biomarkers are generated over short periods of 
time, they have the potential reflect short term changes in lung pathophysiology and 
therefore ultimately may prove superior to FEV1.   
When each marker was analyse individually (using mann-whitney rank sum), the 
markers which were most different were EBC ammonium and pH (i.e. lowest p values).  
When a combined decision tree is used, it can be seen that eNO and EBC nitrite (which 
did not have low p values) are also relevant in subjects who do not have both a low 
ammonium and a low pH. It is interesting to postulate that pH and ammonium may 
represent one component of CF lung disease and that NO and nitrite may represent 
another.  The decision tree deems a low eNO and low nitrite as helping discriminate CF 
from controls, which in itself is surprising as these are thought to be induced by 
proinflammatory cytokines via inducible nitric oxide synthetase.  Perhaps it is not 
inflammation that they are reporting on, instead it could be through the three 
mechanisms discussed in chapter 3.  These mechanisms are CFTR interaction with 
iNOS, reduced nitrosothiol (glutathione) secretion or pseudomonal consumption of 
nitric oxide.  All three modes of action can be directly linked to CFTR function but the 
most significant possiblility is that of CFTR interaction with iNOS.  If EBC nitrite and 
eNO are reporting iNOS function, then these assays could be used to report directly on 
CFTR function i.e they should rise with successful gene therapy. 
Whatever the components of CF lung disease that these markers are reflecting, using the 
decision tree would suggest that the markers which should go forward to use in gene 
therapy trials are EBC ammonium, pH and nitrite and eNO. 
These data show a higher sensitivity to detect CF than FEV1 (67% vs 65%).  As gene 
transfer efficiency with non-viral gene therapy is low, any anticipated improvements 
from baseline will be low, therefore ideally markers would have much higher sensitivity 
and specificity than generated by eNO and EBC markers alone, ideally individually 
such markers would have sensitivity and specificity values close to 100%.   
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To validate these data, a further complete dataset (n=20 in each group) should be 
collected.  Then the decision tree could be tested to see if it can genuinely discriminate 
CF from non-cf subjects.  
It would be possible to utilise this technique to identify the most important markers of 
inflammation in CF subjects by prospectively following them through an exacerbation 
i.e. collected data at time of exacerbation and then again once they had improved back 
to stability.  Then these datasets could be compared using the software to tease out the 
best markers of inflammation. 
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Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 6 – Proteomics 168 
6.0 – Proteomics techniques – All sample types 
6.0.0 Introduction 
After completion of work validating known/established markers, a technique to find 
novel biomarkers was used.  As EBC Total Protein concentration was raised in CF 
subjects, a proteomics approach was chosen to identify the most important proteins. 
This approach involved the global study of proteins within Exhaled Breath Condensate, 
Bronchoalveolar Lavage fluid and Induced Sputum.  The technique employed was mass 
spectrometry with further protein identification using polyacrylamide gel 
electrophoresis coupled with mass spectrometry. 
6.1 Surface Enhanced Laser Desorption Ionisation (SELDI) 
Surface Enhanced Laser Desorption Ionisation Time of Flight (SELDI TOF) is a mass 
spectrometry technology supplied by Ciphergen Biosystems (PBS 2C, Ciphergen, 
USA).  It offers a coupling of “Surface Enhancement” of proteins using on-chip 
chromatographic separation by their chemical class with “Laser Desorption/Ionisation 
Time of Flight” (as with matrix assisted laser deionisation time of flight - MALDI TOF) 
technology. 
6.1.0.0 Surface Enhancement 
Biological samples are applied to different chip surfaces and allowed to bind (figure 
38), then non-bound components are washed off.  This allows separation of the proteins 
into different chemical classes and is important as biological fluids are complex, 
containing a large number of high abundance proteins and less abundant proteins may 
therefore not be detected.  Less abundant proteins are not detected using SELDI due to a 
saturation of the mass spectrometry signal by high abundance proteins (e.g. albumin) 
and also by interference of non-protein compounds e.g. salts and DNA. 
Different chromatographic surfaces allow binding of different proteins reflecting their 
chemical characteristics.  These surfaces are Cationic, Anionic, Hydrophobic, Metal 
Affinity and Normal Phase (Global binding) chip surface (figure 39). 
6.1.0.1 Laser Desorption/Ionisation 
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SELDI (and MALDI) mass spectrometry platforms use a “matrix” to donate protons to 
proteins in the sample.  The matrix and proteins are dried onto a metal chip and this 
chip is then inserted into the instrument.  A vacuum is generated along a time of flight 
tube (1m long in the case of SELDI).  A laser is used to vaporise the sample and then 
the protonated sample is pulled towards the cathode.  As small proteins travel faster, 
they hit the detector first, allowing separation of proteins by mass and charge (MZ+).  
Medium sized proteins hit the detector slightly later and give a stronger signal (due to 
higher momentum).  As larger proteins hit the detector later (after detector has reached 
close to saturation), they elicit a smaller signal (figure 40).  In theory, proteins between 
500Da and 500kDa can be detected, with peak sensitivity between 2kDa and 20kDa.  
The data generated can be viewed in three different ways – spectral view, gel view or 
data view.  (Figure 41) 
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Figure 38 – Application of sample to SELDI chip surface. 
Sample being applied to SELDI chip surface.   
 
Figure 39 – Chip surfaces used in this thesis. 
The five chip surfaces available for experiments enriched for hydrophobic proteins, 
positively charged (anion exchange) and negatively charged (cation exchange) protein, 
binding to specific metals (metal affinity) and non selective (global) binding. 
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Figure 40 – Diagram demonstrating time of flight and signal intensity generated 
for different sized proteins.  
 
 
Figure 41 – SELDI software generated data views 
The actual data generated can be shown as a spectral view (top), as a computer 
generated gel band view (middle) or once the data has been extracted from background 
noise, as a data view (bottom).
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6.1.1 SELDI – Potential Chip/binding buffer combinations 
As well as different chromatographic properties of each chip, adjustments to binding 
conditions can be made.  The optimal combinations were screened using BAL and EBC 
fluid.  Twelve optimal combinations were identified. 
6.1.1.2 Optimised chip/binding buffer conditions 
The protocols for each of these binding and washing conditions were developed through 
multiple experiments using BAL and EBC. The different chip surfaces allow separation 
due to differening chemical characteristics of the proteins. 
Cationic (CM10) and Anionic (Q10) chip surface 
• CM10 at pH4, pH6 and pH8 
• Q10 at pH6, pH8 and pH10 
Global Protein Binding Surface 
• NP20 
Hydrophobic  
• H50 at low acetonitrile elution (10%) 
• H50 at high acetonitrile elution (40%) 
Metal Affinity 
• IMAC Nickel, Copper and Cobalt. 
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6.1.3 SELDI Protocols 
Bioprocessor versus on spot analysis 
The bioprocessor is a funneling system where a larger volume of sample can be added 
to the chip surface. It performs best due to widespread binding across the chip surface 
by avoiding a meniscus (avoids reduced binding at chip perimeter).  It can be used for 
larger sample volumes (e.g.>20µL).  If sample volume is low and its protein 
concentration is low, it is preferable not to dilute the sample before binding to the chip 
surface.  In this case the sample should be applied directly to the chip surface.  
Maximum volume for direct application is 7µL. 
Energy Absorbing Molecules (Matrix) 
Two matrices are available for use with SELDI:- SPA – sinapinic acid and CHCA –
alpha cyano hydroxy cinnaminc acid.  The quality of data (signal intensity) was better 
with SPA than CHCA using test samples of EBC, BAL and induced sputum, therefore 
SPA was used.  SPA was reconstituted with 50% acetonitrile and 0.5% trifluoroacetic 
acid (400µL per eppendorf). 
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6.1.4 SELDI data acquisition 
6.1.4.1 Deflector Settings 
If the signal generated is very strong, this can lead to saturation of the detector of the 
instrument, which would decrease sensitivity.  The matrix used to protonate the sample, 
can produce a signal below 2kDa.  Such small mass protonated compounds can be 
“deflected” away from the detector to improve sensitivity.  The instrument contains a 
mass deflector for this purpose.   
Experimentation revealed improvements in signal with deflector set at 20Da for small 
peptides (i.e. less than 10kDa) and 2500Da for higher mass proteins (i.e. greater than 
10kDa). 
6.1.4.2 Analysis Settings 
Variations between SELDI instruments require that each has to be individually 
calibrated to optimise the signal strength.  To do this, BAL fluid was assayed after being 
bound to a CM10 chip at pH6 and the settings which achieved best signal strength were 
used.  These were a digitiser rate of 500MHz and a deflector voltage of 2650 V. 
Signal to noise data filtering. 
The data generated shows a varying baseline (background noise) and genuine protein 
signals (peaks) within it.  To analyse and extract the data, filtering of baseline noise is 
necessary.  Indeed early publications which did not adequately perform baseline 
filtering, were heavily criticised because some of the “biomarkers” discovered were 
actually baseline noise (Petricoin et al., 2002). Guidance was obtained from the 
manufacturer, who recommended using a signal to noise ratio of at least 3 for peptides 
of less than 10kDa and of greater than 5 for proteins larger than 10kDa).  These settings 
were confimed as detecting genuine signal by checking all data by eye to ensure 
adequate signal detection occurred.
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6.1.5 SELDI Data Analysis 
6.1.5.1 Ciphergen Peaks  
This statistical package was used to analyse the crude data, and was used to identify 
peptides and proteins.  The main process to do this was to identify peaks from the 
background noise (using signal to noise ratios).  As explained above, previous work 
using the SELDI instrument was criticised because data were extracted and analysed 
from areas below limit of detection of the equipment (Petricoin et al., 2002).  To avoid 
such problem, we set peak detection limits on our data set.  Peptides (i.e. <10kDa) with 
a signal to noise ratio of greater than three were considered likely to be genuine and 
proteins (i.e. >10kDa) with a signal to noise of greater than five were considered likely 
to be genuine.  These settings were recommended by Ciphergen representatives, and 
were monitored throughout all experiments by checking a subset of the data by eye. 
These extracted data were then applied to other statistical packages for further analysis. 
Variation in the quantity of protein in different samples leads to a different strength of 
signal.  To compensate for this, the data can be “normalised” to total signal (defined as 
area under the curve) so that all data are comparable.  To identify robust biomarkers, 
strict normalisation criteria were adopted. This effectively normalised all samples to 
their total protein content, and therefore total signal was used as an internal standard for 
all data produced. 
6.1.5.2 Ciphergen Biomarker Wizard 
Using the data extracted from Ciphergen peaks, samples were then unblinded and coded 
into disease groups.  The software allowed identification of the biomarkers most 
different between groups.  Comparison was made using Mann Whitney Rank Sum.  
Significant difference was deemed as having a p value less than 0.001 at this stage. 
Biomarkers which were present in at least 15% of all spectra analysed were chosen for 
differential expression analysis, with a first pass screen of data using a signal to noise 
ratio of 5:1 and a second pass of analysis was applied with a signal to noise of 3:1. 
6.1.5.3 Ciphergen Express 
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This software allowed comparison between data sets (i.e. between subject groups and 
chip surfaces).  Data analysis settings were applied at same settings as using Ciphergen 
Peaks and Biomarker Wizard software to ensure data generated were not different. 
6.1.5.4 Ciphergen Biomarker pattern recognition software  
This package was used to give an estimate of the sensitivity and specificity of each test. 
After data collection and analysis, this software can be used to combine multiple 
markers to generate a decision making tree to improve the sensitivity and specificity by 
combining different markers.
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6.2 Exhaled Breath Condensate – SELDI analysis 
6.2.1 Introduction 
SELDI TOF allows the identification of large numbers of proteins in a biological 
sample, based on molecular weights and chemical characteristics.  It avoids the 
limitations of antibody binding and of only analysing predetermined proteins.  It is able, 
therefore, to identify proteins not previously appreciated to be potentially valuable 
biomarkers.  The technology has been applied to serum and urine to identify disease 
specific biomarkers (Petricoin et al., 2002, Rogers et al., 2003, Seibert et al., 2004) but 
its application to BAL fluid allows a valuable evaluation of proteins in the areas directly 
involved in airways inflammation. 
Exhaled breath condensate contains 0.5-25µg/ml of protein (see chapter 3).  SELDI chip 
surfaces require a protein concentration of at least 5µg/ml to bind to the surface to 
generate reproducible data (5µg/ml concentration recommended by Ciphergen).  
Therefore the concentration of protein EBC is at the lower limit of detection for SELDI 
technology, even though SELDI is considered to be at least 1000x more sensitive than 
ELISA. 
6.2.2 Methods 
To concentrate the sample freeze drying was performed.  As low sample volumes could 
be added to the chip surface (e.g. 5 µl), 1ml of EBC could be concentrated 200 fold.  
This would imply that the protein concentration would be a minimum of 100mcg/ml in 
5µl of concentrated EBC, and should therefore be sufficient for binding to the chip 
surfaces. 
Initial data using EBC at a demonstration by Ciphergen were encouraging, albeit in a 
small dataset (n=4 CF vs n=4 non-CF).  However, once the instrument was purchased, it 
was not possible to reproduce the initial data. 
Indeed reproducibility of any data generated was infrequent.  As reproducibility is a 
vital component of any clinically useful test, this negated further research on EBC. 
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Contamination issues. 
Part of the difficulty with reproducing initial results was that low levels of 
contamination were found to generate a signal. It was realised that the pipette tips used 
for the experiment were a source of contamination as the tips used were from general 
laboratory stock and were racked by hand. 
The tips were changed to preracked, proteomic grade tips and this reduced the 
frequency of contamination being seen. 
A further source of contamination was from the laboratory source of water.  Initial 
experiments used an ELGA ultrapure water filtration system.  Despite frequent 
servicing and changing of the filters, this water source contributed to contamination 
using SELDI.  The water source was changed to Fluka ultrapure water. 
6.2.3 Results 
Once the changes to resolve contamination issues had taken place, this caused a 
significant reduction in the number of proteins detected in EBC.  As techniques to avoid 
contamination improved within each part of the protocol, the number of proteins 
detected fell.  Once we had removed these potential sources of contamination, the 
number of proteins detected fell to zero (figure 42) 
Sporadically a signal was detected with a mass spectrometry profile similar to BAL but 
this had occurred in less than 1 in 20 samples, as shown below (figure 43).  The peaks 
below have been identified as the human alpha defensins 1, 2 and 3 by previous 
researchers (Zhang et al., 2002).  A later publication retracted the source of the alpha 
defensins in their published paper, commenting that the source of the alpha defensins 
may have been contamination – in this case from neutrophils (Zhang et al., 2004).   
6.2.4 SELDI EBC – Discussion 
After contamination issues were improved, we could not generate reproducible data 
from EBC despite confidence that we were within the acceptable range of protein 
concentration for the instrument.  Therefore it was concluded that no proteins could be 
detected with highly sensitive equipement.  It is conceivable that data generated from all 
EBC work reflects contamination and further work to investigate this is warranted. 
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 As only 1 in 20 samples generated acceptable data the decision was made to change the 
focus from EBC onto the proteomic analysis of induced sputum and bronchoalveolar 
lavage fluid for development of novel biomarkers of inflammation and CFTR function.
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 Figure 42. Contamination evident in EBC 
This figure shows two samples of EBC.  The top graph represents data generated after 
using proteomic grade pipette tips and proteomic grade ultrapure water.  The lower 
graph shows data where suspected contamination generated a protein signal.  
Figure 43. Similar profiles of EBC and BAL 
These data show similar profiles of EBC and BAL.  These data were sporadic in nature 
and found not to be repeatable.  The three peptides shown to the left are human alpha 
defensins 1, 2 and 3 (Zhang et al., 2002).
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6.3.0 Effect of EBC on recombinant Interleukin 8. 
From chapter 5, EBC seemed to have a deleterious effect on the detection of interleukin 
8 using ELISA.  SELDI has superior sensitivity at the mass range of cytokines and 
chemokines.  Therefore, we used SELDI to assess whether there was an effect on 
recombinant interleukin 8 by EBC. 
6.3.1 Methods. 
EBC was collected from one healthy control adult, freeze dried and reconstituted 10 
fold as per techniques used in chapter 5.  10 pg of recombinant interleukin 8 (Biosource, 
Belgium) was reconstituted in ultrapure water and then added to either 10 fold 
concentrated EBC or ultrapure water (as a control).  The solutions were then applied to 
a CM10 chip at pH 6. 
6.3.2 Results. 
Recombinant Interleukin 8 was altered by EBC and not by ultrapure water.  A mass 
shift of +251.3 Da was seen when EBC was added to the recombinant interleukin 8 (see 
figure 44). 
6.3.3 Discussion 
A mass shift of 251 Da could represent many different protein modifications by EBC 
(see table 14).  The modifications listed in Table14 could all be with the mass accuracy 
error at this molecular weight (mass accuracy reported to be 300 parts per million with 
SELDI, which is significantly less than MALDI).   
Palmytolation is a protein modification which could theoretically occur in the present of 
EBC, as BAL is comprised of significant quantities of palmitoyl attached to surfactant 
protein C, and it is the loss of the palmitoyl which confers SP-C activity to form 
amyloid sheets (during inflammation) (Gustafsson et al., 2001).  
This interesting observation could give an explanation for the interleukin 8 EBC data 
generated using ELISA. Palmytolation (or another protein modification) of recombinant 
interleukin 8 by EBC would have the potential to mask the epitopes available for 
ELISA detection leading to “decay” of inteleukin 8 signal with time.
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 6 – Proteomics 182 
Figure 44. Mass shift effect of EBC on recombinant interleukin 8. 
These data show the effect of EBC on recombinant interleukin 8 as assayed using 
SELDI. The upper graph shows EBC with an interleukin 8 spike and the lower sample 
shows recombinant interleukin 8 spiked into water as a control.  In the upper graph a 
second smaller peak is seen with a mass shift of +251. 
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Table 14. Post translational modifications at mass range 238-272 
This table shows the mass shift effect on a protein of the different post translational 
modifications in the mass range 238-272 Da.  The mass shift effect seen on inteleukin 8 
with EBC was +251 Da and with a mass accuracy of 300ppm, the modification could 
potentially be any of these modifications. 
Mass Shift Protein Modification 
238 2-(p-biphenyl)isopropyl-oxycarbonyl (Bpoc)  
238 Palmitoylation  
242 Triphenylmethyl (Trityl, Trt)  
243 Tyrosinyl Sulphate  
243 Phospho Tyrosinyl  
252 Pbf (pentamethyldihydrobenzofuransulfonyl)  
252 3,5-Diiodination (of Tyrosine)  
258 a-N-6-Phosphogluconoylation (His Tagged proteins)  
259 N alpha -(gamma-Glutamyl)-Glu2  
266 O-GlcNAc-1-phosphorylation (of Serine)  
266 Stearoylation  
266 Pmc (2,2,5,7,8- Pentamethylchroman-6-sulphonyl)  
272 Geranylgeranylation  
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6.4 SELDI - BronchoAlveolar Lavage analysis 
Samples for this study were kindly supplied by Dr Tom Hilliard as part of the UKGTC 
collaboration.   
CF lung disease commences soon after birth.  It is not yet known if the basic defect 
preludes to an inflammatory defect or to invasion by infecting organisms.  To validate 
non-invasive markers, it is appropriate to identify them in ASL where possible.  Due to 
the progressive nature of CF, generally adults have more severe lung disease, making 
BAL procedures potentially unsafe.  Therefore BAL procedures are avoided as much as 
possible in the adult CF population.  However, in children BAL is performed as part of 
CF (and non-CF) patients routine care.  They are not performed in healthy children.  
The use of sample material from early in life could potentially have advantages for the 
purposes of this thesis, in that infection and inflammation may be present to a lesser 
extent than adults and may therefore reveal surrogate markers of the basic CF defect as 
well as inflammation.  As the control group had non-CF lung disease, there was also the 
potential for identification of CF specific markers of inflammation.  
6.4.1 BAL Methods 
6.4.1.1 Subjects 
Subjects were children undergoing flexible bronchoscopy, for clinical reasons, in a 
single paediatric centre.  Bronchoalveolar lavage (BAL) was performed in 39 children 
with CF and 24 non-CF children with a range of other respiratory diseases [lower 
respiratory tract infection (n=11), chronic cough (8), primary ciliary dyskinesia (7), 
croup (3), others (9)].  The mean age of CF subjects was 7.0 years (0.3-14.8y) and non-
CF subjects 6.3 years (0.4-15.3y).  The reasons for bronchscopy in the CF children were 
as follows: to detect bacterial infection after diagnosis of CF (8 cases), failure to 
respond to antibiotic therapy during a pulmonary exacerbation (24), lobar consolidation 
(5), microbiological surveillance while undergoing a surgical procedure (2). 
6.4.1.2 BAL processing 
Flexible bronchoscopy was carried out under general anaesthesia, with BAL performed 
in the middle lobe using 3 aliquots of 1ml/kg of normal saline.  The return fluid was 
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pooled.  BAL fluid was centrifuged at 2000g x 10min to separate cellular and fluid 
phases.  The supernatant was stored at -800C until analysis.  The cell pellet was 
resuspended, treated with 0.1% dithiothreitol and differential cell counts performed on a 
cytsopin preparation stained with May-Grunwald-Giemsa.  IL-8 concentrations were 
measured by commercial ELISA (R&D, Minneapolis, USA). 
6.4.3 Results 
1277 proteins, >4kDa, were detected using 12 different surfaces and binding conditions.  
202 proteins identified were differentially expressed in the CF samples (p<0.001).  167 
of these were over expressed and 35 were under expressed.  When Bonferroni 
correction and removal of poorer signals was applied, 59 proteins were differentially 
expressed.  The platform software modelling analysis of these proteins gave a ≥90% 
sensitivity and specificity for CF compared to non-CF subjects.  Statistically, the most 
significant biomarker had a predicted mass of 5.163 kDa (Figure 45.1).  This biomarker 
completely discriminates CF from control and most efficiently on the IMAC nickel chip 
surface. 6 example proteins are shown (figure 45). 
6.4.3.1 Bonferroni Correction 
By applying bonferroni correction for multiple comparisons (of total 1287 proteins), the 
significant p value would be >0.000038. Using this correction, there are 59 proteins in 
CF BAL which are different.  Whilst this correction reduces the chances of a type 1 
error, it raises the chance of a type 2 error, meaning that potential biomarkers could be 
lost by applying this correction. As we want robust biomarkers, which would 
discriminate a 5% improvement with gene therapy, bonferroni correction was applied. 
6.4.3.2 Removing weaker signals 
Initial screening of data to remove weak signals was performed by applying settings to 
detect signal/noise ratio >3 and enabling the detecting peaks in >20% of all samples. In 
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spite of this, weak signals were still present. To remove weak signals, data with a mean 
signal intensity of less than 4 were removed from analysis. As the mass deflector was 
set to 4 kDa (for mid mass data recording), proteins below this were removed.  These 
steps further reduced the number of different proteins from 59 to 23. 
6.4.3.3 Duplicate peaks (present on more than 1 surface) 
Some proteins were present on more than one chip surface.  A mass accuracy of , 600 
parts per million is appropriate for SELDI, therefore if >1 protein was present within a 
0.0006% mass range, the less significant was removed.  This procedure identified 2 
duplicates – 5165 IMAC Nickel (and 5167 CM10 pH6) and 64929 Q10 pH10 (and 
64961 Q10 pH6).  This step therefore reduced the number of proteins from 23 to 21 
(Table 15).  The 6 proteins with highest significance are shown as examples (Figure 
45). 
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6.4.4 SELDI BAL Data – 21 proteins with lowest p values 
Rank Chip Surface Protein Mass (Da) p value 
 
1 IMAC Nickel 5165 0.00000003 
2 IMAC Nickel 10623 0.00000139 
3 Q10 pH 10 9594 0.00000276 
4 Q10 pH 6 10361 0.00000426 
5 Q10 pH 6 10380 0.00000484 
6 Q10 pH 6 7507 0.00000626 
7 Q10 pH 6 7552 0.00000711 
8 Q10 pH 8 10611 0.00000752 
9 Q10 pH 6 32665 0.00000916 
10 IMAC Nickel 5323 0.00000974 
11 CM10 pH 4 7266 0.00001129 
12 Q10 pH 10 5041 0.00001175 
13 Q10 pH 6 10336 0.00001175 
14 Q10 pH 10 6968 0.00001620 
15 CM10 pH 6 10589 0.00001964 
16 Q10 pH 6 9651 0.00002756 
17 CM10 pH 8 5031 0.00002771 
18 IMAC Nickel 5300 0.00002969 
19 Q10 pH 6 8687 0.00003104 
20 Q10 pH 6 8879 0.00003104 
21 Q10 pH 10 64929 0.00003366 
Table 15 – Lead 21 proteins in BAL which were different between CF and control 
subjects
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6.4.5 Figure 45. 6 examples of the 21 BAL Biomarkers of CF lung disease. 
1 - IMAC Nickel – 5165Da, p=0.00000003 
 
2 - IMAC Nickel – 10623 Da, p=0.00000139 
 
3 - Q10 pH 10 - 9594 Da, p=0.00000276 
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4 - Q10 pH 6 - 10361 Da, p=0.00000426 
 
5 - Q10 pH 6 - 10380 Da, p=0.00000484 
 
6 - Q10 pH 6 - 7507 Da, p=0.00000626 
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6.4.6 Discussion 
SELDI TOF analysis of BAL generates a large panel of protein biomarkers that 
differentiate, with high statistical significance, CF lung disease from a disease control 
population.  While these biomarkers may prove useful in monitoring CF airways 
inflammation and possibly CFTR function, longitudinal data are required for evaluation 
of robustness and value of individual proteins. 
Even with the application of very restrictive parameters on data analysis (in order to 
avoid excessive claims of significance), 21 potential biomarkers have been found.  
These require specific identification.  Restrictive limits were applied to the data in order 
to avoid making unsustainable claims about the number/value of biomarkers thus 
identified.   
Until the biomarkers have been identified by sequencing, their usefulness will not be 
known.  They may give insights into the pathophysiology of the development of early 
Cystic Fibrosis lung disease.  Undoubtedly some of the markers will also represent CF 
inflammation and it can be anticipated that the markers would consist of cytokine and 
chemokine signalling proteins, markers of innate and acquired immunity, 
killing/defense proteins and potentially other markers of CF lung disease.   
The protein 5165 was completely discriminatory in these samples taken from children 
and it is hoped that if this is also true in the adult population.  Identification of this 
protein would clarify its function and whether it is more likely to reflect inflammation 
or CFTR function. 
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The list of biomarkers generated will be useful independently as they reflect CF specific 
aspects of inflammation, and will also be useful for comparison with induced sputum 
data generated in adults with CF when compared to healthy controls. 
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6.5 Induced Sputum – SELDI analysis 
6.5.1 Introduction 
After identification of potential proteomic biomarkers in BAL of children, induced 
sputum of adults was analysed to investigate whether these markers were detectable 
non-invasively.  There are two components to induced sputum, as with BAL, the 
soluble phase and the cell phase.  As it has been established that the cellular phase of 
CF induced sputum contains high but variable quantities of neutrophils and healthy 
control samples of induced sputum contain a larger proportion of macrophages, it is 
likely that proteomic analysis of the cell phase will simply reflect differences in cell 
count.  It was hypothesised that the soluble phase would include cytokine and 
chemokine signalling proteins, markers of innate and acquired immunity, 
killing/defense proteins and potentially other markers of CF lung disease. 
6.5.2 Methods 
Induced sputum samples were collected from CF adults using the techniques described 
in chapter 2 and proteomic analysis was performed on its soluble phase. 
Initial validation work was performed on samples from healthy controls to ensure that 
data quality was satisfactory.  The quality of data appeared very similar to that of BAL 
samples analysed.  As the hypothesis of this thesis was that non-invasive samples could 
be used as a replacement for invasive samples, induced sputum and bronchoalveolar 
lavage fluid were compared. As induced sputum samples were collected from adults and 
BAL samples from children, it was unfortunately not possible to analyse BAL and 
induced sputum from the same individual. 
6.5.3 Results 
Initial test results revealed a large number of proteins detected on the majority of chip 
surfaces.  The only exception being that very few hydrophobic proteins were detected 
using the hydrophobic chip surface H50.  
202 proteins were differentially expressed in the CF samples (p<0.001) using 12 
different surfaces and binding conditions.  167 of these were over expressed and 35 
were under expressed.  After bonferroni correction was applied, there were 76 proteins 
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which were differentially expressed.  Of these a further 16 were removed because of 
weak signal, leaving 60 proteins.       
Of the remaining 60 proteins, 22 were duplicates and 38 proteins were differentially 
expressed in the CF group.  The 38 proteins are listed in table form (table 16).  Six 
example biomarkers (of 38) were represented graphically (figure 46) 
6.5.4 Discussion 
Data from induced sputum and BAL appeared comparable despite the induced sputum 
coming from adults and the BAL from children.  This is an important observation in 
that, should SELDI be useful for identifying biomarkers of inflammation and CFTR 
function, it is possible that these markers could be detected both in induced sputum and 
BAL. 
The 38 biomarkers were found on five different chip surface/chemical combinations 
(table 16).  As with the BAL data, each marker could be used independently to assess 
response to gene therapy.  The markers detected were highly discriminatory between the 
CF and Non CF group.  The analysis criteria used were rigorous in that a type 2 error 
may have occurred – meaning potential biomarkers have been missed, however this 
decision was made to ensure than efforts to identify biomarkers (see later in chapter) 
were targeted to abundant proteins which were highly different in CF and control 
population. 
These biomarkers could be used either once each protein has been identied/sequenced 
(as an immunoassay) or without identification using SELDI as an endpoint in future 
gene therapy trials. 
Further analysis of this large proteomic dataset is warranted and it is hoped that 
correlation of clinical characteristics such as CF subjects gene defect, lung function 
parameters and bacterial colonisation status would be seen.  Multivariate analysis 
should be performed to see if there are patterns of upregulated proteins.  Once identified 
these protein patterns may give information on pathogenic biological pathways. 
 
6.5.5 Combined data - BAL and Induced Sputum Biomarkers  
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When the BAL and IS data were compared 8 of the 21 lead proteins found in BAL were 
also present and differentially expressed (p=<0.001) in induced sputum.  They had MW 
10589, 5165, 10623, 9594, 10380, 7507, 10611 and 5300Da.  However, in induced 
sputum, of these 8 proteins, only 3 were abundant and highly upregulated in both BAL 
and induced sputum (i.e. after bonferroni correction and removal of weaker signals – 
present in both the 21 BAL markers and the 38 biomarkers).  These were proteins of 
MW 10589, 10611 and 5300 Da.   
The five markers which were present and upregulated in induced sputum (p=<0.001) 
5165, 10623, 9594, 10380 and 7507Da were removed after application of bonferroni 
correction.  It would seem plausible that a type 2 error has occurred, and that these 5 
markers should also be considered potential biomarkers of CF lung disease.
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Rank Chip Surface Protein Mass p value 
 
1 CM10 pH6 10589 0.00000022 
2 CM10 pH4 6340 0.00000031 
3 CM10 pH6 10187 0.00000036 
4 CM10 pH4 5559 0.00000060 
5 CM10 pH6 11768 0.00000079 
6 CM10 pH4 6820 0.00000098 
7 Q10 pH10 13144 0.00000156 
8 Q10 pH10 13202 0.00000156 
9 Q10 pH10 12656 0.00000185 
10 CM10 pH4 5304 0.00000185 
11 CM10 pH4 13185 0.00000185 
12 CM10 pH4 5687 0.00000217 
13 CM10 pH4 7245 0.00000217 
14 CM10 pH6 12708 0.00000231 
15 CM10 pH4 6892 0.00000253 
16 CM10 pH4 5998 0.00000296 
17 Q10 pH6 8868 0.00000459 
18 CM10 pH6 6934 0.00000560 
19 Q10 pH10 6358 0.00000600 
20 CM10 pH6 7354 0.00000647 
21 CM10 pH6 7463 0.00000647 
22 Q10 pH10 15810 0.00000707 
23 CM10 pH4 7836 0.00000850 
24 CM10 pH6 10804 0.00000861 
25 CM10 pH4 9843 0.00001140 
26 Q10 pH6 7706 0.00001187 
27 CM10 pH4 10612 0.00001318 
28 Q10 pH6 8848 0.00001429 
29 CM10 pH6 5409 0.00001507 
30 Q10 pH6 7913 0.00002951 
31 CM10 pH4 6257 0.00003088 
32 CM10 pH4 10846 0.00003546 
33 Q10 pH10 15510 0.00003955 
34 Q10 pH10 7926 0.00004593 
35 CM10 pH6 6863 0.00005050 
36 Q10 pH6 7739 0.00005945 
37 Q10 pH6 6747 0.00007055 
38 CM10 pH6 10645 0.00007436 
Table 16 - SELDI Induced Sputum Data – 38 potential biomarker 
The 38 proteins listed above were detected in induced sputum. 
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1- CM10 pH 6 – 10589 Da, p=0.00000022 
 
2- CM10 pH4 – 6340Da, p=0.00000031 
 
3 - CM10 pH4-10187, p=0.00000031  
 
Figure 46. Induced Sputum - 6 examples (of 38) Biomarkers. 
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4 - CM10 pH4 – 5559 Da, p=0.00000060 
 
5 - CM10 pH4 – 11768, p=0.00000079 
 
6 – CM10 pH4 – 6820 Da, p=0.00000098 
Figure 46. Induced Sputum - 6 examples (of 38) Biomarkers
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6.6 Protein Identification 
6.6.1 Introduction 
Once the 38 biomarkers were detected in induced sputum using SELDI, the next step 
was to identify them.  The technique employed in this thesis was to resolve the protein 
of interest onto a polyacrylamide gel and then to identify the protein using a 
combination of mass spectrometry and web based database searches. 
The mass range of the 38 proteins identified in the induced sputum study was 5kDa to 
13.5kDa. The first step was to separate the individual proteins in induced sputum 
samples.  This was done using polyacrylamide gel separation.  Induced sputum was 
taken from CF subjects whose sputum showed highest abundance of significant 
proteins. 
6.6.1 Polyacrylamide Gel Electrophoresis 
As the mass of proteins to be identified was relatively low (5-16kDa), the separating 
gels used needed to be of high density (i.e. 16%).  A range of gels were tested with 
induced sputum and BAL and the gel which best resolution of proteins was the 
Invitrogen system and NuPAGE Novex Tricine Gel (16%) along with Novex Tricine 
running and sample buffers.  These gels were marketed as giving good resolution of 
proteins in the 5 to 25kDa range. Gels were run using recommended protocols from 
Novex and Novex SimpleBlue SafeStain standards were used.  Destaining of gels was 
performed with a rapid destaining technique using SimpleBlue SafeStain Microwave 
Protocol. 
Once the protein of interest was visualised on the gel, it was punched out in pellets 
using a pipette tip.  The gel was then destained and the protein eluted out of the pellets. 
6.6.2 Trypsin Digestion 
Gel pieces were covered with 100mM Ammonium Bicarbonate/50% Acetonitrile (50-
100ul) and left for 15mins at room temperature.  The supernatant was discarded and the 
procedure repeated three times until all stain was removed. Gel pieces were covered 
with 100% Acetonitrile for 10 mins. Again supernatant was removed and discarded and 
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 6 – Proteomics 199 
gel “speed-vac” dried for 20 mins. Next 10mM DDT in 100mM ammonium bicarbonate 
was added to cover the gel pieces, and left at room temperature for 5 mins, before being 
incubated at 56°C for 1hr.  The DTT was then removed by aspirating it with a pipette 
and 55mM Iodoacetamide in 100mM Ammonium was added.  The gel was then 
incubated for 30 mins at room temperature in the dark, and the supernatant removed 
(this procedure was repeated 3 times).  Gel pieces were dehydrated using 100% 
Acetonitrile for 10 mins, which was then evaporated using a vacuum extractor.  Proteins 
were digested using Sigma modified Bovine Trypsin in 10% Acetonitrile, 25mM 
Ammonium Bicarbonate at 10-20ng/ul.  Digestion occurred by incubating at 37°C for at 
least 16 hours.  
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6.6.4 Mass spectrometry techniques for protein identification 
Once the protein of interest was selected out using gel electropheresis and punched out, 
the punched out pellets were split into 2 portions.  One portion was applied to a Normal 
Phase global binding surface SELDI chip and analysed to see if the correct protein was 
punched out and was relatively pure.  The second portion was digested with trypsin 
overnight at 35oC.   
Different mass spectrometry techniques were used once the protein of interest was 
selected out.  The primary technique used was trypsin digestion and fragment 
identification using SELDI coupled to “Mascot” web searching.  After this the peptide 
fragments were analysed by Quadrupole Time of Flight (Q-TOF) mass spectrometry for 
identification (this component was performed as a service by Ciphergen Biosystems 
(Copenhagen, Denmark).  Independent identification was performed using a tandem 
mass spectrometry technique performed in collaboration with the University of 
Edinburgh proteomics facility - Edinburgh Protein Interaction Centre (EPIC).  
6.6.5 Protein identification using SELDI 
SELDI was used as the main technique to identify proteins from their peptide 
fragments.  Once the trypsin digest of the proteins into peptide fragments was 
completed, the sample was put onto the SELDI chip surface.  The resulting peptide 
fragment solution was then applied to Normal Phase global binding surface SELDI chip 
and analysed to see which peptide fragments were present.  Confirmatory identification 
was performed using Quadrupole Time of Flight (Q-TOF) mass spectrometry. 
6.6.6 Results 
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6.6.6.1 Protein 10589 - Identification using SELDI 
The lead marker found in induced sputum was also one of the most abundant proteins in 
the induced sputum and BAL samples – at mass 10589.  When digested, 8 peptide peaks 
were seen which were not attributable to trypsin.  6 of these 8 peptides had a mass 
within 1 dalton of predicted peptide fragments of Calgranulin A. This generated a 
Mowse Protein score of 105 (Mowse Protein scores greater than 62 are significant 
(p<0.05).  60% of the amino acid sequence for Calgranulin A was detected using 
SELDI (the fragments covered are displayed in bold). (Figure 47). 
MLTELEKALN SIIDVYHKYS LIKGNFHAVY RDDLKKLLET CPQYIRKKG 
ADVWFKELDI NTDGAVNFQE FLILVIKMGV AHKKSHEES HKE 
Protein database searching was performed using the mascot proteomics database - 
http://www.matrixscience.com/search_form_select.html. 
6.6.6.2 Identification using quadrupole TOF 
Further to identification by peptide fragment mass, quadrupole TOF mass spectrometry 
was used (this was performed as a service by Ciphergen Biosystems, Copenhagen) to 
sequence two of the peptide fragments - 1272.69 and 1562.79.  The two sequences were 
confirmed as ALNSIIDVYHK and GNFHAVYRDDLKK respsectively and are both 
present in Calgranulin A.  This gives confident identification based on the Mowse Ion 
Score which was 44 and 43 for each peptide respectively.  A Mowse Ion score of 
greater than 38 indicates identity or extensive homology (p<0.05).  
6.6.6.3 Confirmatory Identification using tandem MS. 
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To confirm this finding – tandem mass spectrometry was used (this was performed in 
collaboration with Dr Andrew Cronshaw of Edinburgh Protein Interaction Centre 
(EPIC) at the University of Edinburgh. 
Calgranulin A identification was confirmed and all 8 digested subunits were sequenced 
giving confident identification (figure 47).
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Figure 47. Peptide profile of protein 10589 digest (Calgranulin A) using 
quadrupole TOF. 
The protein peptide fragments from digestion, by trypsin of the band at 10589Da.  
Peptide fragments are seen from both the digested protein and from trypsin 
(autodigestion).  6 of the peptide masses matched Mascot database search for 
Calgranulin A. The 2 peptides selected for quadrupole TOF sequencing are circled in 
blue. 
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6.6.6.4 Protein 5165  
The 5165 marker which showed complete discrimination in BAL fluid from children 
was upregulated in adults with CF but was not completely discriminatory.  For 
identification purposes, it was very difficult to resolve onto a gel as it was of low 
abundance and had a relatively low mass.  Once on the gel, the techniques outline above 
were applied and peptide digest using SELDI did not confidently identify any peptide 
fragments.  Due to the low abundance of protein eluted from the gel, sequencing by 
either quadrupole or tandem MS was unsuccessful. 
6.6.6.5 Other proteins 
No other proteins were confidently identified.  From the gel bands in the range 5-
13.5kDa.  Calgranulin B was detected using peptide homology.  However attempts to 
confirm by sequencing was not successful.  Haemoglobin alpha and beta chains, 
cytokeratin II were sequenced but did not have confident peptide matching. 
Further work in the area of protein identification using 1D and 2D gel electrophersis 
will continue, but is outwith the time restraints of this body of work.
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6.6.6.6 Calgranulin A 
The biomarker Calgranulin A has been identified with confidence and is known from 
the literature to be important in Cystic Fibrosis and in inflammation but has not been 
proposed as a biomarker of CF lung disease.  It is also known as Cystic Fibrosis antigen 
(Wilson et al., 1977), S100-A8 protein, Migration inhibitory factor-related protein 8 or 
the Calprotectin L1L subunit . 
Calgranulin has a predicted mass of 10828 Da.  Using SELDI we assayed it at 10589.  
The difference in mass is presumably due to post-translational modification e.g. 
cleavage from pro-protein.  It is a member of the S100 protein family - characterised as 
low molecular mass acidic proteins and 2 calcium-binding domains .   
It is expressed in neutrophils and infiltrating monocytes particularly during chronic 
inflammation.  It is abundant in neutrophils and contributes 50% of the total cytosolic 
protein in resting neutrophils.  Its exact function is not known but it is known to be a 
potent chemoattractant (Devery et al., 1994).  It is secreted in response to inflammation 
and to bacterial LPS, and causes neutrophil recruitment from bone marrow (Vandal, 
Rouleau et al. 2003).  Therefore, it is likely to be a marker of inflammation and 
neutrophil recruitment in CF lung disease.  
Calgranulin has also been advocated as a biomarker of other diseases such as COPD  
(Merkel et al., 2005), transitional cell carcinoma of bladder (Tolson et al., 2005), 
ulcerative colitis (Tolson et al., 2005) and colorectal carcinoma (Hoff et al., 2004), and 
therefore cannot be considered to be specifically a marker of CF lung disease. 
Previously, Calgranulin A had been reported as being a potential surrogate marker for 
CFTR function.  It was noted to be raised in CF homozygotes as well as heterozygote 
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carriers (Wilson et al., 1977, Wilson et al., 1975).  As CF heterozygotes do not have 
lung disease or any other signs of CF it may be postulated that calgranulin (previously 
termed CF antigen because of these data) has an activity related to CFTR protein rather 
than solely reporting on neutrophil activity (Hartz et al., 1998, van Heyningen et al., 
1985).  Calgranulin appears to be regulated by CFTR at a transcriptional level, in that if 
CFTR is absent, Calgranulin expression is upregulated (Renaud et al., 1994, Xu et al., 
2003).  Further investigation on the induced sputum of CF heterozygotes is warranted to 
clarify this. 
Certainly a Calgranulin assay should be useful for future gene therapy trials, reporting 
on CF type inflammation and potentially on CFTR function.  Further investigation of 
Calgranulin by SELDI and ELISA is warranted to investigate levels in subjects with 
CF, heterozygote carriers as well as control subjects with other diseases such as non-CF 
bronchiectasis.   
It is encouraging that this lead biomarker found by SELDI shows such promise, and it is 
therefore important that efforts are made to identify the other lead biomarkers as well. 
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6.7 Proteomics discussion 
The biomarkers discovered appear to be very sensitive at detecting CF lung disease.  It 
may be that they are solely reporting on the inflammatory process rather than CFTR 
function.  However markers found in the BAL and induced sputum were found to be 
different from non-CF inflammatory disease and healthy controls suggesting that some 
may be specific for CF lung disease and therefore may be directly reporting on CFTR 
dysfunction. 
It is appropriate to pursue further validation of these markers longitudinally in CF 
subjects during periods of stability and during exacerbation  and in relation to other 
inflammatory lung diseases, in particular, non-CF related bronchiectasis.  Once 
identification of the proteins takes place, they have the potential to give new insights 
into CF pathophysiology.  
These markers appear to be better discriminators than the gold standard non-invasive 
biomarker – FEV1.  As some show complete separation between groups, these offer 
high sensitivity and specificity.  It is hoped that these markers would report on a small 
change in clinical status of the CF patient i.e. after 5 % transfection with wtCFTR gene 
therapy. 
Using SELDI as an endpoint in gene therapy trials is likely to be cost effective in that it 
generates up to 38 different datapoints at around £15-20 per sample.  However it is 
semiquantitative in nature and therefore specific ELISAs for each of the protein 
identified would have the advantage of being truly quantitative. 
Until a CF gene therapy trial takes place, there is no real test of whether these markers 
will be sensitive enough to detect a change in patient status. 
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In the meantime, the best ways to validate these markers is to follow them up 
longitudinally in individual CF subjects during an infective exacerbation, and to test to 
see if they change when the patient improves from a stable baseline i.e. after a medical 
intervention such as nebulised antibiotic – Tobramycin (TOBI).
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7.0 Final Discussion Chapter 
7.1 Hypothesis of thesis 
Markers of inflammation in Cystic Fibrosis Lung Disease are measurable in samples 
collected non-invasively, and can be developed into clinically useful assays. 
These assays would have the ability to reflect the level of 
1. Inflammation in the CF lung. 
2. CFTR function - this would be sensitive enough to detect improvement 
following administration of gene transfer agents 
 
The hypothesis of this thesis can be broken down into two components, firstly that 
markers of inflammation can be measured in samples collected non-invasively and 
secondly that these markers could be developed into clinically useful assays, which 
reflect CF inflammation and CFTR function. 
The first component, that markers can be detected in samples collected non-invasively 
has been shown to be true in both exhaled breath condensate and induced sputum. 
7.2 Exhaled Breath Condensate 
A large component of the work of this thesis was focussed on exhaled breath 
condensate because it was the most attractive sampling method i.e. it proved to be 
simple, safe, well tolerated and could be successfully performed in all subjects 
including young children.  Such a sampling technique would have a positive impact on 
future gene therapy trials in that recruitment to a “non-invasive” group would be easier. 
It would allow samples to be collected in all subjects as well as allowing the study of 
subjects with poorer lung function (i.e. FEV1 less than 40%). 
Markers of inflammation were detectable in EBC.  The majority of markers investigated 
were not discriminatory between CF and Non CF subjects.  Two markers did emerge 
from the EBC research, pH and Ammonium.  These markers did seem to reflect the 
inflammatory process as they are reduced in adults with cystic fibrosis. Therefore, EBC 
could be used as a sampling method for the non-invasive assessment of inflammation.  
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The process by which these markers are lower has not been established.  The lower pH 
may be due to a reduction in activity of the three main proton pumps, generation of an 
inflammatory acid, or by a reduction in buffering capacity.  The marker ammonium 
appears to reflect the proinflammatory cytokine activity that occurs in CF lung disease.  
Exhaled breath condensate therefore does meet the criteria that it can report on the 
increased airway inflammation in CF lung disease. The second component of the 
hypothesis that exhaled breath condensate can be used to assess CFTR function has not 
been proven.  The ion concentrations in EBC were not different between CF and control 
subjects, in keeping with previous vitro and in vivo work.  Therefore, they are unable to 
assess the chloride channel activity.  From the point of view of bicarbonate secretion, it 
has not been possible to assay bicarbonate directly, and the fact that there in no 
difference in EBC pH between CF and Non CF children implies that EBC pH cannot be 
used to measure the postulated deficiency of bicarbonate in ASL.  Therefore, EBC does 
not have the ability to reflect the level of CFTR function in subjects. 
The measurement of EBC pH and ammonium as markers of inflammation should be 
used in future gene therapy trials as they are cheap, quick and simple to perform.  It is 
noted that they do not completely discriminate between CF and non-CF subjects.  This 
does not preclude their use in trials however, as the real power of such markers will be 
longitudinal data collection before, during and after gene therapy application.  The 
strength of longitudinal data collection is that problems of intersubject variability can be 
avoided.  The wide intersubject variability of EBC analysis perhaps reflects wide 
variability in ASL microdroplets collected.  Longitudinal measurements in individuals 
with CF lung disease is even more important as CF exhibits variability in the day to day 
inflammatory state of the lung, combined with variability in the rate of disease 
progression.  Therefore to achieve the highest possible power from gene therapy trials, 
the trial design which should be applied would be the gold standard double blind, 
placebo controlled, randomised trial.  
7.3 Oxidative stress markers in Exhaled Breath and Exhaled Breath Condensate 
The oxidative stress markers investigated in this thesis were exhaled carbon monoxide 
and the EBC marker 8-isoprostane. Both markers were unable to discriminate between 
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the stable CF subject and normal controls.  As there is undoubtedly a marked 
inflammatory process evident clinically in the CF adult even when stable, these markers 
must therefore be relatively insensitive.  Because of this relative insensitivity, it is 
unlikely that an improvement from the stable baseline would be detected.  They should 
therefore not be used as endpoint assays of efficacy of gene transfer. 
7.4 Nitrative stress markers in Exhaled Breath and Exhaled Breath Condensate 
The nitrogen redox balance of the CF lung could be affected for three important 
reasons.  Nitrative stress markers could be increased due to reaction of NO with reactive 
oxygen species in the neutrophil.  The levels of NO that are available for this reaction 
are subject to change for two reasons.  CFTR and iNOS levels appear to be co-
expressed, and iNOS may be an interaction partner for CFTR, leading to reduced iNOS 
and reduced generation of NO in CF subjects. NO is also released from s-nitrosothiols 
(nitrated glutathione).  As glutathione is reduced in the ASL of CF subjects, this 
mechanism may lead to reduced NO release.  These two mechanisms for NO generation 
could potentially alter with successful gene therapy, causing an increase in NO 
expression. 
The products of nitrative stress assayed were exhaled nitric oxide gas, nitrite and 
nitrotyrosine, which respectively are increasingly stable.  There was no detectable 
difference between the stable CF subject and controls and therefore these assays were 
unable to discriminate the two groups. 
However,it could be argued that NO and nitrite should be measured during gene therapy 
trials, as they are cheap simple non-invasive tests.  The reasons they may change with 
gene therapy are due to possible induction of iNOS expression by WT CFTR and 
increased secretion of glutathione by functional CFTR.  
7.5 Chemokines and Cytokines in EBC 
Many markers were assessed with ELISA and with EIA techniques.  The conclusion of 
my work is that appropriate standard curves need to be applied for EBC, and that with 
those investigated in this thesis there was no difference in chemokine or cytokine levels 
in EBC.  Therefore, Chemokine and Cytokine assays of EBC are not suitable for use in 
gene therapy trials. 
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7.6 Proteomics and EBC 
This thesis has shown that by using clean techniques, free from contamination, that 
there are no proteins in EBC that are repeatedly detectable using highly sensitive SELDI 
techniques.  This technique reflects the highest sensitivity of any available proteomics 
instrument, due to its surface enhancement, and therefore until new technologies 
become available, it would be incorrect to assay any proteins in EBC. 
7.7 Induced Sputum  
The induced sputum data supported the findings of the BAL study, and identified 38 
independent markers of CF lung inflammation.  Therefore, sampling by collection of 
induced sputum should be used in gene therapy trials.  The endpoints should be assessed 
by a combination of SELDI as an endpoint and by ELISA where this is available.  The 
implications of this are significant in that non-invasive techniques could be used instead 
of BAL in future trials, obviating the need for general anaesthetics in children and 
restriction of recruitment of adults for trials to those who do not have respiratory failure. 
The results show that there are proteins present in the BAL and induced sputum of CF 
subjects, which are different from healthy controls and subjects with other respiratory 
diseases.  The markers are likely to be reporting on CF type inflammation but 
potentially could also be reporting specifically on CFTR function.  Further studies in 
milder genotypes are warranted, as well as studies in subjects with non-CF 
bronchiectasis. 
The marker Calgranulin is likely to report on neutrophil recruitment to the lung.  It is 
hoped that this will be a sensitive marker of inflammation in the CF lung and it also has 
the potential to report on CFTR function due to calgranulins transcriptional association 
with CFTR, as it is raised in heterozygote carriers as well as homozygotes with CF. 
Therefore, the non-invasive technique induced sputum coupled to proteomic analysis 
would have the ability to reflect the level of inflammation in CF subjects and may also 
report on CFTR function.  It is hoped that these markers will be sensitive enough to 
detect successful wtCFTR gene transfer.
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7.8 Concluding Remarks and Future Directions 
The experiments described in this thesis have confirmed that non-invasive sampling of 
the ASL can provide biomarkers, which are likely to be sensitive and specific for CF 
lung disease.  The principle that these biomarkers are likely to inform on the 
inflammatory status of subjects and potentially on CFTR function has been established. 
It remains to be seen whether they are sensitive and specific enough to report on 
successful CF gene therapy. In additional they may prove useful markers of 
inflammation in CF, helping to monitor patients longitudinally, and to help determine 
when patients might benefit from therapeutic interventions such as intravenous 
antibiotics. 
The definitive validation of these markers can only come with successful gene transfer 
to the CF lung. CF GT trials are planned to start in 2009, and it is anticipated that the 
biomarkers identified in this thesis will be useful in identifying success of gene transfer.  
Until successful gene transfer occurs, we will not know how useful these markers will 
be.  In the meantime, validation of these markers should take place through the 
longitudinal follow up of CF subjects through infective exacerbations and also after 
interventions which cause improvement form baseline – e.g. nebulised antibiotics. 
7.9 Future directions 
Further validation will continue, and as more sensitive proteomic and metabonomic 
tools are developed it is hoped that these will be applied to both EBC and Induced 
Sputum.  The application of the techniques used in this thesis to other lung diseases 
such as Asthma, COPD and lung cancer may give further insight into the 
pathophysiology of such disease and could be used as tools to assist with the diagnosis 
and treatments of such diseases. 
The full uses of the proteomic markers found in this thesis cannot be assessed until the 
markers have been sequenced and identified. Further identification should lead to assay 
developments such as ELISA which is quantitative, rather than semi quantitative 
(SELDI).  Future work would include refinement of the analysis process, selection of 
the optimal surfaces for use in trials and identification of the causes of failed analysis 
i.e. samples which fail to “normalise”.  It is hoped that at this stage proteomic 
Non-invasive markers of inflammation in Cystic Fibrosis lung disease  
Chapter 7 – Final Discussion Chapter 215 
information from the ASL of CF subjects will inform on the pathophysiological 
processes in the lung.  It should be considered that each of the biomarkers found in this 
thesis may not just report on the disease phenotype, but may be potential drug targets as 
causative agents in the inflammatory processes of CF lung disease. 
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